An open  
world  
through  
vaccines  
Annual Report 2022  
 
Bavarian Nordic Annual Report 2022  
2
Our purpose  
An open  
world through  
vaccines  
Providing us comfort  
and security  
Making the world a safer  
and better place  
At Bavarian Nordic, we are working  
to save and improve lives by unlocking  
the power of the immune system  
No matter who we  
are or where we live  
Vaccines are an integral  
part of our lives  
 
Bavarian Nordic Annual Report 2022  
3
Our DNA in Bavarian Nordic  
Protecting lives every day is  
an essential part of our DNA in  
Bavarian Nordic, and we aspire  
to develop vaccines that address  
unmet medical needs for the  
greater good of the global society.  
By improving access to new and better vaccines for the most vulnerable people, we play an important  
role in the vaccine industry that is transforming the lives of individuals, helping to boost the economies  
of low- as well as high-income countries, and making the world a safer and better place.  
 
Bavarian Nordic Annual Report 2022  
4
Contents  
Our response to  
the global mpox  
outbreak  
Our strategy  
and business  
Introduction  
6
7
9
Bavarian Nordic at a glance  
Products and markets  
2022 in numbers  
13  
19  
→
→
11 2022 highlights  
13 Our response to the global mpox outbreak  
15 A message from the Chair  
16 Letter from the CEO  
Sustainability  
33 Protecting our tomorrow  
34 Climate-related financial disclosures  
35 ESG key figures  
Financial Review  
52 Financial review  
53 Sales performance  
55 Income statement  
58 Balance sheet  
Our strategy and business  
19 Our strategy  
Corporate information  
37 Corporate governance  
20 Progress in 2022  
21 Key 2023 priorities  
22 Outlook for 2023  
25 Research and development  
Financial statements  
61 Consolidated financial statements  
40 Risk management  
44 Shareholder information  
46 Board of Directors  
68 Notes  
117 Financial statements of the parent company  
122 Notes  
49 Executive Management  
136 Statement by management on the Annual Report  
137 Independent auditor’s reports  
Read our  
Sustainability  
Report 2022  
Read our  
Remuneration  
Report 2022  
Read our  
Corporate Governance  
Report 2022  
→ → →  
 
Bavarian Nordic Annual Report 2022  
5
Introduction  
In February 2023, we announced  
the acquisition of a portfolio of  
marketed and development-  
stage vaccines from Emergent  
BioSolutions, including manufac-  
turing and R&D facilities.  
→ Bavarian Nordic at a glance  
→ Products and markets  
→ 2022 in numbers  
By the reporting date, the acqui-  
sition is still subject to closing,  
pending approval from the  
authorities and the acquired  
assets are not presented as part  
of our business.  
→ 2022 highlights  
→ Our response to the global mpox outbreak  
→ A message from the Chair  
→ Letter from the CEO  
Read more about the acquisition  
on page 23 →  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
6
Commercial products  
with leading market  
positions:  
Rabies, TBE, Ebola,  
Smallpox,  
Mpox  
At a glance  
Bavarian Nordic is a fully integrated vaccines
5
3
2
company focused on R&D innovation, manufacturing
and commercialization of life-saving vaccines.
Inlicensed  
products:  
Hepatitis B,  
Cholera,  
Japanese  
encephalitis  
Global commercial  
operations with  
own salesforce  
and distribution in  
strategic markets  
End-to-end  
Listed on NASDAQ  
OMX Copenhagen  
C25 (BAVA.CO) and  
ADR (BVNRY)  
More than 1,000  
employees  
worldwide  
Late stage  
pipeline candidates:  
RSV,  
manufacturing at  
highest quality  
standards  
COVID-19  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
7
Products and markets  
Information for patients and  
healthcare professionals  
We have established a diverse portfolio of in-house developed and acquired products addressing infectious  
diseases across the globe, and through our partnerships with governments and international organizations,  
we are working to increase the availability of important vaccines to improve public health.  
Throughout 2022, we have continued to  
expand our digital services for patients and  
healthcare professionals, providing access to  
information about our disease areas and prod-  
ucts. We will continue to launch our websites  
in more countries in 2023.  
Consumer website with relevant disease infor-  
mation. Currently available in English, German,  
Danish, Swedish, Finnish and Estonian.  
Marketed  
vaccines  
Public health and  
preparedness  
Endemic  
diseases  
Travel  
vaccines  
Own products  
Smallpox  
→
www.loweringtherisk.com  
Mpox  
An online resource for healthcare professionals  
with in-depth knowledge about our vaccines  
and the diseases they are addressing. Currently  
available in the US, Germany, Switzerland,  
Sweden, Finland and Estonia.  
Ebola  
Rabies  
Tick-borne encephalitis  
→
In-licensed products  
Hepatitis B  
www.bnvaccines.com  
Cholera  
Japanese encephalitis  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
8
JYNNEOS®  
Mpox and smallpox vaccine  
Rabipur® / RabAvert®  
Rabies vaccine  
Encepur®  
Tick-borne encephalitis vaccine  
Marketing and distribution  
agreements  
Although smallpox was eradicated more than 40  
years ago, vaccines and therapeutics are still in  
demand from governments who prioritize their  
biological preparedness. Through a two-decade  
long partnership with the US government, we have  
developed a non-replicating smallpox vaccine on  
our MVA-BN platform technology, which has been  
approved in the US, Canada and EU. The vaccine is  
also approved for mpox. In response to the global  
mpox outbreak in 2022, we have supplied the  
vaccine to more than 70 countries, including coun-  
tries where the vaccine did not have regulatory  
approval, but was accepted under national emer-  
gency provisions.  
Although the prevalence of rabies in Western  
countries has significantly diminished through  
vaccination campaigns of domesticated animals  
and even among wild-life animals, the risk is still  
present and post-exposure vaccination remains the  
only effective treatment. In other parts of the World,  
the risk of rabies is considered significantly higher,  
particularly in Asia and Africa, and pre-exposure  
vaccination are often recommended for travelers to  
these regions.  
Tick-borne encephalitis (TBE) is prevalent in central,  
eastern and northern Europe and the geographic  
range of the virus appears to have expanded to  
new areas, likely due to a complex combination  
of changes in diagnosis and surveillance, human  
activities and socioeconomic factors, and ecology  
and climate.  
We have entered agreements with Valneva and  
Dynavax to market and distribute their vaccines  
in selected markets. With Valneva, we have a  
mutual agreement, whereby Valneva also markets  
our rabies and tick-borne encephalitis vaccines in  
certain markets.  
IXIARO®  
Our vaccine is available in 14 European countries  
where we are market challenger in key markets  
with Germany representing our largest single-  
market.  
Valneva’s vaccine against Japanese encephalitis,  
which we market and distribute in Germany and  
Switzerland.  
Our vaccine is available in 20 countries and has a  
global market-leading position with the U.S. being  
our largest single-market, primarily due to the need  
for post-exposure vaccinations.  
DUKORAL®  
Valneva’s vaccine against cholera, which we market  
and distribute in Germany and Switzerland.  
Mvabea®  
Ebola vaccine developed on our MVA-BN platform  
technology. Licensed to Janssen (Johnson & Johnson) in  
2014 and now part of their two-dose vaccine regimen  
(Zabdeno® + Mvabea®) approved by the EC in 2020. We  
continue to be manufacturer of the vaccine.  
JYNNEOS is the U.S. brand name. The vaccine is  
marketed as IMVAMUNE® in Canada and IMVANEX®  
in EU.  
HEPLISAV-B®  
Dynavax’ hepatitis-B vaccine, which  
we market and distribute in Germany.  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
9
Revenue 2018-2022  
2022 in numbers  
DKK million  
2022  
2021  
2020  
2019  
2018  
3,151  
We delivered significantly stronger than expected financial results in  
2022, even after eight guidance upgrades during the year, primarily  
resulting from numerous supply contracts for our mpox vaccine, but  
also due to a higher demand for our rabies vaccine.  
1,898  
1,852  
662  
Revenue  
EBITDA  
Cash and cash equivalents at year-end*  
(mDKK)  
(mDKK)  
(mDKK)  
501  
1,741  
3,151 328  
EBITDA 2018-2022  
DKK million  
2022  
2021  
2020  
2019  
2018  
328  
75  
Compared to original guided  
revenue of 1,100 - 1,400 mDKK  
Compared to original guided  
EBITDA of (1,300 - 1,000) mDKK  
Compared to original guided cash  
position of DKK 1,000 - 1,200 mDKK  
See also the financial  
review on page 52 →  
740  
(271)  
(313)  
* The guidance assumed a bank debt level at year-end of DKK 600 million, however remaining bank debt was repaid during the fourth quarter and  
no new debt agreements were implemented.  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
10  
Group key figures 2018-2022  
DKK million  
2022  
2021  
2020  
2019  
2018  
DKK million  
Financial Ratios1)  
2022  
2021  
2020  
2019  
2018  
Income statement  
Revenue  
3,151  
1,450  
213  
1,898  
1,328  
192  
1,852  
1,195  
286  
341  
662  
355  
501  
255  
EBITDA  
328  
75  
740  
5.1  
(271)  
(10.7)  
57.6  
171  
(313)  
(11.2)  
67.5  
127  
Production costs  
Earnings (basic) per share of DKK 10  
Net asset value per share  
Share price at year-end  
(4.9)  
(7.4)  
Sales and distribution costs  
Research and development costs  
Administrative costs  
53  
34  
101.1  
104.7  
83.7  
187  
2.2  
1,183  
376  
399  
409  
386  
180  
213  
269  
293  
278  
173  
Share price/Net asset value per share  
2.1  
2.6  
3.0  
1.9  
Income before interest and tax (EBIT)  
Financial items, net  
(71)  
(314)  
(141)  
(454)  
(465)  
380  
(98)  
282  
(328)  
(16)  
(345)  
(347)  
(355)  
(2)  
Number of outstanding shares at year-end  
(thousand units)  
70,735  
58%  
70,468  
61%  
58,450  
32,389  
32,311  
71%  
(261)  
(332)  
(347)  
Equity share  
56%  
26%  
Income before company tax  
Net result for the year  
(357)  
(362)  
Number of employees, converted to full-time,  
at year-end  
278  
975  
759  
690  
491  
419  
Balance sheet  
Total non-current assets  
Total current assets  
Total assets  
1) Earnings per share (EPS) is calculated in accordance with IAS 33 "Earning per share". Other financial ratios have been calculated in accordance  
with the guidelines from the Danish Society of Financial Analysts.  
7,907  
4,485  
12,391  
7,150  
7,336  
4,754  
12,089  
7,375  
6,378  
2,381  
8,759  
4,894  
2,912  
952  
6,392  
655  
553  
2,508  
3,061  
2,181  
398  
Reconciliation of EBITDA  
7,047  
1,865  
3,134  
2,047  
Income before interest and tax (EBIT)  
Depreciation and amortization (note 9)  
Impairment losses (note 9)  
EBITDA  
(71)  
399  
-
(314)  
388  
1
380  
344  
16  
(328)  
57  
(355)  
42  
Equity  
Non-current liabilities  
Current liabilities  
2,954  
2,287  
2,806  
1,909  
-
-
483  
328  
75  
740  
(271)  
(313)  
Cash Flow Statement  
Securities, cash and cash equivalents  
Cash flow from operating activities  
Cash flow from investment activities  
– Investment in intangible assets  
– Investment in property, plant and equipment  
– Net investment in securities  
2,845  
220  
3,717  
(359)  
1,670  
572  
472  
(276)  
(810)  
(2,311)  
(360)  
1,861  
1,115  
2,317  
(289)  
17  
(877)  
(1,020)  
(361)  
674  
(2,877)  
(575)  
(1,912)  
(484)  
(223)  
(1,202)  
1,335  
(10)  
(202)  
229  
(483)  
(1,779)  
3,536  
Cash flow from financing activities  
636  
246  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
11  
2022 highlights  
Mpox / smallpox  
• In response to the global mpox outbreak, we  
entered numerous agreements with governments  
and organizations to supply our vaccine in 2022  
and beyond.  
• The European Commission approved an extension  
of the marketing authorization for our smallpox  
vaccine to include mpox and disease caused by  
vaccinia virus.  
• Through these agreements, we have expanded  
the access to our vaccine to more than 70 coun-  
tries worldwide and supplied approximately 4  
million doses in 2022.  
• The U.S. government exercised the first options  
valued at USD 119 million under the USD 299  
million contract to supply a freeze-dried version  
of the mpox/smallpox vaccine.  
• To meet the demand, we scaled up our manu-  
facturing capacity at our own manufacturing site  
and through our partnership with the US based  
contract manufacturer, Grand River.  
Read more about our response to the global mpox  
outbreak on page → 13  
• We entered into a 10-year supply contract with  
Canada valued up to USD 470 million, thereby  
continuing our 15-year long partnership to  
improve the country’s preparedness.  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
12  
2022 highlights — continued  
RSV  
Other developments  
COVID-19  
• We initiated a Phase 3 clinical trial of our COVID-19 booster vaccine  
candidate, ABNCoV2 in 4,000 subjects across USA, Belgium and  
Denmark.  
• We initiated a global Phase 3 clinical trial of our MVA-BN RSV vaccine  
candidate for respiratory syncytial virus (RSV) in older adults. Enroll-  
ment of the planned 20,000 subjects was completed in December  
2022.  
• We entered an agreement valued up to USD 83 million with the U.S.  
Department of Defense to further advance our MVA-BN-based vaccine  
candidate against Western, Eastern and Venezuelan equine encepha-  
litis virus.  
• Additional positive data from the Phase 2 study were reported during  
the year, including six-month follow up data which demonstrated  
durable antibody levels across variants of concern.  
• MVA-BN RSV was granted Breakthrough Therapy Designation by the  
FDA as well as access to the PRIME scheme by the EMA – both desig-  
nations are intended to expedite the development and regulatory  
review of the product candidate.  
• Our commercial product portfolio was expanded through agreements  
with Valneva and Dynavax to market and distribute their travel  
vaccines in selected European markets.  
• An additional bulk manufacturing line at our site in Denmark was  
completed to support transfer of Rabipur/RabAvert and Encepur to our  
own manufacturing facility.  
• We entered a license and supply agreement with Nuance Pharma on  
the commercialization of MVA-BN RSV in China and selected Asian  
markets.  
• Our fill and finish facility was approved by the FDA and EMA for the  
final drug production of the mpox / smallpox vaccine.  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
13  
Our response to the global  
mpox outbreak  
However, we also had limited bulk vaccine in stock,  
A new, global health crisis emerged in 2022. Initially, like several times  
before in recent years, sporadic cases of human mpox were reported in  
Europe among returned travelers from areas in Africa where the disease  
is endemic. Also, like in previous cases, we were contacted by health  
authorities to assist with supplies of our smallpox vaccine for healthcare  
workers and close contacts.  
which allowed us to rapidly initiate the final drug  
production (fill and finish) of the vaccine as demand  
rose during the first months of the outbreak. While  
our manufacturing lines were reserved for other  
purposes, and some parts even shut down due to  
a planned expansion, we acted swiftly and reprior-  
itized our plans to enable scale-up of mpox vaccine  
production. Later in the year, we were also able  
to re-initiate manufacturing of the bulk vaccine  
to ensure the continued supply during 2022 and  
beyond.  
However, it quickly became clear, that this outbreak  
was not following the same pattern of previous  
years. Unrelated cases were reported across several  
countries, and numbers rose rapidly. By the end of  
May, more than 600 cases were reported across  
nearly 30 countries and by year-end, this figure had  
increased to more than 84,000 cases in over 100  
countries.  
virus caused the World Health Organization (WHO) to  
declare it a Public Health Emergency of International  
Concern (PHEIC) – a declaration only used six times  
before, of which only two concerned outbreaks with  
global impact (Swine Flu and COVID-19), thus under-  
lining the seriousness of the situation.  
Through numerous agreements with governments  
and organizations, we have distributed more than  
4 million doses of the mpox vaccine during 2022,  
providing access for more than 70 countries world-  
wide. This work continues into 2023, as we remain  
committed to ensuring supply of the vaccine to our  
customers. We will also continue the dialogue with  
governments on planning of their future prepared-  
ness against mpox and other orthopox viruses.  
As the sole manufacturer of an approved mpox  
vaccine, we were contacted by authorities from  
dozens of countries, inquiring about the vaccine.  
Only limited supplies were readily available, as no  
commercial market had previously existed beyond  
the sales to a few government stockpiles for their  
biological preparedness against a related, but far  
more dangerous virus: smallpox.  
Facing this unexpected event with no prior expe-  
rience to draw from, health authorities around the  
globe were challenged to implement measures  
while still trying to understand the epidemiology of  
this disease and how this outbreak was evolving. The  
sudden emergence and widespread incidence of the  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
14  
The mpox vaccine  
Our mpox vaccine, marketed as JYNNEOS® (US),  
IMVAMUNE® (Canada) and IMVANEX® (EU), is based  
on our proprietary technology, MVA-BN®.  
Medicines Agency (EMA), we worked with the  
authorities to expedite a review of data to support  
an extension of the current approval of IMVANEX to  
include mpox. A positive opinion was adopted by  
EMA’s Committee for Medicinal Products for Human  
Use (CHMP) in July 2022 and shortly after, the Euro-  
pean Commission formally gave its approval, which  
is valid in all European Union Member States as well  
as in Iceland, Liechtenstein, and Norway.  
interactions, and we have conducted symposia on  
mpox and presented clinical data on our vaccine at  
international scientific congresses.  
The mpox outbreak has not only contributed to  
improved understanding about the disease and  
its epidemiology, but the widespread use of our  
vaccine has also provided important data on its use  
in a real-life setting. During the fall of 2022, the  
first effectiveness data were reported from national  
authorities and as more and more people have been  
vaccinated, more robust data have been presented  
and continue to accumulate.  
Originally, we began the development of MVA-BN  
as a non-replicating smallpox vaccine suitable for  
immune-compromised people who are not recom-  
mended vaccination with traditional replicating  
vaccines. This development has been supported  
by the US government, through a series of devel-  
opment contracts since 2003. These contracts later  
evolved into procurement contracts, and we started  
delivering the vaccine in the current liquid-frozen  
formulation to the US in 2010 under an emergency  
use provision until approval by the U.S. Food and  
Drug Administration (FDA) in 2019, which included  
the mpox indication. In recent years, we have been  
contracted by the US government to manufacture  
bulk vaccine with the purpose of supplying a freeze-  
dried formulation of the vaccine with a longer shelf  
life. The freeze-dried version has completed the  
clinical development and activities are ongoing to  
prepare for submission of a supplement BLA to the  
FDA for this formulation.  
Real-life effectiveness of the mpox vaccine  
The approval of MVA-BN was based on a compre-  
hensive non-clinical and clinical program encom-  
passing more than 7,000 subjects. The vaccine’s  
effectiveness was inferred from efficacy data  
from animal challenge studies and from a clinical  
trial which demonstrated a comparable immune  
response to ACAM2000, the US approved, replicating  
smallpox vaccine.  
Since 2008, we also have a long-standing partnership  
with the Canadian government on supplying the  
vaccine for both public health preparedness and for  
the national defense. In 2022, this collaboration was  
extended with a 10-year procurement agreement.  
Across several studies, the effectiveness of the  
vaccine after a single dose was shown to be  
consistently around 80% and data have confirmed  
the strong safety profile1,2. We have supported  
and continue to support multiple research groups  
working on the real-life evaluation of MVA-BN, and  
are also supporting two investigator-initiated trials,  
one studying the effectiveness of pre-exposure  
vaccination with MVA-BN in non-endemic countries  
and one determining whether MVA-BN can reduce  
mpox burden of illness in exposed household  
contacts of confirmed cases in endemic countries.  
Expedited approvals for faster and  
broader access to the vaccine  
While MVA-BN had already been approved for mpox  
in the U.S. and Canada, the approval in the EU only  
covered smallpox. Thus, in the initial mpox outbreak  
phase, countries within EU, but also outside, were  
providing the vaccines under local exemptions, such  
as emergency use provisions. Upon recommenda-  
tion from the Emergency Task Force of the European  
The 2022 outbreak was unprecedented and only  
limited knowledge of mpox and MVA-BN existed  
in the scientific community. To help increase  
awareness and knowledge, we have engaged with  
supranational institutions, government authorities  
and health care professionals through numerous  
1
2
Effectiveness of a single-dose Modified Vaccinia Ankara in Human Monkeypox: an observational study, R.Arbel et. al, 2022. https://doi.org/10.21203/rs.3.rs-1976861/v2  
Effectiveness of one dose of MVA-BN smallpox vaccine against monkeypox in England using the case-coverage method, Bertran M. et al., 2022. https://doi.org/10.1101/2022.12.13.22282654  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
15  
A message from the Chair  
Dear Shareholder,  
global commercial organization, which has driven  
our organizational growth to more than 1,000  
employees today.  
Three years ago, we embarked on a new journey. Through a strategic  
acquisition, we endeavored to transform Bavarian Nordic into a commercial  
vaccine company with a global footprint. Leveraging our strong heritage in  
vaccine research, development and manufacturing, we added a commercial  
organization and expanded our presence to key markets with a growing  
portfolio of life-saving vaccines. This was a bold move, but also the right one  
for our company to ensure continued growth and long-term value-creation.  
Our employees have enabled the success of  
Bavarian Nordic, and my thanks goes out to each  
one of you. With all the great achievements, we  
have accomplished over the past 15 years, I am  
proud, but also confident to hand over my respon-  
sibilities to Luc Debruyne, former President Global  
Vaccines at GSK, pending election at the annual  
general meeting and constitution of the Board in  
March 2023.  
The diversification of our product portfolio has  
provided resilience to the challenges imposed by  
the market such as COVID-19. However, these chal-  
lenges also created a new demand, and with that  
an unprecedented global awareness of vaccines and  
their role in improving public health and enabling an  
open world.  
solidified the company, further enabling our efforts  
to develop new life-saving vaccines and growing  
the company.  
After 15 years of serving on the Board of Directors,  
more than half of which I have had the distin-  
guished pleasure to chair the board, I will step down  
at the annual general meeting in 2023. During my  
tenure, Bavarian Nordic has undergone a significant  
transformation, and has become an established  
player in the vaccine market with a diverse portfolio  
of in-house developed and acquired products. The  
pipeline has matured, and we have significantly  
expanded our footprint, through several manu-  
facturing expansions and the establishment of a  
I would also like to thank my fellow board members  
and the executive management team for a great  
collaboration throughout the years, and not least  
their dedication and hard work to continuously drive  
Bavarian Nordic forward towards ambitious targets.  
In 2022, we were called upon by governments from  
around the world to supply our mpox vaccine to help  
fight the global outbreak. For Bavarian Nordic and  
our employees, this has been a highly rewarding  
experience. Firstly, the huge impact of our work and  
our contribution to protecting and saving lives have  
made us immensely proud, and secondly, it has  
Finally, I would like to thank our shareholders for the  
trust you have shown me and the rest of the board  
over the years. It has been a privilege to lead the  
journey so far, and I wish both you and the Company  
a prosperous future.  
Gerard van Odijk  
Chair of the Board of Directors  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
16  
Letter from the CEO  
Prepared for the  
unexpected  
2022 will go over in history as yet another year where things turned out completely different  
than we had anticipated for Bavarian Nordic. The outbreak of mpox, was a first of its kind and  
took the world by surprise, as no one was expecting an outbreak of this magnitude and there  
was little experience in managing the disease. Even after COVID-19, with all the lessons learned  
– or maybe re-learned from pandemics in the past – the public health system around the globe  
was still caught by surprise with the outbreak. One thing, however, fundamentally differed  
from the past: a vaccine had already been developed and licensed.  
Paul Chaplin  
President and CEO  
Only six times over the past decade, the WHO has  
declared a Public Health Emergency of International  
Concern (PHEIC). The global mpox outbreak repre-  
sents the most recent example and Ebola has twice  
been declared a PHEIC. At Bavarian Nordic, we have  
made significant contributions to the fight against  
both diseases. We partnered with Janssen in 2014 to  
further develop and manufacture an Ebola vaccine,  
which has been deployed several times to affected  
areas in West Africa, and which gained regulatory  
approval in 2020. And for mpox, we had already  
developed the smallpox vaccine, which was initially  
approved in the EU and Canada in 2013, and in the  
US in 2019 where mpox was added to the label.  
meet the increasing demand. Since then, we have  
worked tirelessly to manufacture and distribute  
our vaccine to countries all over the world. The  
same vaccine, which historically has been stock-  
piled in the less likely event of the re-emergence  
of smallpox, was suddenly used in real-life and  
became the preferred option for the prevention of  
mpox in millions of people. The call for our vaccine  
and our ability to deliver can largely be ascribed  
to the leadership and foresight of the US govern-  
ment to improve the public health preparedness.  
For two decades, we have partnered with them  
not only to develop our MVA-BN technology as a  
safer, non-replicating smallpox vaccine, but also  
to establish manufacturing to ensure supply of the  
vaccine, which has formed part of the US stockpile  
since 2010.  
Having an approved vaccine significantly reduced  
the time to action, and we swiftly changed our  
priorities to scale up manufacturing to be able to  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
17  
the rabies market, particularly in the US where we  
achieved record sales since RabAvert was licensed.  
gent BioSolutions to acquire their travel vaccine  
portfolio of two marketed travel vaccines and one  
in late-stage development along with the manufac-  
turing, research and development and sales capabil-  
ities to support this expansion, which will establish  
us as a global leader in travel vaccines. This transac-  
tion is now just awaiting customary closing condi-  
tions to be satisfied before it is complete.  
development, however the regulatory require-  
ments for COVID-19 vaccines have been subject to  
change, also affecting the timely initiation of our  
Phase 3 study of ABNCoV2, which was delayed into  
September 2022. Enrollment is continuing into 2023  
and we expect to report topline results for the study  
in mid-2023.  
“We have worked  
tirelessly to  
The global demand for mpox vaccines stretches into  
2023 and even beyond. While many one-off orders  
were secured for delivery in 2022 and 2023, we also  
strengthened our relations with existing and new  
customers, resulting in longer-term commitments. In  
addition to our long-standing US partner, BARDA, we  
have also extended our contracts with Canada, and  
have established important partnerships with the  
EU’s Health Emergency Preparedness and Response  
Authority (HERA) and the Pan American Health  
Organization (PAHO), which have been instrumental  
in expanding access to the mpox vaccine worldwide.  
manufacture  
and distribute  
our mpox  
One of the core strengths of Bavarian Nordic, and of  
our employees, is the ability to always act swiftly to  
change. This is how we have steered through oppor-  
tunities and challenges many times in the past and  
a key attribute to the success we have experienced  
over time. Even now, as we have reached more than  
1,000 employees, we remain agile to ensure we can  
harvest opportunities as they arise, however, not  
least we remain inspired by being able to make a  
change in people’s lives through innovation of novel  
vaccines.  
In December 2022, we successfully completed  
the planned enrollment of 20,000 subjects in the  
Phase 3 study of our RSV vaccine. Results from the  
study are expected by mid-year 2023, potentially  
supporting approval of the vaccine for older adults  
in 2025. By then, we would expect a higher uptake,  
as the market will only start developing later in  
2023, where the first RSV vaccines are expected to  
be approved. Our vaccine could enter as fourth in  
a market that is predicted to be on par with the flu  
vaccine market and with room for several players.  
During 2022, we entered a license and supply agree-  
ment with Nuance Pharma to commercialize the RSV  
vaccine in China and selected Asian markets, where  
we still have a first-in-market potential.  
vaccine to  
countries all  
over the world.”  
We have built a resilient business model based on  
a diverse product portfolio that addresses both the  
private travel segment and public health prepared-  
ness. It is our objective to grow these segments,  
while also expanding our portfolio through the  
advancement of our pipeline and a selective M&A  
approach. Through this combination, we aim to fulfil  
our ambition to achieve annual group sales greater  
than USD 1 billion and secure Bavarian Nordic as one  
of the largest pure play vaccine companies by 2025.  
2022 was never meant to be about mpox. We were  
looking into a year with the continued after-ef-  
fects of COVID-19, particularly on our travel vaccine  
franchise, which saw a significant decline during the  
pandemic. Combined with our significant invest-  
ments in R&D to initiate two Phase 3 trials, we had  
forecasted a significant loss for the year. However,  
as things turned out, we ended up delivering  
an all-time high revenue and a positive EBITDA,  
supported by the unprecedented demand for our  
mpox vaccine, but also a strong performance in  
Paul Chaplin  
President and CEO  
COVID-19 remains high on the agenda with the  
global authorities, although the market is transi-  
tioning to a private market, like flu vaccines. Contin-  
uously advancements are seen in the global vaccine  
In February 2023, we took a significant step forward  
in this endeavor through an agreement with Emer-  
 
Bavarian Nordic Annual Report 2022  
18  
Our strategy  
and business  
→ Our strategy  
→ Progress in 2022  
→ Key 2023 priorities  
→ Outlook for 2023  
→ Research and development  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
19  
Our strategy  
To drive forward this ambition, we have  
In 2020, we launched an ambitious five-year strategy. Building on our  
core strengths in vaccine research, development, and manufacturing, we  
clear and focused priorities:  
accelerated our growth through a strategic product acquisition and expansion  
of our organization to include a full, global commercial infrastructure, thus  
becoming a full-fledged vaccine company with an aspiration to become  
one of the largest pure play vaccine companies by 2025 and deliver annual  
revenues of more than USD 1 billion.  
Market excellence  
Secure profitable growth from current business  
Advance pipeline  
Mature and expand in-house R&D projects  
2025  
one of the largest  
pure play vaccine  
companies  
Strategic and selective M&A  
Increasing revenue through acquisitions  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
20  
Progress in 2022  
Our significant role as a vaccine supplier during the global mpox outbreak demanded a shift in priorities in 2022,  
primarily affecting our manufacturing, but also other parts of our organization. Nevertheless, we managed to keep  
up the planned progress in our pipeline by advancing two pipeline programs into Phase 3 trials, both with significant  
potential to contribute to our long-term growth.  
Markets  
Pipeline  
Strategic and selective M&A  
Sustainability  
After a challenging year in 2021, where the travel  
vaccine market remained significantly hit by the  
COVID-19 pandemic, global travel picked up again  
and vaccine sales rebounded in 2022. While sales  
in the travel segment did not reach pre-COVID-19  
levels, the quarter-by-quarter performance showed  
a clear growth trend that is expected to continue  
into 2023. Importantly, we succeeded in defending  
our market shares in key markets. The US domestic  
rabies business has been more resilient during  
COVID-19 and showed a historically high perfor-  
mance through 2022. Along with the mpox oppor-  
tunity that arose during the year due to the global  
outbreak, which resulted in a significant and unex-  
pected revenue stream, as well as the addition of  
new products to our portfolio through partnerships,  
our core vaccine business performed better than  
anticipated, resulting in all-time high revenues.  
Our primary achievement in research and devel-  
opment in 2022 was the advancement of two key  
pipeline programs into Phase 3 trials. The RSV  
Phase 3 study was initiated in April and reached  
its enrollment target of 20,000 subjects on time in  
December 2022.The start of the Phase 3 study for  
our COVID-19 booster vaccine candidate experienced  
delays, due to late additional regulatory demands  
that have pushed the enrollment completion into  
2023. We also received additional funding from the  
US government to further advance a program for an  
equine encephalitis vaccine.  
Growth through acquisitions has become an  
inherent part of our strategy. We apply a selective  
approach whereby we seek to expand our commer-  
cial portfolio with products that complement our  
existing business and with synergies to our existing  
manufacturing and commercial operations. During  
2022, we have continued to explore M&A opportu-  
nities, resulting in a process for the acquisition of a  
portfolio of marketed and development-stage travel  
vaccines from Emergent BioSolutions, which was  
announced in February 2023 and now just awaiting  
customary closing conditions to be satisfied before  
it is completed.  
Driven by our purpose to save and improve lives by  
unlocking the power of the immune system, our  
success depends on our ability to grow Bavarian  
Nordic and keep delivering novel vaccines that truly  
set a mark on global health. In doing so, we also  
increase our environmental and social footprint on  
the surrounding world, among others. During 2022,  
we have significantly enhanced our commitment to  
the global sustainability agenda and by integrating  
sustainability targets into our overall objectives, as  
well as into our remuneration principles, we have  
ensured accountability for our actions.  
Read more on our sustainability performance on  
page 33 →  
Read more on the acquisition on page 23 →  
→
Sustainability Report  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
21  
Advance pipeline  
Key 2023 priorities  
Mature and expand in-house R&D projects  
Strategic focus  
2023 priorities  
The positive market trends from 2022 for our core vaccine business are  
expected to continue into 2023 and together with increased deliveries of  
mpox vaccines (based on orders secured in 2022), we expect yet another  
record-breaking year for Bavarian Nordic. Importantly, both Phase 3 trials  
Launch of RSV vaccine  
for older adults through  
partnerships.  
Report topline Phase 3 data, assuming statistical threshold has been met.  
Continue manufacturing activities to prepare for commercial launch of the  
product.  
Support the clinical development towards licensure of the vaccine in China with  
our partner Nuance.  
(RSV and COVID-19) are expected to deliver topline results during the year  
and throughout the organization, we are focused on activities that will  
support market launch of the products in the years to come.  
Launch of COVID-19 booster  
vaccine.  
Complete Phase 3 enrollment and report topline data.  
Continue manufacturing activities to prepare for a regulatory submission.  
Approval of freeze-dried  
version of mpox/smallpox  
vaccine.  
Complete transfer of freeze-dried manufacturing process to Bavarian Nordic,  
including final preparations for submission of a supplement BLA to the FDA.  
Market excellence  
Sustainability  
Secure profitable growth from current business  
Strategic focus  
Rabies and TBE  
2023 priorities  
Strategic focus  
2023 priorities  
Reduce our environmental  
footprint  
Implement energy-saving measures at our manufacturing facility to reduce  
natural gas consumption thereby also reducing emissions.  
Defend and gain market shares for Rabipur/RabAvert and Encepur in key  
markets (US and Germany).  
Waste recycling rate >50%.  
Ensure a good customer service with continuous supply of both products.  
A healthy, engaging and  
diverse workplace  
Employee turnover equal to or lower than global industry standards.  
Maintain gender equality among leaders.  
Mpox  
Deliver on secured orders, supported by own manufacturing and US-based  
CMO and continue dialogue with governments to secure preparedness.  
Accident rate ≤ last 3-year average.  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
22  
Outlook for 2023  
The financial expectations for 2023 outlined below do not include the impact of the acquisition of the  
travel vaccine portfolio from Emergent BioSolutions announced in February 2023. The acquisition is  
pending final closing, upon which the Company will update its 2023 outlook. See also page 23.  
Key assumptions  
2023 financial  
Revenue  
vaccine in China under our agreement with  
Nuance Pharma. No other RSV income assumed  
in 2023.  
• Capitalization of ABNCoV2 development costs:  
approximately DKK 300 million.  
outlook  
The revenue guidance reflects the following  
assumptions:  
• Milestone payments to AdaptVac of approximately  
DKK 300 million; pending successful outcome of  
the Phase 3 study and regulatory submissions.  
Revenue, DKK million  
• Smallpox/mpox vaccines: only confirmed orders  
have been included and amounts to approxi-  
mately DKK 4,400 million.  
Research and development costs  
• Total investments in research and development  
amount to approximately DKK 1,900 million,  
including ABNCoV2 capitalized costs of approxi-  
mately DKK 300 million.  
~6,000  
• Other tangible investments: approximately DKK  
250 million.  
• Both the rabies and the TBE businesses are  
expected to grow with more markets expected to  
return to pre-COVID levels.  
• Non-capitalized research and development costs  
amount to approximately DKK 1,600 million of  
which the RSV project accounts for approximately  
DKK 1,000 million.  
• Net working capital is expected to increase by  
approximately DKK 1,500 million due to planned  
inventory buildup during tech-transfer of manu-  
facturing from GSK and due to increased sales.  
• Ebola revenue will only be included based on actual  
orders. No revenue included in the guidance.  
EBITDA, DKK million  
• Milestone payments of DKK 195 million in total,  
which will be triggered by the expected start  
of Phase 1 and Phase 3 clinical trials of the RSV  
Investments  
• Capitalization of tech-transfer activities for  
acquired vaccines: approximately DKK 100 million  
The outlook is based on the following assumptions  
on currency exchange rates of DKK 7.00 per 1 USD  
and DKK 7.45 per 1 EUR.  
~2,200  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
23  
Strategic acquisition  
of travel vaccine portfolio  
In February 2023, we announced an agreement with Emergent BioSolutions to acquire  
their travel vaccine portfolio, which includes two marketed vaccines for the prevention  
of typhoid fever and cholera and a Phase 3 vaccine candidate in development for  
the prevention of Chikungunya virus, all products that will expand and diversify our  
portfolio and establish us as a global leader in travel vaccines.  
The agreement also includes a vaccine manufac-  
turing facility in Switzerland, an R&D site in Cali-  
fornia, and a specialty sales force in both EU and US  
markets, in total encompassing approximately 280  
employees.  
commercial synergies to our existing business by  
enhancing our US presence and increasing scale in  
European markets, where we are not present today.  
market. Chikungunya represents a significant market  
opportunity, as there are no approved vaccines for  
the prevention of the disease, which is spread to  
humans by infected mosquitoes. The disease can  
cause severely debilitating joint pain and is preva-  
lent in many tropic and subtropic regions visited by  
Western travelers.  
markets for the commercial products which are  
underprioritized today and with a large upside from  
the Chikungunya program.  
In addition to the manufacturing of the acquired  
vaccines, the Swiss facility will add to our overall  
capacity and together with our existing facilities  
provide expanded future flexibility and optionality.  
Operations at the facility will remain uninterrupted  
during the take-over, which is also the case for the  
R&D facility in San Diego, US, which is focused on  
bringing the Chikungunya vaccine candidate to the  
A brief overview of the acquisition  
Total acquisition price of up to USD 380 million,  
including USD 270 million in an upfront payment and  
up to USD 110 million in future conditional milestone  
payments, subject to the successful development  
of the Chikungunya vaccine (USD 80 million) and  
sales performance of the marketed vaccines (USD 30  
million).  
This acquisition is aligned with our strategy to  
expand our commercial footprint through organic  
growth and launch of new products from our own  
R&D pipeline, combined with a selective M&A  
approach. The addition of two market-leading,  
and revenue-generating vaccines provides clear  
Building on our successful experience from the  
takeover and integration of two vaccines from GSK  
in 2020, we see this acquisition as a low-risk trans-  
action with a significant potential to grow existing  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
24  
Financial implications in 2023 of the  
travel vaccine portfolio acquisition  
from Emergent BioSolutions  
The acquired business is expected to add approx-  
imately DKK 200 million to revenue and a loss  
of approximately DKK 400 million to EBITDA, not  
included in the current company financial guidance  
for 2023.  
The expected loss is due to investments in the  
Manufacturing  
facility  
R&D  
Commercial  
operations  
Chikungunya Phase 3 program and inclusion of  
necessary one-off integration costs. The financial  
impact from the acquired business is pending final  
closing of the transaction and the timing thereof  
after which the Company will update its full-year  
guidance.  
capabilities  
Cell-culture based facility in  
Bern, Switzerland  
San Diego,  
CA. USA  
EU and US specialty  
sales force  
~280  
employees  
2 marketed vaccines  
Phase 3 vaccine candidate  
Vivotif® typhoid vaccine  
Vaxchora® cholera vaccine  
CHIKV VLP vaccine candidate  
targeting Chikungunya  
Approved in >25 markets in US/EU  
Potential launch in 2025  
325 mUSD  
500 mUSD  
estimated annual market size  
estimated annual market size  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
25  
Research and development  
Solid progress was made in our pipeline during 2022, where we advanced two programs into Phase  
3 clinical trials. Both programs are expected to deliver topline results in 2023 and they both hold the  
potential to significantly contribute to our growth strategy and save lives. Additionally, our program for an  
equine encephalitis vaccine was re-introduced into the pipeline after reaching an agreement with the U.S.  
Department of Defense, who will fund the further development of the vaccine.  
Our clinical pipeline  
A detailed description of the pipeline programs,  
including results from clinical trials, is disclosed  
in company announcements and in the pipeline  
section on our website:  
→
www.bavarian-nordic.com  
Indication  
Product candidate  
Phase 1  
Phase 2  
Phase 3  
MVA-BN RSV  
Phase 3 enrollment completed.  
Topline results expected mid-2023  
Addressing a large unmet medical need in respiratory disease in the  
older population  
RSV  
→ Read more on page 26  
ABNCoV2  
Phase 3 enrolling with expected  
completion and topline results in  
mid-2023.  
Next-generation COVID-19 booster vaccine candidate designed for  
broad protection without need for variant-specific adaptation.  
SARS-CoV-2  
→ Read more on page 28  
MVA-BN WEV  
TAEK-VAC  
Phase 1 completed.  
Phase 2 planned in 2024  
US-funded development program to develop a vaccine against  
variants of mosquito-borne equine encephalitis.  
Equine encephalitis  
Immuno-oncology  
→ Read more on page 30  
Phase 1 ongoing  
Targeted immunotherapy designed to arm the body’s own immune  
system to seek and destroy cancer cells.  
→ Read more on page 31  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
26  
RSV  
Our vaccine candidate has been designed to provide broad protection  
against respiratory syncytial virus (RSV). The high level of protection  
demonstrated in a human challenge trial provides us confidence that the  
vaccine has significant potential in the future market for RSV vaccines.  
MVA-BN RSV is being developed for prevention of  
RSV in older adults. The vaccine candidate is based  
on our proprietary vaccine platform technology,  
MVA-BN, and incorporates five distinct RSV antigens  
to stimulate a broad immune response against both  
RSV subtypes (A and B). In a clinical Phase 2 double-  
blinded, placebo-controlled human challenge trial,  
a significant reduction in viral load was reported  
in vaccinated subjects versus placebo and MVA-BN  
RSV demonstrated a vaccine efficacy of up to 88.5%  
when active RSV infection was confirmed by cell  
culture3.  
Clinical trials to-date have furthermore shown  
MVA-BN RSV to have an acceptable safety profile as  
previously observed for MVA-BN or other recombi-  
nant MVA-BN based vaccines.  
Based on the preliminary clinical evidence, indi-  
cating that the vaccine may demonstrate a substan-  
tial improvement over available therapy on a  
clinically significant endpoint, MVA-BN RSV received  
special designations from U.S. and EU regulatory  
authorities in 2022, intended to expedite the  
development and regulatory review of the product  
candidate. In February, the U.S. Food and Drug  
Administration (FDA) granted MVA-BN RSV Break-  
through Therapy Designation for the prevention of  
RSV in older adults, and in June, the European Medi-  
cines Agency (EMA) granted access to its priority  
medicines (PRIME) scheme for MVA-BN RSV in active  
immunization for the prevention of LRTD caused RSV  
in adults ≥60 years of age.  
We have previously reported results from a Phase  
2 trial of MVA-BN RSV in 421 subjects aged 55 years  
and older, demonstrating that the vaccine was  
well-tolerated and induced both broad and durable  
antibody and T-cell responses against RSV, as well  
as mucosal immune responses that may be impor-  
tant for protection against RSV. The Phase 2 program  
in older adults included a revaccination of subjects  
after one year, following which the immune  
responses were rapidly and significantly increased,  
notably in subjects with the weakest immunity prior  
to the booster vaccination4.  
MVA-BN® RSV  
Completed  
Partnership in  
place for China  
As part of the strategy to commercialize the vaccine  
globally, we entered into a regional license and  
supply agreement with Nuance Pharma in the first  
quarter of 2022 on the development and commer-  
vaccine candidate  
with competitive  
Phase 2 efficacy  
data in older adults  
enrollment of  
20,000 subjects  
in global Phase  
3 study, data  
and selected Asian  
markets  
expected mid-2023  
3
4
https://www.medrxiv.org/content/10.1101/2022.12.02.22283030v1.full.pdf  
Jordan E. et al. 2010. J. Infect, Dis. 28:223(6). 1062-1072  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
27  
cialization of MVA-BN RSV for adults in China and  
selected Asian markets. The milestone-based  
agreement has a total value of up to USD 225 million  
in addition to tiered, double-digit royalties. Nuance  
Pharma obtains rights to commercialize MVA-BN RSV  
in Chinese Mainland, Hong Kong, Macau, Taiwan,  
South Korea and Southeast Asia and will be respon-  
sible for all material costs, including development  
and regulatory. Nuance Pharma is planning the  
initiation of a Phase 3 trial of MVA-BN RSV in 2023.  
About RSV  
RSV is a common virus that usually causes mild,  
cold-like symptoms, but in serious cases can lead to  
severe lung infections, including bronchiolitis and  
pneumonia, which ultimately can lead to death.  
By the age of 2 years, most infants have experi-  
enced their first RSV infection, followed by frequent  
reinfections throughout life, because RSV infections  
do not induce a sustainable, long-lasting protective  
immunity.  
In April 2022, we initiated a global, randomized,  
double-blind Phase clinical study of MVA-BN RSV  
in adults ≥60 years of age. The primary objective  
of the study will assess the efficacy of the vaccine  
candidate against lower-respiratory tract disease  
(LTRD) caused by RSV compared to placebo. In  
December 2022, we reached the planned enrollment  
of 20,000 subjects in the study. Topline results from  
the study are anticipated in mid-2023.  
Infants, older adults and immunocompromised  
individuals are most susceptible to serious compli-  
cations from infection with RSV. An estimated  
5.2 million cases of RSV occurred in high-income  
countries among adults aged ≥60 years in 2019,  
leading to 470,000 hospitalizations and 33,000  
in-hospital deaths5, thus representing a significant  
burden to the healthcare system. Currently there is  
no approved vaccine against RSV.  
5
Savic, M.; Penders, Y.; Shi, T.; Branche, A.; Pirçon, J.-Y. Respiratory syncytial virus disease burden in adults aged 60years and older in high-in-  
come countries: A systematic literature review and meta-analysis. Influenza Other Respir Viruses 2023, 17, e13031.  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
28  
COVID-19  
ABNCoV2 is a virus-like particle (VLP)-based vaccine  
candidate in development as a universal booster  
vaccine for COVID-19. The goal is to create a longer-  
lasting vaccine protection with broader efficacy that  
obviates the need for continuously adapting to new  
variants of the SARS-CoV-2 virus. We have licensed  
the vaccine candidate from AdaptVac.  
adenovirus-based vaccines) was able to demon-  
strate a strong boosting effect, increasing the  
existing levels of SARS-CoV-2 neutralizing antibodies  
against both the Wuhan variant and variants of  
concern (Alpha, Beta, Delta) to levels reported to be  
highly efficacious (>90%) against SARS-CoV-26.  
A post-pandemic market for COVID-19 vaccines is shaping up. Broad  
and durable protection are key differentiators for a commercially viable  
vaccine and based on clinical results demonstrated thus far, our vaccine  
candidate is well-positioned to take a share of the future market.  
During 2022, we reported additional results from the  
ABNCoV2 Phase 2 clinical program:  
We have concluded the Phase 2 clinical devel-  
opment of ABNCoV2 with results confirming the  
vaccine candidate’s ability to boost neutralizing  
antibodies to levels reported to be highly efficacious  
against SARS-CoV-2, both when used for primary  
vaccination and when used as a booster in subjects  
previously vaccinated with mRNA- or adenovi-  
rus-based vaccines. A global Phase 3 trial of the  
vaccine candidate was initiated in 2022 with antici-  
pated results in 2023.  
• In February, we reported results from a seroposi-  
tive group (n=66) receiving a lower booster dose  
(50 μg) of ABNCoV2 and a seronegative group  
(n=28) receiving two doses of ABNCoV2 (100 μg)  
four weeks apart. In both groups, high levels of  
neutralizing antibodies against SARS-CoV-2 were  
observed.  
• In May, we reported further data from the sero-  
positive groups, showing that vaccination with  
either 50 μg or 100 μg of ABNCoV2 induced a  
significant boost to the neutralizing antibodies  
against the Omicron variant in the majority of  
subjects (87%).  
Phase 2 – additional results  
reported during 2022  
Primary results from the Phase 2 clinical program  
were reported in 2021, showing that vaccination  
with 100ug ABNCoV2 in 103 seropositive subjects  
(previously vaccinated with approved mRNA- or  
ABNCoV2, a  
Phase 2 data  
Phase 3 ongoing  
with read-out in  
2023  
VLP-based,  
demonstrated  
durable and broad  
antibody responses  
against variants of  
concern  
non-adjuvanted  
COVID-19 booster  
vaccine candidate  
6
P. B. Gilbert et al., Science 10.1126/science.abm3425 (2021)  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
29  
• In October, we reported follow-up results,  
demonstrating that six months post the booster  
vaccination with ABNCoV2, the neutralization  
antibody titers against Wuhan and the Omicron  
variant remained high and at levels associated  
with a greater than 90% efficacy. Six months post  
vaccination, neutralization titers were six times  
higher than pre-boost titers against Wuhan and  
nearly 10 times higher than the pre-boost titers  
for Omicron BA.1. This represented less than a  
50% decline in the peak neutralizing titers after  
six months. Compared to the data published for  
mRNA vaccines7,8,9, the antibody decay appears  
less sharp, indicating a potentially longer duration  
of protection across variants of concern.  
Phase 3 initiated – data expected in 2023  
In September 2022, we initiated a double-blind,  
controlled Phase 3 clinical trial of ABNCoV2 in 4,000  
adult subjects who either previously completed  
primary vaccination or have already received one  
booster dose of a licensed COVID-19 vaccine. One  
cohort is evaluating the safety and tolerability of the  
vaccine in 3,000 subjects receiving a single 100 µg  
dose of ABNCoV2 (US sites). A second cohort of 1,000  
subjects, who are randomized to receive either a  
single 100 µg dose of ABNCoV2, or a single 30 µg  
adult booster dose of Comirnaty (Denmark and  
Belgium sites)  
The primary endpoint of the trial is to assess  
non-inferiority of ABNCoV2 compared to Comirnaty®  
in terms of neutralizing antibodies against the  
SARS-CoV-2 (Wuhan wild type). Other variants of  
concern will be assessed as secondary endpoints.  
The vaccine was generally well-tolerated, with no  
related serious adverse events reported and no  
relevant difference in the safety profile between  
subjects receiving either 50 μg or 100 μg of  
ABNCoV2.  
Initial trial results are expected in mid-2023.  
The Phase 3 development of ABNCoV2 is largely  
funded through an agreement with the Danish  
State.  
7
8
9
Bellusci et al. Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination  
Forgacs et al. The Effect of Waning on Antibody Levels and Memory B Cell Recall following SARS-CoV-2 Infection or Vaccination  
Qu et al. Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants (letter)  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
30  
MVA-BN WEV is a multi-valent vaccine candidate  
developed under contracts with the US government  
to address the unmet medical need for a vaccine  
against western, eastern and Venezuelan equine  
encephalitis viruses, which are rare, but potentially  
deadly viruses transmitted to humans by mosquitos.  
more, the agreement includes options valued at USD  
28 million to support Phase 3 preparations.  
Equine encephalitis  
About equine encephalitis viruses  
Continuing our long-standing collaboration with the US government on  
public health preparedness, our MVA-BN vaccine platform technology  
has been selected for the development of a vaccine against the rare,  
but potentially deadly mosquito-borne viruses: western, eastern and  
Venezuelan equine encephalitis virus.  
Western, Eastern and Venezuelan equine enceph-  
alitis viruses belong to the family alphavirus, and  
are transmitted through mosquitos, as well as  
birds and some mammals. While the viruses vary  
in infection rates and severity of disease, all three  
pathogens are associated with risks of flu-like  
symptoms, potential central nervous disorders, and  
death. All three viruses are considered as potential  
biological threats, having been investigated as  
potential biological weapons at various times in the  
past century. The viruses belong to the U.S. list of  
prioritized pathogens amongst other agents, like  
smallpox, anthrax and other lethal diseases, which  
are covered by the current vaccination policy for  
U.S. military personnel being deployed around the  
globe. However, there are currently no approved  
vaccines for human use against any of the equine  
encephalitis viruses.  
The first contract valued up to USD 36 million was  
awarded by the U.S. Department of Defense (DoD) in  
2018 and included the demonstration of protective  
efficacy in animals and a Phase 1 first-in-human  
trial of MVA-BN WEV. Results from this trial were  
reported in 2020, showing that the vaccine was well  
tolerated and immunogenic across all dose groups.  
Neutralizing antibody responses were observed  
against Venezuelan equine encephalitis virus in all  
dose groups, with peak levels reached after the  
second vaccination. Recent data has confirmed  
neutralizing antibody responses also against  
western and eastern equine encephalitis viruses  
that were durable throughout the six-months follow  
up period.  
In December 2022, we entered a new agreement  
valued up to USD 83 million with DoD for the  
advanced development of MVA-BN WEV. The base  
agreement of USD 55 million has been secured for  
the period 2023-2026 and covers the costs for a  
clinical Phase 2 dose finding study of MVA-BN WEV,  
further non-clinical studies, process development  
and manufacturing of clinical trial material. Further-  
In recent years, the U.S. has seen a rise in human  
cases of eastern equine encephalitis, particularly  
in the southern and northeastern parts of the  
country, correlating with increased observations  
of mosquitos carrying the virus in these regions.  
According to the U.S Centers for Disease Control and  
Prevention (CDC), 38 cases were reported in 2019,  
compared to an annual average of 7 cases over the  
past decade. On average, more than 4 of 10 infected  
individuals die after contracting the virus .  
MVA-BN® WEV  
has completed  
Phase 1 clinical  
development  
demonstrating  
potential for broad,  
and long-term  
protection  
Development  
funded by the U.S.  
Department of  
Defense  
Phase 2 planned for  
2024  
10 https://clinicaltrials.gov/ct2/show/NCT04131595  
11 https://www.cdc.gov/easternequineencephalitis/statistics-maps/index.html  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
31  
Immuno-oncology  
While infectious disease vaccine remains our primary focus, we have continuously  
worked to advance our science through the discovery of novel immunotherapy  
candidates with potential to transform oncology treatments.  
TAEK-VAC represents a next generation immuno-on-  
cology candidate, which leverages our MVA-BN plat-  
form technology, purposed to arm the body’s own  
immune system to seek and destroy cancer cells.  
A Phase 1 open label trial of intravenous admin-  
istration of the vaccine candidate in patients with  
advanced HER2 and brachyury-expressing cancers  
is ongoing. During 2022, the first stage of the study  
was completed, confirming the dose for stage 2,  
which has now opened for enrollment. In this stage,  
two cohorts will initially enroll patients with either  
chordoma (TAEK-VAC given as monotherapy) or  
HER2-positive breast cancer (TAEK-VAC in combina-  
tion treatment with trastuzumab). Once safety of the  
combination treatment has been established in the  
second cohort, two further combination treatment  
cohorts will be opened for recruitment.  
Providing the body with as many tools as possible  
significantly increases its chances to eradicate the  
disease. This tactic includes: priming antigen-spe-  
cific T-cell activation; inducing T-cell expansion,  
migration and invasion into tumor sites; modifying  
tumor microenvironments to allow T-cell func-  
tion and killing; induction of natural killer cells to  
account for tumor cells that cannot be recognized by  
T-cells; and overcoming T-cell inhibitory (checkpoint)  
signals.  
 
Bavarian Nordic Annual Report 2022  
32  
Sustainability  
→ Protecting our tomorrow  
→ Climate-related financial disclosures  
→ ESG key figures  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
33  
Protecting our  
tomorrow  
Protecting lives is our core business, and 2022 was  
truly a year of proof of our ability to make an impact  
on public health, which was demonstrated by our  
efforts to secure access to our mpox vaccine glob-  
ally. With several pipeline candidates in late-stage  
development, which could potentially be approved  
in a few years, we aim to launch more vaccines that  
address significant unmet medical needs  
Our progress on sustainability  
is reported in our sustaina-  
bility report, which covers our  
reporting obligations cf. sections  
99a, 99b, and 107d of the Danish  
Financial Statements Act and  
Article 8 of the EU Taxonomy  
Regulation.  
In the endeavor, we remain aware of our responsi-  
bility to the global community beyond public health,  
and during 2022, we have continued to advance our  
efforts secure a sustainable and responsible busi-  
ness in the future. This commitment is reflected in a  
strengthened accountability for our actions, through  
the incorporation of relevant environmental, social  
and governance (ESG) targets into the remuneration  
principles for the Executive Management and the  
organization as a whole.  
→
Read our Sustainability Report  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
34  
Climate-related financial disclosures  
In 2022, we mapped our key risks and opportunities  
arising from climate change. We conducted our first  
scenario analysis based on the recommendations  
from the Task Force on Climate-Related Financial  
Disclosures (TCFD).  
Our assessment did not reveal significant financial  
or operational risks to our business in the short-  
to medium term. Going forward, we will assess  
climate-related risks and opportunities against the  
selected scenarios as part of our annual enterprise  
risk management process.  
Recommendation  
Our disclosure in brief  
The initial assessment, which we conducted in 2022, did not reveal any significant near-  
term risks or opportunities when testing against the selected climate-related scenarios.  
Going forward, the assessment will be integrated in our annual review of the business  
strategy and in our Enterprise Risk Management (ERM) process and resilience plans will  
be developed as needed.  
Strategy  
Disclose the actual and  
potential impacts of  
climate-related risks  
and opportunities on  
the organization’s  
businesses, strategy,  
and financial  
Specifically, we assessed climate-related risks and  
opportunities against two physical and two tran-  
sition scenarios under different timeframes, and  
current and planned actions to mitigate risks and  
leverage opportunities have been identified.  
The TCFD recommendations provide a framework  
for disclosure of the governance, strategy, risk  
management and metrics and targets used in the  
assessment of the company’s climate-related risks  
and opportunities. Our compliance with the recom-  
mendations is outlined in the table below.  
planning where such  
information is material.  
To integrate the identification and management of climate hazards and/or the risks posed  
by the transition to a low-carbon economy into our existing systems and processes,  
we have integrated climate assessments into our Enterprise Risk Management (ERM)  
process, which is coordinated by the Finance department and reported to the Finance Risk  
and Audit Committee. Each risk has a defined risk mitigation plan directed by relevant  
members of the senior leadership team.  
Risk Management  
Disclose how the  
organization identifies,  
assesses, and manages  
climate-related risks.  
Task Force on Climate-related Financial Disclosures (TCFD) reporting recommendations  
Recommendation  
Our disclosure in brief  
As with the general risk management, we have anchored the responsibility and oversight  
of environment, social and governance (ESG) issues with the Finance, Risk and Audit  
Committee in the Board of Directors. Our executive management is responsible for  
executing the sustainability strategy by setting targets and driving actions in their  
respective functions. Our ESG Committee, which is chaired by a member of executive  
management, comprises subject-matter experts from the organization who ensure that  
activities are aligned and communicated to stakeholders, externally as well as internally.  
To strengthen accountability for our actions, sustainability is linked to the performance-  
based remuneration throughout the company, including Executive Management.  
Governance  
Disclose the  
organization’s  
governance around  
climate-related risks  
and opportunities.  
Relevant climate-related metrics are disclosed in the table on the next page with further  
details available in our sustainability report.  
Metrics and Targets  
Disclose the metrics  
and targets used to  
assess and manage  
relevant climate-  
related risks and  
opportunities where  
such information is  
material.  
We have not yet set any targets. However, during 2022, we have established a baseline to  
enable goal setting for future reductions in energy and emissions.  
Read more in the Sustainability Report →  
Read more in the Sustainability Report →  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
35  
ESG key figures  
Unit  
2022  
2021  
2020  
2019  
2018  
Key figures for selected environmental  
Environmental data1  
social and governance areas are provided in  
accordance with the recommendations set  
out in “ESG key figures in the annual report”  
from the Danish Finance Society / CFA  
Society Denmark, FSR – Danish Auditors, and  
Nasdaq Copenhagen.  
CO2e, scope 1  
Metric tons  
1,765  
988  
1,422  
1,085  
1,381  
1,175  
909  
1,178  
964  
1,398  
CO2e, scope 2  
Metric tons  
Energy Consumption  
Water Consumption  
GJ  
m3  
53,325  
21,772  
42,577  
17,023  
45,110  
19,170  
34,137  
14,770  
32,527  
11,610  
Social data1  
Full-Time Workforce  
Gender Diversity2  
FTE  
874  
59  
55  
19  
8
734  
61  
56  
14  
7
607  
61  
56  
9
465  
N/A  
51  
421  
N/A  
50  
%
Gender Diversity, Management  
Employee Turnover Ratio  
Sickness Absence3  
%
%
10  
13  
For the sections regarding environmental and social data in the table  
below, the data has been subject to an independent auditor’s review  
in the form of limited assurance. The Independent Auditor’s Assurance  
Report can be found in our sustainability report.  
Days per FTE  
6
6
6
Governance data4  
Gender Diversity, Board  
Board Meeting Attendance Rate  
CEO Pay Ratio  
%
%
20  
99  
22  
29  
99  
16  
29  
97  
16  
29  
98  
15  
14  
97  
Times  
N/A  
1
Data derived from the Company’s sustainability reports 2018-2022.  
2
3
4
Data not collected before 2020  
Sickness absence does not include offices in the USA.  
Data derived from the Company’s annual reports 2018-2022, except for CEO pay ratio, which is presented in the 2022 remuneration report.  
 
Bavarian Nordic Annual Report 2022  
36  
Corporate  
information  
→ Corporate governance  
→ Risk management  
→ Shareholder information  
→ Board of Directors  
→ Executive Management  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
37  
Corporate governance  
Bavarian Nordic remains focused on good corporate governance, having  
implemented the recommendations from the Committee of Corporate  
Governance (Komitéen for god Selskabsledelse) for companies listed on the  
Nasdaq Copenhagen exchange.  
Management believes that the Company is operated  
in compliance with guidelines and recommenda-  
tions that support the Company’s business model  
and can create value for Bavarian Nordic’s stake-  
holders. Regularly and at least once a year, Manage-  
ment monitors adherence to the recommendations  
on corporate governance in order to ensure the  
best possible utilization of and compliance with the  
recommendations and legislation.  
The Board of Directors  
The Board is responsible for the overall strategic  
management and the financial and managerial  
supervision of Bavarian Nordic, as well as for regular  
evaluation of the work of the Corporate Manage-  
ment. In addition, the Board supervises the Company  
in a general sense and ensures that it is managed  
in an adequate manner and in accordance with  
applicable law and the Company’s articles of associ-  
ation. The Board discharges its duties in accordance  
with the rules of procedure of the Board, which are  
reviewed and updated by all members of the Board.  
At the beginning of 2022, the Board of Directors  
(“the Board”) consisted of eleven members: seven  
external members and four employee represent-  
atives. The external members are elected by the  
shareholders at the annual general meeting for  
terms of one year; retiring members are eligible  
for re-election. The Board elects a chair and deputy  
chair from among its members. The employee  
representatives are elected by the employees for  
a four-year term, which expires in 2025 for the  
currently elected employees.  
In accordance with Section 107 b of the Danish  
Financial Statements Act, Bavarian Nordic has  
published a statutory report on Corporate Govern-  
ance for the financial year 2022 on the Company’s  
website:  
Board committees  
Member of the Board since 2010, Erik G. Hansen  
did not seek re-election at the 2022 annual general  
meeting, and in August, Elizabeth McKee Anderson,  
member of the Board since 2017, resigned from her  
position due to conflicting interests as she assumed  
a similar role with the board of GSK. Both positions  
remained vacant during the year.  
To support the Board in its duties, the Board has  
established and appointed three subcommittees: a  
Finance, Risk and Audit Committee, a Nomination  
and Compensation Committee and a Science, Tech-  
nology and Investment Committee. The committees,  
which comprise only shareholder-elected members  
of the Board are charged with reviewing issues  
→
www.bavarian-nordic.com/corporategovernance  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
38  
pertaining to their respective fields that are due to  
be considered at board meetings. More information  
about the committees, including the terms of refer-  
ence which specify the tasks and responsibilities for  
each of the committees are available on the Compa-  
ny’s website:  
mittee’s work, accomplishments and composition.  
The Chair heads the annual evaluation, which is  
conducted at least every third year by an external  
consultant. The process, whether it is facilitated  
internally or by external consultants, evaluates  
topics such as board dynamics, board agenda,  
quality of the material that is submitted to the  
Board, discussions at the Board meetings, the chair’s  
leadership of the Board, strategy, Board composition  
and Board competencies. Typically, the process is  
further facilitated by each Board member filling out  
a detailed questionnaire, and the Board members  
are asked to score to which extent they agree to  
the individual questions. The results of the ques-  
tionnaire are then discussed at a subsequent Board  
meeting, and the individual comments submitted  
are used in the planning and handling of future  
Board meetings. The 2022 self-evaluation was  
facilitated by an external consultant and, in general,  
key conclusions were positive with a continued  
satisfaction with the Board’s work as well as the  
work in the committees. Organizational develop-  
ment and continued optimization of Board meeting  
planning and efficiency will continue to be a focus  
area in 2023.  
statutory report on Corporate Governance on the  
Company’s website:  
sents Executive Management and relevant business  
functions and who meets regularly to review and  
assess risks, training, and the levels of compliance.  
The Finance, Risk and Audit Committee receives  
regular updates from the Business Ethics Compliance  
Committee. In 2022, it was decided – in line with  
the Company’s growth – to appoint a global Chief  
Compliance Officer who, together with the Business  
Ethics Compliance Committee, has overall oversight  
of the Company’s global compliance program. At the  
same time, it was decided to appoint a US Compli-  
ance Officer to have specific oversight of the US  
compliance program.  
→
www.bavarian-nordic.com/corporategovernance  
Remuneration policy and report  
→
The remuneration of the Board and the Executive  
Management is governed by the remuneration  
policy which was updated in 2022 and subsequently  
approved by the shareholders at the annual general  
meeting on April 5, 2022.  
Board committees  
Diversity in the Board  
The Board of Directors currently has a representation  
of one female member elected by the shareholders.  
On 23 August 2022, the other female member  
elected by the shareholders at the annual general  
meeting in April 2022 resigned from the Board. The  
Board of Directors has since initiated a process to  
identify one or more new candidates for recommen-  
dation for election at the annual general meeting  
in March 2023 and the Board of Directors expects  
by then to adhere to the guidelines from the Danish  
Business Authority on equal gender distribution on  
the Board.  
In accordance with section 139 b in the Danish  
Companies Act, Bavarian Nordic has prepared a report  
on the remuneration of the individual members of  
the Board and Executive Management in 2022.  
Business ethics is prioritized on all levels in the  
organization, and all employees are trained annually  
in our Code of Conduct, which is also available to  
external stakeholders via our website. Violations of  
the Code of Conduct may be reported through the  
Ethics Hotline (whistleblower scheme), which is also  
accessible on our website. There were no reports in  
2022.  
→
Remuneration Policy  
→
Remuneration Report  
→
Business ethics  
Code of Conduct  
Evaluation of the Board  
The Board and its subcommittees conduct every  
year a self-evaluation of the Board's and subcom-  
To ensure corporate oversight of the Company’s  
global business ethics compliance risks, we have a  
Business Ethics Compliance Committee who repre-  
For more details on the work and composition of the  
Board and its committees, reference is made to the  
→
Ethics Hotline  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
39  
Data ethics policy  
The data ethics policy is  
based on 8 principles:  
1. Our Executive Management is dedicated to  
ensuring and maintaining a high standard of data  
ethics  
See all our policies on:  
Bavarian Nordic has a data ethics policy to ensure  
we maintain strong data ethics in our company.  
The data ethics policy is based on 8 principles and  
supplements our general procedures and policies for  
processing (personal) data.  
→
www.bavarian-nordic.com  
2. We ensure accountability for data processing  
In 2022, we have carried out initiatives to support  
the data ethics principles. We have implemented  
new procedures as well as improved existing  
procedures about how we use data. Further, a series  
of awareness training activities have been carried  
out for relevant stakeholders to make sure relevant  
stakeholders know how to use data in compliance  
with our data ethics policy.  
3. We require an appropriate level of data ethics for  
processing activities carried out by third parties  
4. We ensure that the processing activities carried  
out provide value to the data subjects, and are  
transparent and secure  
5. We train our employees and monitor processing  
activities  
We continue to actively work with supporting and  
implementing the data ethics principles into our  
way of doing business.  
6. We maintain an Ethics Hotline, where violations of  
data protection laws can be reported by internal  
and external stakeholders  
7. We identify and monitor the use of new technolo-  
gies for processing of data  
8. We carry out internal controls  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
40  
Risk management  
Bavarian Nordic’s business model spans the full value chain from  
research and development, over production to commercialization and  
rests on the ability to innovate and commercialize new vaccines. The  
business model covers partnership business, complex governmental  
sales and direct sales. By the nature of our business, we are exposed  
to a variety of risk along our value chain.  
Bavarian Nordic has a thorough risk management  
and mitigation process, whereby Bavarian Nordic is  
managing the risks through risk identification, risk  
monitoring and risk mitigation. The process is an  
integrated part of the Bavarian Nordic operational  
procedures and the management processes. The  
Finance, Risk and Audit Committee (FRAC) owns  
and overseas the risk management process and is  
closely monitoring the risks on a quarterly basis,  
including selected deep dives on specific risks. The  
Board of Directors receives regular risk updates from  
FRAC which is taken into consideration in the Board’s  
overall decisions about the company strategy.  
The formal process ensures both bottom-up and  
top-down identification and handling of risks. In  
this process key risks are first identified through a  
bottom-up process including description of the risks  
and mitigating actions taken to reduce either the  
likelihood of occurrence or the potential impact.  
Residual risk after agreed mitigating actions is  
further mitigated by insurance where this is relevant  
and possible. All risks have assigned risk owners,  
normally at the Executive level, and assigned  
risk-responsible employees who monitors and miti-  
gates the risks closely.  
The table below summarizes some of the key risks that are important to Bavarian Nordic’s  
business including examples of mitigating actions.  
Risk area  
Risks  
Mitigating actions  
Disruptions to Bavarian Nordic’s supply  
chain caused by breakdowns in facilities  
and/or manufacturing issues could have a  
significant impact on the ability to supply  
products at the right time and could impact  
both customer relations and financial  
performance.  
•
Update and maintain risk assessment for  
equipment and implement preventive  
maintenance where necessary  
Dual sourcing strategies to secure adequate  
inventory levels  
Manufacturing  
and Supply  
•
•
Ensure redundant equipment where  
possible  
•
•
Adequate inventory for all core components.  
Internal quality audits, including mock  
inspections.  
•
•
Shelf-life extension initiatives  
Disaster recovery plans and backup  
strategies.  
To be continued  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
41  
Risk area  
Risks  
Mitigating actions  
Risk area  
Risks  
Mitigating actions  
Disruptions, including hacking, malware, or  
other external attempts to disrupt Bavarian  
Nordic’s ability to operate, could have a  
significant impact on the Company’s IT  
infrastructure and systems, from inability to  
perform operationally to inability to perform  
commercial sales or perform R&D.  
•
Constantly having continuity plans updated;  
Incl. having updated internal processes for  
data recovery  
Internal procedures for security monitoring  
and vulnerability assessment.  
Plans for micro-segmentation to reduce the  
impact of attacks  
Training and awareness campaigns both  
inside the IT department and within the  
business.  
Externally performed maturity assessments  
test, incl. gap analysis and gap closure plan  
identification  
Involvement of third-party cyber security  
specialist to ensure a constant overview of  
threats and preventative measures available  
Perform annual security penetration tests  
and audits by a third party  
Bavarian Nordic is constantly developing and  
maturing processes and systems to support  
expansion and growth; in-efficient processes  
or systems could restrict BNs ability to scale  
up and deliver on the growth potential across  
products and markets  
•
•
•
Investment in internal Systems incl ERP and  
BI systems  
Constant standardization of processes and  
quality systems  
Employee training  
Cybersecurity  
Systems and  
Processes  
•
•
•
Bavarian Nordic is increasingly using Contract  
manufacturers (CMOs) and these vendors  
may be delayed or fail in delivering. Such  
delays will impact the Company’s ability to  
deliver and generate revenue or progress  
development as planned.  
•
•
Strong internal Sales and Operations  
planning and governance  
Failure to supply  
from vendors or  
subcontractors  
The impact could influence revenue or costs.  
Continuously demand planning for  
+24months across products and markets  
Adequate safety inventory for core products  
Quality control during technology transfer  
phase  
•
•
•
•
•
•
•
•
The delivery from such contract  
•
Close supply chain control and direct  
monitoring of key vendors  
manufacturers is dependent on the ability to  
transfer the technology used; such transfer  
may fail or be delayed which could cause  
delays to Bavarian Nordic’s delivery and  
revenue.  
Bavarian Nordic is strategically and  
Professional vendors selected for supporting  
the clinical trials; close and constant follow  
up from Bavarian Nordic  
Close dialogue with authorities (e.g., FDA  
and EMA) to secure optimal path to approval  
and compliance with GMP etc.  
Strong quality system in place to ensure  
compliance with standards agreed with and  
required by authorities.  
Use of adaptive trial designs to minimize  
financial risk and impact of failure.  
Communication with experts and regulators,  
to discuss regulatory strategy and  
Development  
of the future  
pipeline  
operationally focused on the development of  
two phase 3 studies which require significant  
internal resources, focus and funding.  
The development of products in the pipeline  
including clinical trials can be delayed or  
even abandoned. The product approval  
phase can be delayed or even fail.  
All clinical material and production facilities  
require regulatory approval; such approvals  
can be delayed or even fail.  
Bavarian Nordic is dependent on timely  
delivery of materials for production or R&D;  
supply chain challenges could delay or hinder  
BNs revenue or ability to pursue growth  
opportunities  
•
•
All steps in the above approval or clinical  
phases are associated with risks and can fail.  
development of recommendation  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
42  
Risk area  
Risks  
Mitigating actions  
Risk area  
Risks  
Mitigating actions  
Not complying with laws, incl anti-corruption  
laws, regulations or any other compliance  
requirements could damage the Company’s  
reputation, result in significant fines and  
impede the Company’s ability to operate.  
•
•
•
•
•
Follow and monitor the established internal  
compliance structure and governance.  
Internal and external legal resources  
available.  
Monitor development in relevant laws and  
regulations.  
Allocation of internal resources to secure  
adaptation of new rules and regulations.  
Constant monitoring by the Business Ethics  
Compliance Committee  
Partnering with other companies and  
government bodies in the industry is  
a central element of the Company’s  
strategy. Loss of partnerships, e.g., due  
to collaboration issues, failed projects or  
similar, could have a significant impact  
on the Company’s reputation and future  
performance.  
•
•
Frequent interactions with partners to build  
Laws,  
Regulations and  
Compliance  
Partnering  
and maintain common understanding.  
Processes in place to resolve potential  
issues.  
Increasing demands for transparency and  
progress on ESG coming from multiple stake-  
holders as investors, lawmakers, customers,  
partners and future talents. There is a risk of  
not living up to the changing and increasing  
standards that can impact the ability to  
attract funding, customers, suppliers or new  
employees  
Continuous follow, review and assess new  
and changing requirements and take actions  
accordingly  
Set and deliver on targets/selected ESG KPIs  
that demonstrate Bavarian Nordic’s commit-  
ment to drive sustainable business and  
deliver on ESG  
Not living up  
to external ESG  
requirements  
Bavarian Nordic is competing in markets  
where prices may be determined by the local  
supply/demand, including products from  
competitors that are significantly larger than  
Bavarian Nordic. If Bavarian Nordic cannot  
effectively compete in these markets, it will  
have an adverse impact on future revenue  
and profit. Pressure from local healthcare  
politics to reduce costs may impact Bavarian  
Nordic’s pricing or volume. Geopolitical or  
macroeconomic changes or health crises,  
e.g., pandemics, could impact demand,  
pricing and access to vaccinations.  
•
•
Secure an engaged and competent sales,  
marketing and medical affairs organization.  
Leverage focus rather than size vis-a-vis  
competition.  
Look for and leverage differentiation.  
Build strong relations through dedication  
and focus to achieve preferred supplier  
status.  
Commercializa-  
tion and  
Competition  
•
•
Develop systematic and efficient data struc-  
ture and platform  
Bavarian Nordic is dependent on the ability  
to attract and retain talents for many  
functions. In times of high competition  
for the right talents or adverse impact on  
Bavarian Nordic’s image, it could impact  
the Company’s ability to perform at high  
standards and compete against other  
companies.  
•
•
•
•
Perform employer branding  
•
Develop early-stage pipeline of new  
platforms and vaccines to stay competitive.  
Attraction  
Provide training and development.  
Offer competitive remuneration package.  
Identifying and develop key talents, incl  
talent programs  
and retention  
of talent and  
employees  
Competitors might develop product  
candidates with higher potential which  
could reduce the value of Bavarian Nordic’s  
pipeline and products.  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
43  
Risk area  
Risks  
Mitigating actions  
Risk area  
Risks  
Mitigating actions  
Significant fluctuations in the DKK/USD and  
other currencies which Bavarian Nordic is, or  
could be exposed to, could impact financial  
positions. Potential disputes with tax authori-  
ties could result in additional tax payments.  
•
•
Aim to create natural hedges by matching  
income and expenses in USD and EUR.  
Material net USD exposure is hedged using  
FX contracts or options. Material net EUR  
exposure can also be hedged using FX  
contracts.  
Frequent monitoring of planned cash flows  
in other currencies allows for hedging when  
the risk is identified.  
Taxes are paid where the Company oper-  
ates, and intercompany transactions are  
priced and governed by agreements in  
compliance with OECD’s transfer pricing  
guidelines.  
Proactive work with tax authorities to  
ensure alignment on tax situation and  
avoidance of negative surprises.  
Lack of funds could eventually make it  
difficult for the Company to pursue the  
strategy e.g. investments in development  
and manufacturing facilities.  
Some development projects require funding  
from third parties and if this is not available  
it can result in delays or even termination of  
the project.  
•
•
Ensure solid financial planning  
Optimize the timing of income from partner  
agreements.  
Maintain working capital at appropriate  
levels to free liquidity.  
Keep spending and investments at appro-  
priate levels to stretch the liquidity runway.  
Ensure constant knowledge about financing  
options available in the market.  
Secure access to bank financing if/when  
needed.  
Strong relations with key existing or poten-  
tial investors of development.  
For ABNCoV2 largely mitigated  
Currency  
exposure and  
tax disputes  
Lack of funding  
for general  
operations or  
development  
programs  
•
•
•
•
•
•
•
Currency risks  
and additional  
financial risks  
are further  
explained in  
note 23 in the  
consolidated  
financial  
specifically  
•
•
statements.  
•
The validity of patents is crucial for the  
company to secure future revenues  
and return on the investments made in  
development. Patents might be challenged  
by competitors.  
Dedicated and experienced resources  
involved in the filing of patent applications  
to minimize vulnerability to future invalidity  
actions, and with ability to defend patents if  
such actions are filed.  
Intellectual  
property rights  
(IP)  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
44  
Shareholder information  
Bavarian Nordic has been listed on the Nasdaq  
Copenhagen exchange since 1998 under the symbol  
BAVA. The Company is included in the OMXC25 index  
and the OMXC Large Cap index.  
warrants, see note 30 in the consolidated financial  
statements.  
Distribution of share capital  
Ownership  
8%  
64%  
At the end of 2022, Bavarian Nordic had approx-  
imately 112,000 registered shareholders owning  
92% of the outstanding shares. The remaining 8%  
were held by non-registered shareholders. Bavarian  
Nordic held 0.21% of the share capital as treasury  
shares, which have been repurchased to meet obli-  
gations under incentive schemes for the Company's  
Board and Executive Management. See note 30 in  
the consolidated financial statements.  
Non-registered  
Denmark  
For US investors, Bavarian Nordic has a sponsored  
Level 1 American depositary receipt (ADR) program  
with Deutsche Bank Trust Company Americas acting  
as the depositary bank. Three ADRs represent one  
Bavarian Nordic share and the ADR symbol is BVNRY.  
15%  
Europe  
Share capital  
The Company’s share capital was DKK 707,353,760  
by year-end 2022, comprising 70,735,376 shares with  
a nominal value of DKK 10 each. Each share carries  
one vote.  
The following shareholder had publicly informed  
Bavarian Nordic that they own five per cent or more  
of the Company’s shares:  
13%  
During the year, 266,983 new shares were issued as  
a consequence of warrant exercise by employees  
during the year, raising proceeds of DKK 38 million.  
North America  
ATP Group, Hillerød, Denmark, 10.12% as of  
December 31, 2022  
By December 31, 2022, there were 3,652,007  
Share price development  
outstanding warrants, which entitle warrant holders  
to subscribe for 3,652,007 shares of DKK 10 each.  
Thus, the fully diluted share capital amounted to  
DKK 743,873,830 at year-end, comprising 74,387,383  
shares. For further information about outstanding  
Bavarian Nordic’s shares closed the year at DKK  
213.40, corresponding to a 21% decrease over the  
year, compared to a decrease of 13% in the OMXC25  
index and a decrease of 11% in the Nasdaq Biotech-  
nology (NBI) index.  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
45  
The year-low was DKK 115.75 on May 9, 2022, and  
the year-high was DKK 401.70 on August 3, 2022  
– based on the daily closing prices of Bavarian  
Nordic’s shares. An unusually high price volatility  
could be observed in the international stock market  
in general and in the Bavarian Nordic share in  
particular. External factors like the war in Ukraine,  
high inflation and rapidly rising interest rates caused  
uncertainties in the market. For our share specifi-  
cally the mpox outbreak created an unprecedented  
awareness that had a significant spillover effect on  
the share price.  
Investor relations  
shareholder portal can be accessed via our investor  
relations website, along with financial reports,  
company announcements, investor presentations,  
and more. To register shares by name, shareholders  
must contact their custodian bank.  
Financial calendar 2023  
March 2, 2023  
Annual report  
Bavarian Nordic maintains an active dialogue with  
shareholders, analysts, prospective investors and  
other stakeholders by providing relevant, timely  
and correct communication about relevant stra-  
tegic, economic, financial, operational and scientific  
affairs of the Company. This work is carried out  
by Management and Investor Relations through  
frequent interactions with the investor community  
via participation in investor conferences, meetings  
and conference calls.  
March 30, 2023  
Annual General Meeting  
Visit our investor relations website:  
May 9, 2023  
Three-month interim report (Q1)  
→
www.bavarian-nordic.com/investor  
August 23, 2023  
Half-year interim report (Q2)  
Contact our investor relations team:  
Through our online shareholder portal, registered  
shareholders can request admission cards and/  
or vote by proxy for the general meetings. The  
At year-end Bavarian Nordic had a market capitaliza-  
tion of DKK 15 billion.  
→
November 16, 2023  
Nine-month interim report (Q3)  
Share price development compared to indices  
In connection with the publication of financial  
reports, Management will host a conference call to  
present the results followed by Q&A for investors  
and analysts. These events are being webcast live  
and on-demand through the Company’s website.  
Bavarian Nordic  
OMX Copenhagen C25  
NASDAQ BIOTECH  
150  
120  
90  
Additional information about the annual general  
meeting will become available on our website no  
later than 3 weeks before the event. Shareholders  
who have requested so will receive a notification via  
e-mail.  
60  
→
www.bavarian-nordic.com/agm  
30  
Jan ‘22 Feb ‘22 Mar ‘22 Apr ‘22 May ‘22 Jun ‘22  
Jul ‘22  
Aug ‘22 Sep ‘22 Oct ‘22 Nov ‘22 Dec ‘22  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
46  
Board of Directors  
Gerard van Odijk, MD, Chair  
Anders Gersel Pedersen,  
MD, PhD, Deputy chair  
Former Executive Vice President of Research and Devel-  
opment of H. Lundbeck A/S.  
Peter Kürstein, MBA  
Frank Verwiel, MD, MBA  
Independent advisor for the pharmaceutical industry  
and former president and chief executive officer of Teva  
Pharmaceuticals Europe B.V.  
Former president and chief executive officer and Chair  
of Radiometer Medical ApS.  
Former president and chief executive officer of Aptalis  
Pharma, Inc.  
Chair of the board of Ferrosan Medical Devices Holding  
A/S. Deputy chair of the board of FOSS A/S, Experimen-  
tarium, and American Chamber of Commerce. Member  
of the board of N. Foss & Co. A/S and Den Erhvervsdriv-  
ende Fond Gl. Strand, Dansk BørneAstma Center and Art  
2030. Member of the executive board of Mijamax ApS.  
Chair of the board of Intellia Therapeutics, Inc.  
Chair of the supervisory board of Hubrecht Organoid  
Technology. Member of the supervisory board of Centre  
for Human Drug Research.  
Member of the board of Genmab A/S, Hansa Biopharma  
AB and Bond Avillion 2, an entity of Avillion LLP. Chair of  
the board of Aelis Farma.  
Special competencies: Extensive strategic, operational  
and international experience within the pharmaceutical  
industry.  
Special competencies: Medical qualifications and  
extensive executive background within publicly traded  
and private companies in the international healthcare  
industry.  
Mr. Gersel is also the CEO of his private holding  
company Gerselconsult ApS.  
Special competencies: Extensive board and manage-  
ment experience from publicly traded, international  
healthcare companies.  
Special competencies: Scientific knowledge and large  
drug development experience within neuroscience and  
oncology. Extensive board and management experience  
from publicly traded, international pharmaceutical and  
biotech companies.  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
47  
Anne Louise Eberhard, MSc Law, and BSc  
Linette Munksgaard Andersen  
Manager, Customer Service,  
Shipping and Distribution  
Thomas Alex Bennekov  
Anja Gjøl  
Karen Merete Jensen  
Sr. App. and Integration Analyst  
Scientist.  
QA Specialist.  
Informatics and Management Accounting  
Former Senior Executive Vice President and Global Head  
of Corporate and Institutional Banking of Danske Bank  
A/S, and former Chief Commercial Officer at Intrum AB.  
Employee-elected.  
Employee-elected.  
Employee-elected.  
Employee-elected.  
Member of the board of FLSmidth & Co. A/S and its  
subsidiary FLSmidth A/S, Oterra A/S and group compa-  
nies, Knud Højgaards Fond, Den Danske Unicef Fond,  
and VL 52 ApS. Chair of the board of Finansiel Stabilitet  
SOV, Moneyflow Group A/S and its subsidiary Money-  
flow 1 A/S. Member of the executive board of EA Advice  
ApS. Faculty Member at Copenhagen Business School,  
Board Educations.  
Board  
Shares held in  
Year of birth Bavarian Nordic  
First elected  
Term expires  
Independent  
Nationality  
Gerard van Odijk, chair  
2008  
2010  
2012  
2016  
2019  
2021  
2021  
2021  
2021  
2023  
2023  
2023  
2023  
2023  
2025  
2025  
2025  
2025  
No1  
No1  
Yes  
Yes  
Yes  
No2  
No2  
No2  
No2  
Dutch  
Danish  
Danish  
Dutch  
1957  
1951  
1956  
1962  
1963  
1974  
1968  
1980  
1959  
28,433  
16,959  
19,222  
2,972  
1,371  
-
Anders Gersel Pedersen, deputy chair  
Peter Kürstein  
Special competencies: Extensive finance, risk manage-  
ment and ESG experience as well as board experience  
from publicly listed companies.  
Frank Verwiel  
Anne Louise Eberhard  
Danish  
Danish  
Danish  
Danish  
Danish  
Linette Munksgaard, employee-elected  
Thomas Bennekov, employee-elected  
Anja Gjøl, employee-elected  
Karen M. Jensen, employee-elected  
1,313  
-
139  
1
2
Gerard van Odijk and Anders Gersel Pedersen are not considered independent under the Danish corporate governance recommendations due to being a member of the board for more than 12 years.  
Employee-elected members are not considered independent under the Danish corporate governance recommendations  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
48  
Meeting Attendance  
Number of meetings attended by each board member out of the total number of meetings within the member’s term  
Finance, Risk, and Audit  
Nomination and  
Science, Technology, and  
Investment Committee  
Board of Directors  
(C)  
Committee  
Compensation Committee  
Gerard van Odijk  
(C)  
Peter Kürstein  
Elizabeth McKee Anderson1  
Anders Gersel Pedersen2  
Erik G. Hansen3  
(C)  
(DC)  
(C)  
Frank Verwiel4  
Anne Louise Eberhard5  
(C)  
Karen M. Jensen, employee-elected  
Anja Gjøl, employee-elected  
Thomas Bennekov, employee-elected  
Linette Munksgaard, employee-elected  
1 Elizabeth McKee Anderson left the Board in August 2022  
2 Anders G. Pedersen changed membership from the Nom.Com. Committee to the FRAC Committee in May 2022 and became Chair of the STI Committee in November 2022  
3 Erik G. Hansen left the Board in April 2022  
4 Frank Verwiel changed membership from the FRAC Committee to the STI Committee in June 2022  
5 Anne Louise Eberhard became member of the STI Committee in June 2022  
C: Chair, DC: Deputy chair  
Meeting attended  
Meeting not attended  
Not a Board member at the time  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
49  
Executive Management  
Paul Chaplin  
Henrik Juuel  
Jean-Christophe May  
President and Chief Executive Officer  
Executive Vice President, Chief Financial Officer  
Executive Vice President, Chief Commercial Officer  
Paul Chaplin, PhD is a British national, born in 1967.  
He joined Bavarian Nordic in 1999 as director of  
immunology. Prior to joining the Company, Mr.  
Chaplin worked for several years both in the UK and  
Australia developing vaccines against infectious  
diseases. He was appointed vice president in 2004,  
and president and chief executive officer in 2014.  
Henrik Juuel, MSc is a Danish national, born in 1965.  
He joined Bavarian Nordic in November 2018 from  
Orexo AB. Prior to Orexo Mr. Juuel has held senior  
positions at several large and diverse organizations  
including Group CFO of Virgin Mobile (Central and  
Eastern Europe), CFO of GN ReSound and NNE Phar-  
maplan, as well as several senior finance positions  
at Novo Nordisk  
Jean-Christophe (JC) May, PharmD, MBA is a French  
national, born in 1967. He joined Bavarian in 2020  
from GlaxoSmithKline (GSK), where he served as  
vice president and global vaccines commercializa-  
tion leader and was responsible for global strategic  
leadership and performance.  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
50  
Laurence De Moerlooze  
Anu Helena Kerns  
Russell Thirsk  
Executive Vice President, Chief Medical Officer  
Executive Vice President, People and Organization  
Executive Vice President, Chief Operating Officer  
Laurence De Moerlooze, PhD is a Belgian national,  
born in 1964. She joined Bavarian in 2020 from  
Takeda Vaccines, where she served as Vice President  
and Global Program Lead for vaccines against the  
Zika virus and Norovirus. Before Takeda she worked  
at GSK for more than 15 years, holding various  
leading roles in medical affairs and vaccine devel-  
opment.  
Anu Helena Kerns, MSc is a Danish national, born  
in 1972. She joined Bavarian Nordic in 2020 from  
Novo Nordisk, where she served for 11 years holding  
various leadership roles with increasing responsi-  
bilities, including 5 years abroad where she was  
responsible for establishing a new regional organi-  
zational structure and driving the HR development  
and communication strategy. Prior to Novo Nordisk,  
Ms. Kerns worked for 8 years in the financial sector  
with employer branding, reputation management,  
and change communication.  
Russell Thirsk, MSc is a British national, born in 1968.  
He joined Bavarian Nordic in April 2022 from GSK  
Vaccines in Belgium where he served as Head of  
Operations, a role he assumed after GSK acquired  
Novartis’ vaccine business, where he served for  
more than two decades, holding leadership roles of  
increasing responsibility in vaccine manufacturing  
operations across various geographies.  
 
Bavarian Nordic Annual Report 2022  
51  
Financial  
Review  
→ Financial review  
→ Sales performance  
→ Income statement  
→ Balance sheet  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
52  
Financial review  
The financial review is based on the Group’s consolidated  
financial information for the year ended December 31, 2022,  
with comparative 2021 figures for the Group in brackets. There  
is no significant difference in the development of the Group  
and the Parent Company (except if noted specifically below).  
In 2022, the Company generated revenues of DKK  
3,151 million (DKK 1,898 million) compared to the  
latest guidance of DKK 2,800 - 3,000 million. The  
improved revenue is largely resulting from the ship-  
ment of more mpox vaccines than anticipated in the  
latest guidance, which reflected some uncertainty  
related to the timing of deliveries and invoicing  
towards the end of 2022. Also, a continued strong  
performance in the rabies business has contributed  
to the improvement. The income before interest  
and taxes (EBIT) was a loss of DKK 71 million (loss of  
DKK 314 million) and EBITDA was an income of DKK  
328 million (income of DKK 75 million) compared to  
the latest guided loss in the interval DKK -200 to 0  
million. The higher sale combined with a general  
cost-conscious approach improved the operating  
result.  
Securities, cash, and cash equivalents as of  
December 31, 2022, amounted to DKK 2,845 million  
(DKK 3,717 million). The total amount includes a repo  
loan position of DKK 1,104 million (DKK 500 million);  
The net cash and cash equivalent position is hence  
DKK 1,741 (DKK 3,217 million) compared to a guid-  
ance of > DKK 1,700 million. The guidance assumed  
a bank debt level at year-end of DKK 600 million,  
however remaining bank debt was repaid during the  
fourth quarter and no new debt agreements were  
implemented.  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
53  
Sales performance  
Revenue 2022  
DKK million  
JYNNEOS/IMVAMUNE/IMVANEX  
Rabipur/RabAvert revenue amounted to DKK 879  
million (DKK 506 million) for the year. The 74%  
growth in revenue versus the prior year was driven  
by continued and significant market growth in the  
US and Germany. The US market grew by 32% versus  
the prior year and RabAvert now has a market share  
of approximately 69%, slightly above the level  
seen prior to competition facing a stockout situa-  
tion during late 2019 and the first half of 2020. The  
German market grew by 286%, however the market  
has not yet fully recovered from the COVID-19  
pandemic. Rabipur achieved a market share of 95%,  
slightly above the 2021 level.  
The majority of revenue (~80%) was derived from  
Historically, JYNNEOS/IMVAMUNE/IMVANEX has been  
sold to few governments as part of their biological  
preparedness against smallpox. However, the 2022  
global mpox outbreak created a significant, new  
demand for the vaccine, which is the only FDA- and  
EC-approved vaccine against mpox.  
Germany, where the TBE market saw strong growth  
in the second half of the year, resulting in an overall  
growth of 9% in 2022. Encepur sales however  
declined, due to a temporary stock-out situation  
during the second half of 2022, also resulting in a  
minor loss of the 2022 market share, which dropped  
to 28%.  
79  
164  
Third-party  
products  
Other income  
Revenue from the sale of JYNNEOS/IMVAMUNE/  
IMVANEX for the full year was DKK 1,730 million  
(DKK 734 million) and includes revenues from  
ongoing contracts with the US government as  
well as new contracts with various other govern-  
ments and organizations in response to the global  
monkeypox outbreak, which has driven the growth  
versus the prior year.  
299  
Third-party products  
Encepur  
Revenue from the sale of third-party products was  
DKK 79 million (DKK 0 million), which is related to  
the sale of DUKORAL and IXIARO (Valneva products  
assumed in the first quarter of 2022) and HEPLISAV-B  
(Dynavax product assumed in the second quarter of  
2022).  
Encepur  
The market for tick-borne encephalitis (TBE) vaccines  
has made a good recovery during 2022, although it  
remained below the pre-COVID-19 market.  
879  
Rabipur/  
RabAvert  
1,730  
JYNNEOS/  
IMVAMUNE/  
Rabipur/RabAvert  
Other revenue  
The rabies vaccine market showed strong signs of  
recovery, particularly in the US, our largest single  
market for post-exposure prophylaxis, which has  
been more resilient during COVID-19. The European  
market, which is a travelers’ vaccine market, still  
lags behind, although significant growth was seen  
in 2022.  
Other revenue totaled DKK 164 million (DKK 295  
million) and included an upfront milestone payment  
of DKK 83 million from our license and supply  
agreement with Nuance on our RSV vaccine, DKK 51  
million from contract work, and DKK 30 million from  
the sale of bulk drug substance for the Ebola vaccine  
to Janssen.  
Encepur revenue amounted to DKK 299 million (DKK  
363 million) for the year, i.e., a decrease of 18%  
versus the prior year.  
IMVANEX  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
54  
Revenues by quarter  
mDKK  
Q1 2022  
Q2 2022  
117  
Q3 2022  
578  
Q4 2022  
1,035  
190  
FY 2022  
1,730  
879  
FY 2021  
734  
YOY change  
135%  
JYNNEOS/IMVAMUNE/IMVANEX  
Rabipur/RabAvert  
Encepur  
-
117  
69  
234  
144  
38  
338  
506  
74%  
-18%  
N/A  
62  
24  
299  
363  
Third-party products  
Other revenue  
14  
11  
15  
79  
-
120  
320  
4
15  
26  
164  
295  
-44%  
66%  
Total  
537  
1,004  
1,290  
3,151  
1,898  
Rabipur/RabAvert sales by quarter  
Encepur sales by quarter  
mDKK  
mDKK  
80  
98  
Q1  
Q2  
Q3  
Q4  
Q1  
Q2  
Q3  
Q4  
117  
69  
127  
146  
144  
234  
160  
338  
71  
62  
138  
190  
47  
24  
2021  
2022  
2021  
2022  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
55  
Income statement  
Revenue  
In the Parent Company revenue was DKK 212 million  
lower than in the Group as sale of RabAvert in  
the US and Rabipur and Encepur in Switzerland is  
handled by the subsidiaries. The internal sale from  
the Parent Company to the subsidiaries is made  
under a commissionaire transfer pricing setup. The  
variance in revenue between Group and Parent  
Company is influenced by phasing of both external  
and internal sale. In 2021, the revenue in the Parent  
Company was DKK 40 million higher than the Group  
revenue due to inventory build-up at subsidiaries.  
three quarters of 2022. In 2021 other production  
costs were also impacted by limited absorption of  
indirect production costs due to the shutdown but  
also due to production of RSV Phase 3 clinical trial  
material, which contributed to a low commercial  
utilization of the manufacturing capacity.  
Revenue for the year was DKK 3,151 million (DKK  
1,898 million). The sale of JYNNEOS/IMVAMUNE/  
IMVANEX mpox/smallpox vaccine amounted to  
DKK 1,730 million – an increase of DKK 997 million  
compared to last year, where the majority was  
related to sale of bulk drug substance batches and  
liquid-frozen finished products to the U.S. Govern-  
ment (DKK 644 million). Sale of Rabipur/RabAvert  
increased by DKK 374 million and reached DKK 879  
million, whereas sale of Encepur decreased by DKK  
64 million and reached 299 million, partly due to a  
temporary stock-out situation in some markets. Sale  
of other products amounted to DKK 108 million (DKK  
260 million), primarily related to sale of third-party  
products of DKK 79 million, whereas the sale in 2021  
related to sale of Ebola vaccine to Janssen.  
3,151  
Revenue mDKK  
in 2022  
The product rights to Rabipur/RabAvert and Encepur  
are amortized over 20 years, on a straight-line basis,  
with an annual amortization of DKK 273 million and  
recognized as production costs.  
1,450  
Production costs mDKK  
in 2022  
Production costs  
Sales and distribution costs  
Production costs amounted to DKK 1,450 million  
(DKK 1,328 million). Costs related directly to revenue  
amounted to DKK 665 million (DKK 562 million) of  
which cost of goods sold totaled DKK 645 million  
(DKK 540 million).  
The sales and distribution costs amounted to DKK  
213 million (DKK 192 million) split between costs for  
distribution of products of DKK 37 million (DKK 16  
million) and costs for running the commercial organ-  
ization and activities of DKK 176 million (DKK 176  
million). The increase in distribution costs is closely  
linked to the higher sale of mpox vaccines.  
213  
Sales and distribution costs  
mDKK in 2022  
Revenue from ongoing contract work amounted to  
DKK 51 million (DKK 35 million) and included recog-  
nition of revenue of HPV milestone payment of DKK  
16 million, following Janssen’s termination of the  
development contract.  
Other production costs totaled DKK 512 million (DKK  
493 million) of which net write-downs of inventory  
amounted to DKK 36 million compared to DKK 172  
million in 2021. The bulk manufacturing facility was  
shut down for a year due to the expansion of the  
facility for future production of Rabipur/RabAvert  
and Encepur. The shutdown resulted in a limited  
absorption of indirect production costs for the first  
An upfront milestone payment of DKK 83 million  
was received under our license and supply agree-  
ment with our RSV partner Nuance.  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
56  
Research and development costs  
EBIT/EBITDA  
Financial expenses were DKK 339 million (DKK 189  
The total research and development spending were  
DKK 1,203 million (DKK 421 million). The amount  
included research and development spend for  
funded contract costs of DKK 20 million (DKK 22  
million). These costs are recognized as produc-  
tion costs in the income statement. The amount  
shown as research and development costs in the  
income statement totaled DKK 1,183 million (DKK  
399 million), see note 6. The increase compared to  
2021 was driven by initiation of the RSV Phase 3.  
Capitalized research and development costs incurred  
in 2022 related to ABNCoV2 development project  
amounted to DKK 593 million (DKK 130 million), split  
between development in progress (note 15) n (DKK  
108 million) and commercial scale-up activities at  
CMO recognized as prepayments (note 21) DKK 303  
million (DKK 22 million).  
Income before interest and tax (EBIT) was a loss of  
DKK 71 million (loss of DKK 314 million).  
million) and consisted of unwinding* of the discount  
related to deferred consideration, DKK 103 million  
(DKK 134 million), currency adjustments on deferred  
consideration DKK 11 million (DKK 2 million income),  
interest expense on debt of DKK 17 million (DKK 18  
million), negative fair value adjustments on securi-  
ties of DKK 190 million (net loss of DKK 39 million)  
and net loss on derivative financial instruments DKK  
18 million (DKK 0 million).  
1,203  
Research and Development  
spending mDKK in 2022  
EBITDA was an income of DKK 328 million (income  
of DKK 75 million). Amortization of product rights  
related to Rabipur/RabAvert and Encepur amounted  
to DKK 273 million (DKK 273 million) whereas depre-  
ciation and impairment losses on other fixed assets  
amounted to DKK 126 million (DKK 115 million).  
328  
EBITDA mDKK in 2022  
Financial income and financial expenses  
Financial income was DKK 79 million (DKK 49  
million) and consisted of adjustment of deferred  
consideration due to change in estimated timing  
of payments, DKK 54 million (DKK 32 million),  
interest income on securities of DKK 20 million  
(DKK 11 million), and a net foreign exchange gain  
of DKK 5 million (net gain of DKK 4 million). In 2021  
the interest on repo transactions amounted to an  
income of DKK 2 million due to negative interest  
rates. In 2022 the net interest on repo transactions  
were DKK 0 million due to increased interest rates  
during the year.  
The net value adjustment of deferred consideration  
was an expense of DKK 60 million (DKK 100 million),  
consisting of the three components described above.  
In the Parent financial statements, the financial  
income was DKK 113 million (DKK 81 million) and  
included interests on receivables from subsidiaries  
of DKK 30 million (DKK 23 million). The financial  
expenses were DKK 341 million (DKK 190 million).  
Administrative costs  
Administrative costs totaled DKK 376 million (DKK  
293 million), an increase of DKK 83 million compared  
to last year. The companywide increase in number  
of employees and activity level during 2022 has  
also resulted in an increased level of administrative  
costs.  
Income before company tax was a loss of DKK 332  
million (loss of DKK 454 million).  
*
The deferred consideration for product rights is measured at net  
present value and the difference between the net present value  
and the amounts due is recognized in the income statement as  
a financial expense over the period until expected payment date  
using the effective interest method.  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
57  
Tax on income for the year  
net securities and cash position amounted to DKK  
1,741 million (DKK 3,217 million). The Company also  
maintained unutilized credit lines of DKK 20 million  
(DKK 243 million) as of such date.  
RabAvert and Encepur technology transfer project,  
DKK 130 million (DKK 87 million), and capitalized  
costs related to the ABNCoV2 development asset,  
DKK 290 million (DKK 108 million). The net invest-  
ment in securities was a cash contribution of DKK  
674 million (net investment spend of DKK 1,779  
million).  
Tax on the income for the year was an expense  
of DKK 16 million (DKK 10 million) and related  
primarily to taxes paid in Bavarian Nordic GmbH  
and Bavarian Nordic Inc. The parent company had  
a net loss for the year of DKK 342 million (net loss  
of DKK 470 million), and a taxable income of DKK 0  
million reached by increasing the tax assets. Since  
further tax assets have been built up during the  
year and the two Phase 3 studies will continue in  
2023, Management assesses that the deferred tax  
asset should remain at DKK 0 million on the balance  
sheet. Following the tax position in the parent  
company the effective tax rate for the Group was  
negative by 4.8% (negative 2.3%). The Company  
retains the right to use the tax losses carried  
forward that was written down in prior years.  
575  
Cash and cash equivalents  
mDKK in 2022  
Cash flows  
Cash flow from operating activities totaled a net  
contribution of DKK 220 million (net spend of DKK  
359 million) following the positive EBITDA of DKK  
328 million (DKK 75 million). Net change in working  
capital was negative by DKK 149 million (negative  
by DKK 469 million) due to a higher level of trade  
receivables following the higher sale. The increase  
in inventories is partly offset by higher trade paya-  
bles as substantial purchases were made from Glax-  
oSmithKline towards the end of the year to support  
the production tech transfer activities.  
Cash flow from financing activities was a contri-  
bution of DKK 636 million (DKK 3,536 million), split  
between ABNCoV2 funding from Danish Ministry of  
Health DKK 400 million (DKK 160 million), increase  
in repo position DKK 604 million (DKK 500 million)  
and proceeds from warrant exercise DKK 38 million  
(DKK 107 million), partly offset by repayment of the  
European Investment Bank loan of DKK 372 million.  
During 2021 net proceeds of DKK 2.8 billion was  
raised through capital increases.  
22  
Cash flow from operating  
activities mDKK in 2022  
Net result  
Cash flow spend on investment activities totaled  
DKK 877 million (DKK 2,877 million) and included  
DKK 595 million (DKK 372 million) in milestone  
payments to GlaxoSmithKline and DKK 361 million  
(DKK 483 million) of investments in property, plant  
and equipment primarily related to the expansion  
of the drug substance facility for future production  
of Rabipur/RabAvert and Encepur. Investment in  
other intangible assets amounted to DKK 425 million  
(DKK 203 million) and included the ongoing Rabipur/  
The Group reported a net loss for the year of DKK  
347 million (net loss of DKK 465 million).  
The net cash flow for 2022 was negative by DKK 22  
million (positive by DKK 301 million).  
Liquidity and capital resources  
As of December 31, 2022, the Company had cash  
and cash equivalents of DKK 575 million (DKK 592  
million), held investments in securities of DKK 2,270  
million (DKK 3,125 million) and had a repo loan  
position of DKK 1,104 million (DKK 500 million). The  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
58  
Balance sheet  
The balance sheet total was DKK 12,391 million as of  
December 31, 2022 (DKK 12,089 million).  
from DKK 579 million to DKK 196 million. For further  
details regarding the capitalization see note 16.  
22 million) has been recognized as non-current  
prepayments. As part of the scale-up activity future  
commercial batches have been produced, totaling  
costs of DKK 132 million. Since the product is not  
yet approved, these costs have been recognized  
as current prepayments and will be reclassified to  
inventory once product approval is obtained.  
to GlaxoSmithKline during 2022. The adjustment of  
the net present value of the deferred consideration,  
both in terms of change in assumed timing of the  
future milestone payments and unwinding of the  
discount, amounted to DKK 53 million (DKK 100  
million).  
Assets  
Inventories stood at DKK 919 million (DKK 480  
million), of which the inventory of Rabipur/RabAvert  
and Encepur products amounted to DKK 578 million  
(DKK 305 million) as per December 31, 2022. The  
positive sale development for Rabipur/RabAvert  
has resulted in a reversal of write-down by DKK  
43 million. A write-down of DKK 78 million was  
recorded during 2022, primarily related to Encepur.  
Intangible assets stood at DKK 5,943 million (DKK  
5,804 million) with the main asset being the product  
rights to Rabipur/RabAvert and Encepur of DKK  
4,640 million (DKK 4,913 million). The product rights  
are amortized on a straight-line basis over their  
expected useful lives of 20 years with an annual  
amortization of DKK 273 million.  
The deferred consideration to GlaxoSmithKline does  
not include the sales milestone of EUR 25 million  
included in the asset purchase agreement with  
GlaxoSmithKline as the Company does not assess  
the sales milestone to be probable as of December  
31, 2022.  
As of December 31, 2022, cash and securities stood  
at DKK 2,845 million (DKK 3,717 million).  
Bavarian Nordic’s cash and cash equivalents are  
primarily invested in deposit accounts with highly  
rated banks and in short-term Danish government  
and mortgage bonds.  
Acquired rights and development in progress related  
to the development of ABNCoV2 stood at DKK 1,013  
million (DKK 734 million). The asset includes the  
upfront payment to AdaptVac of DKK 30 million,  
the net present value of probable future sales  
and development milestones DKK 596 million and  
capitalization of development costs for running  
the Phase 2 and Phase 3 study DKK 398 million. For  
further description of the asset and the accounting  
policy see note 15.  
Receivables stood at DKK 720 million (DKK 557  
million), of which trade receivables amounted to  
DKK 523 million (DKK 382 million) and prepayments  
amounted to DKK 154 million (DKK 109 million). The  
increase in trade receivables compared to year-end  
2021 relates to sale of mpox vaccines.  
Under the terms of the license and collaboration  
agreement concluded with AdaptVac in July 2020,  
the Company is committed to payment of potential  
future development and sales milestones and tiered  
royalties. Management assesses that the likeli-  
hood of future regulatory approval of the ABNVoC2  
vaccine is high, hence some of the milestone  
payments to AdaptVac are expected to become  
payable. The net present value of the probable mile-  
stone payments amounts to DKK 591 million (DKK  
596 million) and has been recognized as deferred  
consideration. The adjustment of the net present  
value of the deferred consideration, both in terms of  
change in assumed timing of the future milestone  
Equity  
After the transfer of the result for the year, equity  
stood at DKK 7,150 million (DKK 7,375 million).  
Scale-up activities to prepare for future produc-  
tion of drug substance for commercial launch of  
ABNCoV2 is taking place at the contract manufac-  
turing organization (CMO) which also produced the  
Phase 3 clinical trial material. Costs related to the  
scale-up activities are recognized as prepayments  
and will be recognized as inventory in concurrence  
with future purchase of products from the CMO.  
As of December 31, 2022, DKK 193 million (DKK  
Liabilities  
The present value of the future milestone payments  
to GlaxoSmithKline for the acquisition of the product  
rights has been recognized as deferred consider-  
ation. Deferred consideration amounted to DKK  
2,021 million (DKK 2,551 million), a decrease of DKK  
530 million compared to December 31, 2021. Two  
milestones with a total of DKK 595 million were paid  
Property, plant and equipment stood at DKK 1,684  
million (DKK 1,413 million). The expansion of the  
drug substance facility for future production of  
Rabipur/RabAvert and Encepur was completed end  
of 2022 and reduced the asset under construction  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
59  
payments and unwinding of the discount, amounted  
to DKK 5 million (DKK 0 million).  
Company has received the upfront payment of DKK  
80 million and milestone payments amounting  
to DKK 480 million. The funding has been recog-  
nized as prepayment and loan from Government.  
Management expects to receive the remaining two  
milestone payments in beginning of 2023. As per  
December 31, 2022, amortized costs amount to DKK  
6 million (DKK 511 thousand). See further description  
in note 25.  
At initial recognition of the deferred consideration a  
corresponding asset of DKK 596 million was recog-  
nized under the ABNCoV2 development project, see  
description above under ‘Assets’ and note 24.  
In August 2021, the Company entered a funding  
agreement with the Danish Ministry of Health to  
further advance the development of ABNCoV2. The  
agreement is valued at up to DKK 800 million and  
aims to support the completion of the development  
towards licensure of ABNCoV2 as a booster vaccine.  
As of December 31, 2022, debt to credit institutions  
amounted to DKK 1,123 million (DKK 893 million) and  
included a repo position of DKK 1,104 million (DKK  
500 million) and a mortgage loan of DKK 19 million  
(DKK 21 million). The European Investment Bank  
loan of DKK 372 million was repaid in October 2022  
Under the agreement, Bavarian Nordic is entitled to  
an upfront payment of DKK 80 million, in addition  
to payments of up to DKK 720 million, which are  
contingent upon reaching a number of predefined  
milestones. All payments are potentially subject to  
repayment, however only upon successful approval  
and achievement of a certain level of commercial  
success. Half of the repayments shall be paid by  
delivery of vaccines to the Danish Ministry of Health  
whereas the remaining part of the repayments can  
be settled in either royalty payments from the sale  
of the vaccine to other customers or by delivery  
of further vaccines. As per December 31, 2022, the  
 
Bavarian Nordic Annual Report 2022  
60  
Financial  
statements  
→ Consolidated financial statements  
→ Notes  
→ Financial statements of the parent company  
→ Notes  
→ Statement by management on the Annual Report  
→ Independent auditor’s reports  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
61  
Financial statements – Group  
Contents  
Financial statements  
Notes  
18. Inventories  
Consolidated income statements  
1. Significant accounting policies  
19. Trade receivables  
20. Other receivables  
21. Prepayments  
22. Other liabilities  
Consolidated statements of comprehensive income  
Consolidated statements of cash flow  
2. Significant accounting estimates and judgments  
3. Revenue  
Consolidated statements of financial position – Assets  
Consolidated statements of financial position – Equity and liabilities  
Consolidated statements of changes in equity  
4. Production costs  
5. Sales and distribution costs  
6. Research and development costs  
7. Adminstrative costs  
23. Financial risks and financial instruments  
24. Deferred consideration  
25. Prepayment and loan from Government  
26. Debt to credit institutions  
8. Staff costs  
9. Depreciation, amortization and impairment losses  
10. Fees to auditor appointed at the annual general meeting  
11. Financial income  
27. Lease liabilities  
28. Prepayment from customers  
29. Related party transactions  
12. Financial expenses  
30. Share-based payment  
13. Tax for the year  
31. Contingent liabilities and other contractual obligations  
32. Significant events after the balance sheet date  
33. Approval of the consolidated financial statements  
14. Earnings per share (EPS)  
15. Intangible assets  
16. Property, plant and equipment  
17. Right-of-use-assets  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
62  
Consolidated income statements  
Consolidated statements of comprehensive income  
For the years ended December 31, 2022 and 2021  
For the years ended December 31, 2022 and 2021  
DKK thousand  
Note  
2022  
2021  
DKK thousand  
Note  
2022  
2021  
Revenue  
3
3,150,793
1,449,531
1,701,262
1,897,875
1,327,560
570,315
Net result for the year  
(347,382)
(464,775)
Production costs  
Gross profit  
4,8,9  
Items that may subsequently be reclassified to the income statement:  
Exchange rate adjustments on translating foreign operations  
7,002
10,081
Sales and distribution costs  
Research and development costs  
Administrative costs  
5,8  
6,8,9  
212,932
1,183,092
376,023
191,783
399,159
292,920
883,862
Change in fair value of financial instruments entered into to  
hedge future cash flows  
33,245
(542)
Tax on other comprehensive income  
Other comprehensive income after tax  
Total comprehensive income  
13  
-
-
7,8,9,10  
Total operating costs  
1,772,047
40,247
9,539
Income before interest and tax (EBIT)  
(70,785
(313,547
(307,135
(455,236
Financial income  
11  
12  
78,537
339,363
50,233
191,116
Financial expenses  
Income before company tax  
(331,611)
(454,430)
Revenue  
DKK million  
EBITDA  
DKK million  
Tax on income for the year  
13  
15,771
10,345
Net result for the year  
(347,382)
(464,775)
Earnings per share (EPS) – DKK  
Basic earnings per share of DKK 10  
Diluted earnings per share of DKK 10  
2022  
2021  
3,151  
2022  
2021  
328  
75  
14  
14  
(4.9)
(4.9)
(7.4)
(7.4)
1,898  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
63  
Consolidated statements of cash flow  
For the years ended December 31, 2022 and 2021  
DKK thousand  
Note  
2022  
2021  
DKK thousand  
Note  
2022  
2021  
Net result for the year  
(347,382)
(464,775)
Investments in product rights  
Investments in other intangible assets  
Investments in property, plant and equipment  
Investments in financial assets  
Investments in securities  
15, 24  
15  
(594,920)
(425,411)
(361,244)
(169,460)
(371,849)
(203,475)
(483,127)
(39,041)
Adjustment for non-cash items:  
Financial income  
16  
11  
12  
(78,537)
339,363
15,771
(50,233)
191,116
10,345
Financial expenses  
(414,613) (2,115,796)
1,088,243 336,342
Tax on income for the year  
Depreciation, amortization and impairment  
Share-based payment  
Disposal of securities  
9
399,247
49,284
388,310
56,857
30  
Cash flow from investment activities  
(877,405) (2,876,946)
Changes in inventories  
Changes in receivables  
Changes in current liabilities  
(439,029)
(133,167)
423,407
41,039
(364,393)
(146,007)
Payment on loans  
26  
26  
27  
(374,339)
1,003,661
(21,981)
37,918
-
(2,173)
660,000
(19,507)
107,183
Proceeds from loans  
Repayment of lease liabilities  
Proceeds from warrant programs exercised  
Proceeds from capital increase  
Costs related to issue of new shares  
Purchase of treasury shares  
Cash flow from operations (operating activities)  
228,957
(337,741)
2,856,596
(57,438)
(8,581)
(111)
Received financial income  
Paid financial expenses  
Paid company taxes  
18,552
(24,244)
(3,212)
6,198
(24,383)
(2,574)
(9,328)
Cash flow from financing activities  
Cash flow of the year  
635,820 3,536,080
Cash flow from operating activities  
220,053
(358,500)
(21,532)
300,634
Cash and cash equivalents as of January 1  
591,820
5,119
285,487
5,699
Currency adjustments  
Cash and cash equivalents as of December 31  
575,407
591,820
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
64  
Consolidated statements of financial position – Assets  
December 31, 2022 and 2021  
DKK thousand  
Note  
2022  
2021  
DKK thousand  
Note  
2022  
2021  
Non-current assets  
Current assets  
Inventories  
Product rights  
4,639,895
1,013,484
14,768
4,912,830
733,770
18  
919,072
480,043
Acquired rights and development in progress  
Software  
Trade receivables  
Other receivables  
Prepayments  
19  
20  
21  
523,145
43,263
381,624
66,517
22,985
Intangible assets in progress  
Intangible assets  
274,490
134,371
153,934
720,342
108,840
556,981
15  
5,942,637
5,803,956
Receivables  
Land and buildings  
630,138
24,765
345,953
10,011
Securities  
23  
2,269,759
575,407
3,124,795
591,820
Leasehold improvements  
Cash and cash equivalents  
Securities, cash and cash equivalents  
Plant and machinery  
321,745
511,195
196,130
254,530
223,467
578,707
1,412,668
2,845,166
3,716,615
Fixtures and fittings, other plant and equipment  
Assets under construction  
Total current assets  
Total assets  
4,484,580
4,753,639
Property, plant and equipment  
16 1,683,973
12,391,246 12,089,269
Right-of-use assets  
17  
67,433
75,843
Other receivables  
Prepayments  
20  
21  
5,086
207,537
212,623
4,778
38,385
43,163
Financial assets  
Total non-current assets  
7,906,666
7,335,630
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
65  
Consolidated statements of financial position – Equity and liabilities  
December 31, 2022 and 2021  
DKK thousand  
Note  
2022  
2021  
Equity  
Share capital  
Treasury shares  
Retained earnings  
Other reserves  
707,354
(1,463)
704,684
(1,112)
6,300,575
143,521
6,588,908
82,187
Equity  
7,149,987
7,374,667
Liabilities  
Deferred consideration  
Prepayment and loan from Government  
Debt to credit institutions  
Lease liabilities  
24  
25  
26  
27  
2,324,657
566,420
17,008
2,569,090
160,511
18,896
45,834
57,547
Non-current liabilities  
2,953,919 2,806,044
Deferred consideration  
Debt to credit institutions  
Lease liabilities  
24  
26  
27  
28  
287,436
1,105,583
24,487
-
577,667
874,373
21,266
16,904
263,611
3,743
Prepayment from customers  
Trade payables  
605,928
6,337
Company tax  
Other liabilities  
22  
257,569
150,994
Current liabilities  
2,287,340 1,908,558
5,241,259 4,714,602
12,391,246 12,089,269
Total liabilities  
Total equity and liabilities  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic
Annual Report 2022  
66  
Consolidated statements of changes in equity  
December 31, 2022  
Reserves for  
Reserves  
for currency  
adjustment  
fair value  
Share  
capital  
Treasury  
shares  
Retained  
earnings  
of financial
Share-based  
instruments  
The share capital comprises a total of 70,735,376 shares  
of DKK 10 as of December 31, 2022 (70,468,393 shares).  
The shares are not divided into share classes, and each  
share carries one vote.  
Treasury shares  
In May 2022, the Board of Directors decided to launch  
a share buy-back program, under which the Company  
bought back 71,562 of its own shares (31,747 shares  
in 2021). The purpose of the share buy-back program  
was to meet the Company's obligations arising from  
the share-based incentive program for the Executive  
Management and the Board of Directors. Under the  
share-based incentive program, payment of half of the  
achieved bonus for 2021 for members of the Executive  
Management are converted to restricted stock units for  
a value corresponding to half of the achieved bonus.  
The restricted stock units will be released to the Exec-  
utive Management 3 years after grant. This to further  
increase the long-term shared interests between the  
Executive Management and the Company's share-  
holders. The Board of Directors is granted restricted  
stock units corresponding to 50% of the annual fee  
(excl. committee fee). The vesting period for those  
restricted stock units is also 3 years.  
Treasury shares represent 0.16% (0.18%) of the total  
share capital.  
For further information about share based payment see  
note 30.  
DKK thousand  
payment  
Equity  
Equity as of January 1, 2022  
704,684
(1,112)
6,588,908
(347,382)
-
(30,559
(1,351)
114,097
7,374,667
Comprehensive income for the year  
Net result for the year  
-
-
-
-
-
-
-
-
-
(347,382)
7,002
Other comprehensive income  
Exchange rate adjustments on translating foreign operations  
7,002
Change in fair value of financial instruments entered into  
to hedge future cash flows  
-
-
-
-
33,245
33,245
-
33,245
Total comprehensive income for the year  
-
-
(347,382)
7,002
-
(307,135
Transactions with owners  
Share-based payment  
-
-
-
46,145
17,898
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
53,976
53,976
Warrant programs exercised  
2,670
-
(10,897)
37,918
Warrant programs expired  
-
-
-
(17,898)
-
-
Capital increase through private placement  
Costs related to issue of new shares  
Purchase of treasury shares  
-
-
-
-
(111)
-
-
(111)
(9,328)
-
-
-
(716)
365
(351)
(8,612)
3,729
59,049
Transfer regarding restricted stock units  
Total transactions with owners  
(4,094)
21,087
2,670
82,455
Equity as of December 31, 2022  
707,354
(1,463)
6,300,575
(23,557)
31,894
135,184
7,149,987
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic
Annual Report 2022  
67  
Consolidated statements of changes in equity  
December 31, 2021  
Reserves for  
Reserves  
for currency  
adjustment  
fair value  
Share  
capital  
Treasury  
shares  
Retained  
earnings  
of financial
Share-based  
instruments  
The share capital comprises a total of 70,468,393 shares  
of DKK 10 as of December 31, 2021 (58,450,112 shares).  
The shares are not divided into share classes, and each  
share carries one vote.  
Rules on changing Articles of Association  
Changing the Articles of Association requires that the  
resolution passes by at least 2/3 of the votes as well as  
2/3 of the voting capital represented.  
DKK thousand  
payment  
Equity  
Equity as of January 1, 2021  
584,501
(1,077)
4,246,359
(464,775)
-
(40,640)
(809)
106,019
4,894,353
Comprehensive income for the year  
Net result for the year  
-
-
-
-
-
-
-
-
-
(464,775)
10,081
Other comprehensive income  
Exchange rate adjustments on translating foreign operations  
10,081
Change in fair value of financial instruments entered into  
to hedge future cash flows  
-
-
-
-
(542)
(542)
-
(542)
Total comprehensive income for the year  
-
-
(464,775)
10,081
-
(455,236
Transactions with owners  
Share-based payment  
-
-
-
126,729
695
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
38,584
(24,492)
(695)
-
38,584
107,183
-
Warrant programs exercised  
4,946
-
Warrant programs expired  
-
-
-
Capital increase through private placement  
Costs related to issue of new shares  
Purchase of treasury shares  
115,237
2,741,359
(57,438)
(8,263)
4,242
2,856,596
(57,438)
(8,580)
-
-
-
-
-
(317)
282
-
-
Transfer regarding restricted stock units  
Restricted stock units converted to cash bonus at exercise  
Total transactions with owners  
-
-
(4,524)
(795)
8,078
-
(795)
120,183
(35)
2,807,324
2,935,550
Equity as of December 31, 2021  
704,684
(1,112)
6,588,908
(30,559
(1,351)
114,097
7,374,667
Transactions on the share capital  
DKK thousand  
2022  
2021  
2020  
2019  
2018  
Share capital as of January 1  
Issue of new shares  
704,684  
2,670  
584,501  
120,183  
704,684  
323,891  
260,610  
584,501  
323,106  
785  
322,451  
655  
Share capital as of December 31  
707,354  
323,891  
323,106  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic
Annual Report 2022  
68  
Note 1  
Significant accounting policies  
Implementation of new and revised standards and  
interpretations  
Management has assessed the impact of new or  
amended and revised accounting standards and  
interpretations (IFRSs) issued by the IASB and IFRSs  
endorsed by the European Union effective on or after  
January 1, 2022. It is assessed that application of  
amendments effective from January 1, 2022 has not had  
a material impact on the consolidated
financial state-  
ments for 2022. Furthermore, Management does not  
anticipate any significant impact on future periods from  
the adoption of these amendments.  
The specific disclosures required by IFRS are provided  
in the Consolidated Financial Statements unless the  
information is considered immaterial to the users of the  
financial statements.  
Intra-group income and expenses together with all  
intra-group profits, receivables and payables are  
eliminated on consolidation. In the preparation of the  
consolidated financial statements, the book value of  
shares in subsidiaries held by the parent company is set  
off against the equity of the subsidiaries.  
Basis of preparation  
The consolidated financial statements for Bavarian  
Nordic have been prepared in accordance with the  
International Financial Reporting Standards (IFRS) as  
adopted by the EU and Danish disclosure requirements  
for the consolidated financial statements of listed  
companies. Danish disclosure requirements for the  
presentation of consolidated financial statements are  
imposed by the Statutory Order on Adoption of IFRS  
issued under the Danish Financial Statements Act.  
The accounting policies are unchanged from last year  
except for changes due to implementation of new and  
revised standards that were effective January 1, 2022.  
The consolidated financial statements are presented in  
Danish kroner (DKK), which is the functional currency of  
the parent company.  
The consolidated financial statements are presented on  
a historical cost basis, apart from derivative financial  
instruments, securities and liability relating to phantom  
shares, which are measured at fair value.  
The accounting policies have been consistently applied  
for the financial year and for the comparative figures  
except for implementation of new standards and  
amendments, see further below.  
In the narrative sections of the consolidated financial  
statements comparative figures for 2021 are shown in  
brackets.  
Accounting policies  
The accounting policies for specific line items are  
described in the notes to the financial statements. Set  
out below is a description of the accounting policies for  
the basis of consolidation, foreign currency translation  
and the cash flow statement.  
Foreign currency translation  
On initial recognition, transactions denominated in  
currencies other than the Group’s functional currency  
are translated at the exchange rate ruling at the trans-  
action date.  
Receivables, payables and other monetary items  
denominated in foreign currencies that have not been  
settled at the balance sheet date are translated at the  
exchange rates at the balance sheet date.  
Exchange differences between the exchange rate at  
the date of the transaction and the exchange rate at  
the date of payment or the balance sheet date, respec-  
tively, are recognized in the income statement under  
financials. Property, plant and equipment and intan-  
gible assets, inventories and other nonmonetary assets  
acquired in foreign currency and measured based on  
historical cost are translated at the exchange rates at  
the transaction date.  
On recognition in the consolidated financial state-  
ments of subsidiaries whose financial statements are  
presented in a functional currency other than Danish  
kroner (DKK), the income statements are translated at  
the average exchange rates of the respective months.  
Recognition and measurement  
Income is recognized in the income statement when  
generated. Assets and liabilities are recognized in  
the balance sheet when it is probable that any future  
economic benefit will flow to or from the Group and  
the value can be reliably measured. On initial recog-  
nition, assets and liabilities are measured at cost.  
Subsequently, assets and liabilities are measured as  
described in the description of the accounting policies  
in the respective notes to the financial statements.  
Standards and interpretations not yet in force  
At the date of publication of the consolidated financial  
statements, a number of new and amended standards  
and interpretations have not yet entered into force or  
have not yet been adopted by the EU. Therefore, they  
are not incorporated in the consolidated financial state-  
ments.  
None of the new or amended standards and interpre-  
tations are expected to have a material impact on the  
consolidated financial statements.  
Basis of consolidation  
The consolidated financial statements include Bavarian  
Nordic A/S and the subsidiaries in which the Group
holds more than 50% of the voting rights or otherwise  
has control.  
Applying materiality  
The consolidated financial statements are a result of  
processing large numbers of transactions and aggre-  
gating those transactions into classes according to their  
nature or function. The transactions are presented in  
classes of similar items in the consolidated financial  
statements. If a line item is not individually material, it  
is aggregated with other items of a similar nature in the  
consolidated financial statements or in the notes.  
Principles of consolidation  
The consolidated financial statements are prepared  
on the basis of the financial statements of the parent  
company and the individual subsidiaries, and these are  
prepared in accordance with the Group’s accounting  
policies and for the same accounting period.  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic
Annual Report 2022  
69  
Note 1  
Significant accounting policies (continued)  
Balance sheet items are translated at the exchange  
rates at the balance sheet date. Exchange differences  
arising on the translation of foreign subsidiaries’  
opening balance sheet items to the exchange rates at  
the balance sheet date and on the translation of the  
income statements from average exchange rates of the  
respective months to exchange rates at the balance  
sheet date are recognized as other comprehensive  
income.  
In the cash flows from operating activities, net profit for  
the year is adjusted for non-cash operating items and  
changes in working capital.  
Cash flows from investing activities include cash flows  
from the purchase and sale of intangible assets, prop-  
erty, plant and equipment, investments and securities.  
Cash flows from financing activities include cash flows  
from the raising and payment of loans and capital  
increases.  
Additionally, cash flows from assets held under finance  
leases are recognized by way of lease payments made.  
that are considered to match the content of those line  
items. For line items not considered to be covered by  
line items defined in the taxonomy, entity-specific  
extensions to the taxonomy have been incorporated.  
Except for subtotals, these extensions are anchored to  
standard elements of the ESEF taxonomy.  
Consistently with the requirements of the ESEF Regu-  
lation, the annual report approved by Management is  
comprised of a ZIP file bava-2022-12-31-en.zip, which  
includes an XHTML file that may be opened using  
standard web browsers, and a number of technical  
XBRL files enabling mechanical retrieval of the XBRL  
data incorporated.  
Segment reporting  
The Group does not prepare segment reporting inter-  
nally and therefore only reports one operating segment  
externally.  
Geographic spilt of revenue and revenue from major  
customers is disclosed in note 3 to the consolidated  
financial statements. Geographic location of noncurrent  
assets is disclosed in note 15 and 16 to the consolidated  
financial statements.  
Reporting under the ESEF Regulation  
The Commission Delegated Regulation (EU) 2019/815 on  
the European Single Electronic Format (ESEF Regulation)  
requires the use of a particular electronic reporting  
format for annual reports of listed companies in the  
EU. More specifically, the ESEF Regulation requires the  
annual report to be prepared in XHTML format with  
iXBRL tagging of the consolidated financial statements  
including notes.  
The Company’s iXBRL tagging has been made using the  
ESEF taxonomy disclosed in the annexes to the ESEF  
Regulation and developed based on the IFRS taxonomy  
published by the IFRS Foundation. The 2021 version of  
the ESEF taxonomy has been used in the annual report  
for 2022.  
The line items in the consolidated financial statements  
are XBRL-tagged to the elements of the ESEF taxonomy  
Net asset value per share:  
Equity  
Number of shares at year-end  
Share price/Net asset value per share:  
Market price per share  
Net asset value per share  
Equity share, %:  
Equity x 100  
Total assets  
Earnings per share and diluted earnings per share are  
calculated in accordance with IAS 33 “Earnings per  
share” and specified in note 14.  
Cash flow statement  
The cash flow statement is prepared in accordance with  
the indirect method on the basis of the Group’s net  
result for the year. The statement shows the Group’s  
cash flows broken down into operating, investing and  
financing activities, cash and cash equivalents at year  
end and the impact of the calculated cash flows on the  
Group’s cash and cash equivalents.  
Cash flows in foreign currencies are translated into  
Danish kroner (DKK) at the exchange rate on the trans-  
action date.  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic
Annual Report 2022  
70  
Note 2  
Significant accounting estimates and judgments  
Note 3  
Revenue  
Significant accounting estimates  
In the preparation of the consolidated financial state-  
ments, Management makes a number of accounting  
estimates, which form the basis for the presentation,  
recognition and measurement of the Group's assets and  
liabilities.  
The recognition and measurement of assets and liabil-  
ities often depend on future events that are somewhat  
uncertain. In that connection, it is necessary to assume  
a course of events that reflects Management’s assess-  
ment of the most probable course of events.  
The key accounting estimates identified are those that  
have a significant risk of resulting in a material adjust-  
ment to the measurement of assets and liabilities in  
Accounting policies  
Sale of goods  
Revenue from sale of goods is recognized when  
Bavarian Nordic has transferred control of products sold  
to the buyer and it is probable that Bavarian Nordic  
will collect the consideration to which it is entitled  
for transferring the products. Control of the products  
is transferred at a point in time, typically on delivery.  
The amount of sales to be recognized is based on the  
consideration Bavarian Nordic expects to receive in  
exchange for its goods. When sales are recognized,  
Bavarian Nordic also records estimates for a variety of  
sales deductions, including product returns as well as  
rebates and discounts to government agencies, whole-  
salers, health insurance companies, managed health-  
care organisations and retail customers. Revenue is  
measured net of value added tax, duties, etc. collected  
on behalf of a third party.  
Where contracts contain customer acceptance criteria,  
Bavarian Nordic recognizes sales when the acceptance  
criteria are satisfied.  
Where absolute amounts are known, the rebates are  
recognized as other liabilities. Wholesaler charge-backs  
are netted against trade receivable balances.  
The pricing mechanisms in the US market and the  
different kind of rebates are described below.  
the following reporting period. Management bases its  
estimates on historical experience and various other  
assumptions that are held to be reasonable under the  
circumstances. The estimates and underlying assump-  
tions are reviewed on an ongoing basis. If necessary,  
changes are recognised in the period in which the  
estimate is revised. Management considers the key  
accounting estimates to be reasonable and appropriate  
based on currently available information. The actual  
amounts may differ from the amounts estimated as  
more detailed information becomes available.  
Management has made the following accounting esti-  
mates which significantly affect the amounts recog-  
nized in the consolidated financial statements:  
customers in the US include private payers, Group  
Purchasing Organizations (GPOs) and government  
payers. GPOs play a role in negotiating price conces-  
sions with drug manufacturers for the commercial  
channels, and determine which drugs are offered as  
preferred options on their drug lists.  
US Medicaid & Medicare rebates  
Medicaid & Medicare are government insurance  
programmes. Medicaid and Medicare rebates have  
been estimated using a combination of historical expe-  
rience, product and population growth, price increases,  
and the impact of contracting strategies. The calcula-  
tion also involves interpretation of relevant regulations  
that are subject to changes in interpretative guidance  
from government authorities. Bavarian Nordic adjusts  
the provision periodically to reflect actual sales perfor-  
mance.  
Accounting policy  
Key accounting estimates and judgements  
Note  
Revenue  
Estimate of US sales deductions and provisions for sales rebates  
3
Intangible assets  
Estimate regarding impairment of assets; assessment whether future sales  
15  
and development milestones have become probably; assessment whether  
development costs should be expensed or capitalized  
Inventories  
Estimate of indirect production costs capitalized and inventory write-down  
18  
Wholesaler charge-backs  
Wholesaler charge-backs relate to contractual arrange-  
ments between Bavarian Nordic and indirect customers  
whereby products are sold at contract prices lower  
than the list price originally charged to wholesalers.  
A wholesaler charge-back represents the difference  
between the invoice price to the wholesaler and the  
indirect customer’s contract price. Accruals are calcu-  
lated for estimated charge-backs using a combination  
of factors such as historical experience, current whole-  
saler inventory levels, contract terms and the value of  
claims received but not yet processed.  
Pricing mechanisms in the US market  
In the US, sales rebates are paid in connection with  
government and commercial programmes. Key  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic
Annual Report 2022  
71  
Note 3  
Revenue (continued)  
Accounting policies (continued)  
Significant accounting estimates  
Provisions for sales deductions  
Sales discounts and rebates are predominantly issued  
in the US in connection with the US Federal and State  
Government Healthcare programs, namely Medicare  
and Medicaid, and commercial rebates.  
The estimate of sales discounts and rebates is based on  
a calculation which includes a combination of historical  
utilization data, combined with expectations in relation  
to the development in sales and utilization. Further-  
more, specific circumstances regarding the different  
programs are considered. The obligations concerning  
sales discounts and rebates are incurred at the time the  
sale is recorded. However, the actual discount or rebate  
related to a specific sale may be invoiced later.  
Bavarian Nordic considers the provisions established  
for sales discounts and rebates to be reasonable and  
appropriate based on currently available information.  
However, the actual amount of discounts and rebates  
may differ from the amounts estimated as more  
detailed information becomes available.  
Partner contracts  
Whether a component of a multiple element contract  
has value to the partner on a stand-alone basis is based  
on an assessment of specific facts and circumstances  
and is associated with judgement. This applies also to  
the assessment of whether a license transfers rights  
associated with ownership of an intangible asset.  
Furthermore, allocation of the total consideration of a  
contract to separately identifiable components requires  
considerable estimates and judgement to be made by  
Management.  
At inception and throughout the life of a contract  
Management is performing an analysis of the agree-  
ment with its partners based on available facts and  
circumstances at each assessment date such as histor-  
ical experience and knowledge from the market to the  
extent obtainable. This includes also an understanding  
of the purpose of the deliverables under the contract  
and the negotiation taken place prior to concluding the  
contract.  
Other discounts and sales returns  
Other discounts are provided to wholesalers, hospi-  
tals, pharmacies, etc. They are usually linked to sales  
volume or provided as cash discounts. Accruals are  
calculated based on historical data and recorded as a  
reduction in gross sales at the time the related sales  
are recorded. Sales returns are related to damaged or  
expired products.  
Agreements with commercial partners generally  
include non-refundable upfront license and collabora-  
tion fees, milestone payments, the receipt of which is  
dependent upon the achievement of certain clinical,  
regulatory or commercial milestones, as well as royal-  
ties on product sales of licensed products, if and when  
such product sales occur, and revenue from the supply  
of products. For these agreements that include multiple  
elements, total contract consideration is attributed to  
separately identifiable components on a reliable basis  
that reasonably reflects the selling prices that might be  
expected to be achieved in stand-alone transactions  
provided that each component has value to the partner  
on a stand-alone basis. The allocated consideration is  
recognized as revenue in accordance with the principles  
described above.  
Sale of services and licenses  
Furthermore, revenue comprises the fair value of the  
consideration received or receivable for income derived  
from development services where revenue is measured  
at the expected net sales price.  
Sales of licenses that transfer the rights associated with  
ownership of intellectual property are recognized at  
a point in time when control is transferred. Revenue  
from development services and licenses that do not  
transfer the right of ownership to intellectual property  
are recognized over time in line with the execution and  
delivery of the work.  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic
Annual Report 2022  
72  
Note 3  
Revenue (continued)  
Other product sale for 2022 consist of the following:  
•
Sale of Mvabea (Ebola vaccine) to Janssen.  
•
Sale of Dukoral and Ixiaro licensed from Valneva  
•
Sale of Heplisav-B licensed from Dynavax  
In 2022 revenue achieved on the Danish market  
amounted to DKK 19.3 million (DKK 0 million).  
In 2022 no customer represented more than 10% of  
total revenue.  
In 2021 the following customers represented more than  
10% of total revenue:  
•
Biomedical Advanced Research and Development  
Authority (BARDA), USA, DKK 675.3 million.  
•
Janssen Pharmaceutica NV, Belgium, DKK 260.2  
million.  
DKK thousand  
2022  
2021  
MVA-BN smallpox vaccine sale  
1,730,472  
733,593  
Rabipur/RabAvert  
879,341  
505,769  
Encepur  
298,736  
363,054  
Other product sale  
108,496  
260,225  
Sale of goods  
3,017,045 1,862,641  
Milestone payments  
83,048  
-
Contract work  
50,700  
35,234  
Sale of services  
133,748  
35,234  
Revenue  
3,150,793  
1,897,875  
Total revenue includes:  
Fair value adjustment concerning financial instruments entered into to hedge revenue  
-
(7,072)  
Geographic split of revenue:  
USA  
841,527  
1,066,800  
Germany  
650,208  
258,288  
Belgium  
335,399  
264,410  
France  
268,186  
26,088  
Canada  
197,283  
10,516  
United Kingdom  
169,203  
16,975  
Hong Kong  
115,599  
-
Saudi Arabia  
100,442  
-
Australia  
97,655  
2,504  
Switzerland  
70,986  
24,142  
Other geographic markets  
304,305  
228,152  
Revenue  
3,150,793  
1,897,875  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic
Annual Report 2022  
73  
Note 3  
Revenue (continued)  
Accounting for contract with Biomedical Advanced  
Research and Development Authority (BARDA)  
In April 2020, BARDA placed a new order for the manu-  
facturing and supply of JYNNEOS®, at a total value of  
USD 202 million. The contract expansion covered manu-  
facturing of 35 bulk drug substance (BDS) batches and  
the supply of up to 1.4 million doses of liquid-frozen  
JYNNEOS®. At year-end 2022 only 6 BDS batches remain  
to be manufactured and invoiced.  
In June and July 2022, BARDA ordered in total 5,500,000  
doses of liquid-frozen JYNNEOS®, for delivery in 2022  
and 2023.  
When BDS batches are invoiced to BARDA the BDS  
batches remain in the Company's physical possession  
until filling as final product. The filling takes place  
either at the Company's facility in Kvistgaard or at  
CMO's (a bill-and-hold arrangement). Revenue is recog-  
nized once the BDS are releasable according to contract  
with BARDA.  
Payment is due within 30 days after invoicing.  
of MVA-BN® RSV in China, which will be conducted  
separately from the Company’s own Phase 3 trial  
planned for initiation later in the first half of 2022 to  
support a U.S. Biologics License Application.  
Under the terms of the agreement, Bavarian Nordic has  
received an upfront payment of USD 12.5 million and  
is eligible to receive future milestone payments of up  
to USD 212.5 million that are triggered upon achieve-  
ment of certain clinical, regulatory, and commercial  
milestones, in addition to tiered, double-digit royalties  
on future net sales. The received upfront payment has  
been recognized as revenue. The future milestone  
payments will be recognized as revenue once the mile-  
stones are achieved.  
Nuance Pharma will assume all costs and responsibility  
for the clinical development, regulatory filings, and  
commercialization of the vaccine in territories covered  
by the agreement. Subject to Chinese regulatory  
authority (National Medical Products Administration,  
NMPA) approval, Phase 1 and Phase 3 trials are planned  
for the vaccine approval in China.  
Accounting for license and collaboration agree-  
ments with Nuance Pharma  
In March 2022, Bavarian Nordic entered into an  
exclusive license and supply agreement with Nuance  
Pharma, on the development and commercialization  
of MVA-BN® RSV against respiratory syncytial virus  
(RSV) in adults in Chinese Mainland, Hong Kong, Macau,  
Taiwan, South Korea and certain Southeast Asian  
countries. The agreement entails clinical development,  
including a Phase 3 trial to support regulatory approval  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic
Annual Report 2022  
74  
Note 4  
Production costs  
DKK thousand  
2022  
2021  
Cost of goods sold  
644,683  
539,789  
Contract costs  
19,889  
21,959  
Other production costs  
512,024  
492,877  
Amortization of product rights  
272,935  
272,935  
Production costs  
1,449,531  
1,327,560  
Note 5  
Sales and distribution costs  
Accounting policies  
Sales and distribution costs comprise costs incurred for  
the sale and distribution of products sold during the  
year. This includes costs incurred for sales campaigns,  
training and administration of the sales force and for  
direct distribution, marketing and promotion. Also  
included are salaries and other costs for the sales,  
distribution and marketing functions, loss allowance for  
expected credit losses, amortization, depreciation and  
other indirect costs.  
Other production costs amounted to DKK 512.0 million  
(DKK 492.9 million), of which net write-downs of inven-  
tory amounted to DKK 35.5 million compared to DKK  
171.6 million in 2021. Development in write-downs is  
further described in note 18.  
The bulk manufacturing facility has been shutdown for  
a year due to the expansion of the facility for future  
production of Rabipur/RabAvert and Encepur. The  
shutdown resulted in a limited absorption of indirect  
production costs for the first 3 quarters of 2022. In 2021  
other production costs were also impacted by limited  
absorption of indirect production costs due to the shut-  
down in fourth quarter but also due to production of  
RSV Phase 3 clinical trial material, which contributed  
to a low commercial utilization of the manufacturing  
capacity.  
The product rights to Rabipur/RabAvert and Encepur are  
amortized over 20 years with an annual amortization of  
DKK 272.9 million.  
Accounting policies  
Production costs consist of costs incurred in gener-  
ating the revenue for the year. Costs for raw materials,  
consumables, production staff and a proportion of  
production overheads, including maintenance, amorti-  
zation, depreciation and impairment of intangible and  
tangible assets used in production as well as operation,  
administration and management of the production  
facility are recognized as production costs. Amortization  
of acquired product rights are recognized as production  
costs. In addition, the costs related to excess capacity  
and write-down to net realisable value of goods on  
stock are recognized.  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic
Annual Report 2022  
75  
Note 6  
Research and development costs  
2022  
2021  
DKK thousand  
Research and development costs incurred this year  
1,202,981  
421,118  
Of which:  
Contract costs recognized as production costs (note 4)  
(19,889)  
(21,959)  
Research and development costs recognized in the income statement  
1,183,092  
399,159  
Note 7  
Adminstrative costs  
Accounting policies  
Administrative costs include costs of Group Manage-  
ment, staff functions, administrative personnel, office  
costs, rent, short-term lease payments and depreciation  
not relating specifically to production, research and  
development or sales and distribution.  
Fair value adjustment concerning financial instruments entered into to hedge research  
and development costs  
30,201  
-
Accounting policies  
Research and development costs include salaries and  
costs directly attributable to the Group’s research and  
development projects, less government grants. Further-  
more, salaries and costs supporting direct research and  
development, including costs of patents, rent, leasing  
and depreciation attributable to laboratories, and  
external scientific consultancy services, are recognized  
under research and development costs. No indirect or  
general overhead costs that are not directly attributable  
to research and development activities are included in  
the disclosure of research and development expenses  
recognized in the income statement.  
Research costs are expensed in the year they occur.  
Development costs are generally expensed in the year  
they occur. In line with industry custom, capitaliza-  
tion of development costs does not begin until it is  
deemed realistic that the product can be completed  
and marketed and it is highly likely that a marketing  
authorization will be received. In addition, there must  
be sufficient certainty that the future earnings to the  
Under the Group’s accounting policies development  
costs are generally expensed in the year they occur.  
During the development of ABNCoV2, the Group has,  
however, started capitalization of directly related  
development cost at commencement of the phase 2  
studies as – unlike most other development candidates  
- the feasibility of developing a final vaccine and obtain  
regulatory approval is considered likely, because the  
development of other COVID-19 vaccine candidates  
based on the same antigen has been successful.  
Furthermore, the Group has ensured significant finance  
of the development through the funding obtained from  
Danish Ministry of Health and a minimum demand  
agreed in the agreement with the Danish Ministry of  
Health. See further description in note 15.  
Research and development costs include expenses for  
external clinical research organizations, or CRO's, of DKK  
874.9 million (DKK 160.5 million).  
Group will cover not only production costs, direct distri-  
bution and administrative costs, but also the develop-  
ment costs.  
Contract research and development costs incurred to  
achieve revenue are included in "Research and devel-  
opment costs incurred this year" in the below tabel and  
then transferred under "Contract costs recognized as  
production costs" to be recognized as production costs.  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic
Annual Report 2022  
76  
Note 8  
Staff costs  
2022  
2021  
DKK thousand  
Wages and salaries  
664,791  
535,670  
Contribution based pension  
52,635  
44,114  
Social security expenses  
24,861  
21,431  
Other staff expenses  
48,373  
34,510  
Share-based payment, see specification in note 30  
49,284  
57,652  
Staff costs  
839,944  
693,377  
Staff expenses are distributed as follows:  
Production costs  
333,547  
259,719  
Sales and distribution costs  
89,304  
70,727  
Research and development costs  
198,838  
178,439  
Administrative costs  
168,259  
137,332  
Capitalized salaries  
49,996  
47,160  
Staff costs  
839,944  
693,377  
Average number of employees converted to full-time  
874  
734  
Number of employees as of December 31 converted to full-time  
975  
759  
The Group only has defined contribution plans and pays  
regular fixed contributions to independent pension  
funds and insurance companies.  
2022  
2021  
DKK thousand  
Staff costs include the following costs:  
Board of Directors:  
Remuneration  
5,475  
5,202  
Share-based payment  
1,750  
1,950  
Remuneration to Board of Directors  
7,225  
7,152  
Executive Management:  
Salary  
9,873  
8,661  
Paid bonus  
2,068  
3,956  
Other employee benefits  
692  
678  
Contribution based pension  
1,367  
2,048  
Share-based payment  
13,485  
9,035  
Corporate Management  
27,485  
24,378  
Salary  
11,527  
11,630  
Paid bonus  
2,947  
2,946  
Other employee benefits  
1,362  
1,237  
Contribution based pension  
1,472  
1,430  
Share-based payment  
8,756  
7,193  
Salary and benefits in notice period  
7,851  
7,378  
Other Executive Management  
33,915  
31,814  
Remuneration to Executive Management  
61,400  
56,192  
Total Management remuneration  
68,625  
63,344  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic
Annual Report 2022  
77  
Note 8  
Staff costs (continued)  
Note 9  
Depreciation, amortization and impairment losses  
2022  
2021  
DKK thousand  
Depreciation and amortization included in:  
Production costs  
352,554  
348,243  
Sales and distribution costs  
73  
34  
Research and development costs  
6,403  
4,718  
Administrative costs  
40,217  
34,697  
Depreciation and amortization  
399,247  
387,692  
Hereof loss from disposed fixed assets  
1,175  
5,259  
Impairment losses included in:  
Production costs  
-
618  
Impairment losses  
-
618  
CEO and President of the Company Paul Chaplin and CFO  
Henrik Juuel constitute the Corporate Management in  
the Parent Company.  
COO Russell Thirsk, CPO Anu Kerns, CCO JC May and CMO  
Laurence De Moerlooze constitute the Other Executive  
Management.  
Restricted stock units  
In March 2022 Corporate Management was granted  
12,682 restricted stock units (excl. matching shares)  
(8,833 restricted stock units) at a value of DKK 2.1 million  
(DKK 2.0 million) at grant. Other Executive Management  
was granted 9,896 restricted stock units (excl. matching  
shares) (7,580 restricted stock units) corresponding to  
a value of DKK 1.6 million (DKK 1.7 million) at grant. In  
April 2022 CEO Paul Chaplin was granted 17,109 restricted  
stock units (excl. matching shares) as a part of the reten-  
tion agreement at a value of DKK 2.7 million. In April  
2022 COO Russell Thirsk was granted 4,446 restricted  
stock units (excl. matching shares) as a sign-on bonus at  
a value of DKK 0.7 million.  
In April 2022, the members of the Board of Directors  
were granted in total 11,795 restricted stock units (7,127  
restricted stock units) corresponding to 50% of their  
fixed fee amounting to DKK 1.8 million (DKK 2.0 million).  
For further description of restricted stock units see note  
30.  
Warrants  
In December 2022 Corporate Management was granted  
126,487 warrants (137,030 warrants) with a fair value  
of DKK 9.9 million (DKK 10.4 million). Other Executive  
Management was granted 122,300 warrants (108,788  
warrants) with a fair value of DKK 9.6 million (DKK 8.3  
million).  
Fair value calculated based on Black-Scholes, cf. note 30.  
Incentive programs for the Executive Management and  
other employees are disclosed in note 30.  
Members of the Executive Management have contracts  
of employment containing standard terms for members  
of the Executive Management of Danish listed compa-  
nies, including the periods of notice that both parties  
are required to give and competition clauses. If a  
contract of employment of a member of the Executive  
Management is terminated by the Company without  
misconduct on the part of such member, the member of  
the Executive Management is entitled to compensation,  
which, depending on the circumstances, may amount to  
a maximum of 8-18 months' remuneration. In the event  
of a change of control the compensation can amount to  
24 months' remuneration.  
The product rights to Rabipur/RabAvert and Encepur are  
amortized over 20 years with an annual amortization  
of DKK 272.9 million. The amortization is recognized as  
part of cost of goods sold under production costs.  
The product rights was acquired from GlaxoSmithKline  
as per December 31, 2019. See further description in  
note 15.  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic
Annual Report 2022  
78  
Note 10  
Fees to auditor appointed at the annual general  
meeting  
2022  
2021  
DKK thousand  
Audit of financial statements  
2,208  
2,173  
Other assurance services  
176  
160  
Tax advisory  
501  
720  
Other services  
143  
213  
Fees  
3,028  
3,266  
The fee for non-audit services provided to the Group  
by Deloitte Statsautoriseret Revisionspartnerselskab,  
Denmark, amounted to DKK 0.3 million (DKK 0.6  
million) and consisted of assurance work related to  
the assistance with compliance reviews, and other  
accounting and tax advisory services.  
Note 11  
Financial income  
2022  
2021  
DKK thousand  
Financial income from bank and deposit contracts  
26  
1,739  
Interest income from financial assets measured at amortized cost  
26  
1,739  
Financial income from securities  
19,543  
11,045  
Adjustment of deferred consideration due to change in estimated timing of payments  
54,390  
32,185  
Currency adjustment deferred consideration  
-
1,677  
Net foreign exchange gains  
4,578  
3,587  
Financial income  
78,537  
50,233  
Accounting policies  
Interest income is recognized in the income statement  
at the amounts relating to the financial year. Financial  
income also includes net positive value adjustments of  
financial instruments and securities, adjustment of the  
net present value of provisions and net currency gains.  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic
Annual Report 2022  
79  
Note 12  
Financial expenses  
2022  
2021  
DKK thousand  
Interest expenses on debt  
16,640  
18,487  
Interest expenses on financial liabilities measured at amortized cost  
16,640  
18,487  
Fair value adjustments on securities  
190,301  
39,056  
Unwinding of the discount related to deferred consideration  
103,049  
133,573  
Currency adjustment deferred consideration  
11,597  
-
Net loss on derivative financial instruments at fair value through the income statement  
17,776  
-
Financial expenses  
339,363  
191,116  
Accounting policies  
Interest expenses are recognized in the income state-  
ment at the amounts relating to the financial year.  
Financial expenses also include adjustment of net  
present value of the deferred consideration, cf. note 24,  
negative value adjustments of financial instruments  
and securities and net currency losses.  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic
Annual Report 2022  
80  
Note 13  
Tax for the year  
2022  
2021  
DKK thousand  
Tax recognized in the income statement  
Current tax on profit for the year  
15,738  
8,923  
Adjustments to current tax for previous years  
33  
1,422  
Current tax  
15,771  
10,345  
Deferred tax  
-
-
Tax for the year recognized in the income statement  
15,771  
10,345  
Tax on income for the year is explained as follows:  
Income before company tax  
(331,611)  
(454,430)  
Calculated tax (22.0%) on income before company tax  
(72,954)  
(99,975)  
Tax effect on:  
Different tax percentage in foreign subsidiaries  
572  
168  
Non-recognized deferred tax asset on current year losses in foreign subsidiaries  
(1,953)  
32,072  
Income ()/expenses that are not taxable/deductible for tax purposes  
(4,443)  
2,249  
Special tax credit  
(46,946)  
(16,898)  
Change in unrealized intra-group profits  
(25,099)  
30,258  
Change in non-recognized tax asset  
166,561  
63,762  
Adjustments to previous years non-recognized tax asset  
-
(2,713)  
Adjustments to current tax for previous years  
33  
1,422  
Tax on income for the year  
15,771  
10,345  
Tax recognized in other comprehensive income  
Tax on change in fair value of financial instruments entered into to  
hedge future cash flows  
Tax recognized in equity  
Tax on share based payment  
Tax on income is an expense of DKK 15.8 million (DKK  
10.3 million), corresponding to an effective nega-  
tive tax rate of negative 4.8% (negative 2.3%). The  
parent company’s taxable income for 2022 is zero. Tax  
expensed in 2022 relates mainly to Bavarian Nordic  
GmbH and Bavarian Nordic, Inc.  
'Income()/expenses that are not taxable/deductible  
for tax purposes' primarily relates to the 30% step  
up deduction on research and development costs  
according to Section 8B of the Danish Tax Assessment  
Act.  
Deferred tax is measured using the balance sheet  
liability method on all temporary differences between  
accounting values and tax values. Deferred tax liabili-  
ties arising from temporary tax differences are recog-  
nized in the balance sheet as a liability.  
Deferred tax assets arising from temporary deductible  
differences and tax losses carried forward are recog-  
nized when it is probable that they can be realized by  
offsetting them against taxable temporary differences  
or future taxable profits. At each balance sheet date,  
it is assessed whether it is probable that there will be  
sufficient future taxable income for the deferred tax  
asset to be utilized.  
Deferred income tax is provided on temporary taxable  
differences arising on investments in subsidiaries,  
unless the parent company is able to control the timing  
when the deferred tax is to be realized and it is likely  
that the deferred tax will not be realized within the  
foreseeable future.  
Deferred tax is calculated at the tax rates applicable on  
the balance sheet date for the income years in which  
the tax asset is expected to be utilized.  
Accounting policies  
Income tax for the year comprises current tax and  
deferred tax for the year. The part relating to the profit  
for the year is recognized in the income statement, and  
the part attributable to items in the comprehensive  
income is recognized in the comprehensive income  
statement.  
The tax effect of costs that have been recognized  
directly in equity is recognized in equity under the rele-  
vant items.  
Current tax receivable is recognized in the balance  
sheet under current asset.  
Current tax payable is recognized in the balance sheet  
under current liabilities.  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic
Annual Report 2022  
81  
Note 13  
Tax for the year (continued)  
2021  
Recognized  
January 1, in
the income  
Recognized December
31,  
in the income  
31,  
DKK thousand  
2021  
statement  
in equity  
2021  
Product rights  
(94,360)  
83,939  
-
(10,421)  
Other intangible assets  
377  
(377)  
-
-
Property, plant and equipment  
38,342  
22,158  
-
60,500  
Right-of-use assets  
373  
(3)  
-
370  
Development projects for sale  
32,446  
-
-
32,446  
Accrued project costs  
(181)  
181  
-
-
Receivables  
18  
19  
-
37  
Provisions  
17,930  
(17,930)  
-
-
Financial instruments  
178  
-
119  
297  
Share-based payment  
15,397  
6,726  
5,871  
27,994  
Tax losses carried forward  
362,209  
(693)  
-
361,516  
Not recognized tax asset  
(372,729)  
(94,020)  
(5,990)  
(472,739)  
Recognized deferred tax assets  
-
-
-
-
2022  
Adjustment  
Recognized  
January 1,  
to previous
Recognized December
DKK thousand  
2022  
year  
statement  
in equity  
2022  
Product rights  
(10,421)  
-
73,302  
-
62,881  
Acquired rights and development  
in progress  
-
-
(2,659)  
-
(2,659)  
Property, plant and equipment  
60,500  
4,184  
23,440  
-
88,124  
Right-of-use assets  
370  
-
(83)  
-
287  
Development projects for sale  
32,446  
-
-
-
32,446  
Unrealized intra-group profits  
-
(46,364)  
25,099  
-
(21,265)  
Receivables  
37  
-
154  
-
191  
Financial instruments  
297  
-
-
(7,314)  
(7,017)  
Share-based payment  
27,994  
-
5,282  
(5,871)  
27,405  
Tax losses carried forward  
361,516  
66,843  
42,026  
-
470,385  
Not recognized tax asset  
(472,739)  
(24,663)  
(166,561)  
13,185  
(650,778)  
Recognized deferred tax assets  
-
-
-
-
-
Deferred tax  
Recognized deferred tax assets relate to temporary  
differences between the tax base and accounting  
carrying amount and tax losses carried forward.  
Deferred tax assets arising from temporary deductible  
differences and tax losses carried forward are recog-  
nized to the extent they are expected to be offset  
against future taxable income.  
Recognized tax losses carried forward relate to  
Bavarian Nordic A/S and the two Danish subsidiaries  
Aktieselskabet af 1. juni 2011 I and Aktieselskabet af 1.  
juni 2011 II.  
The tax value of non-recognized tax losses carried  
forward in Bavarian Nordic A/S and the two Danish  
subsidiaries amounts to DKK 470.4 million (DKK 361.5  
million), whereas the tax value of non-recognized  
temporary deductible differences amounts to DKK 180.4  
million (DKK 111.2 million). Tax rate used for Danish  
entities is 22%.  
The Company's right to use the tax losses carried  
forward is not time-limited.  
Change in non-recognized deferred tax asset also  
includes deferred tax on intercompany transactions  
between Bavarian Nordic A/S and Bavarian Nordic, Inc.  
and Bavarian Nordic Switzerland AG under the Distri-  
bution Agreements for sale of Encepur and Rabipur/  
RabAvert in US and Switzerland, DKK 25.1 million (DKK  
30.3 million).  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic
Annual Report 2022  
82  
Note 14  
Earnings per share (EPS)  
2022  
2021  
DKK thousand  
Net result for the year  
(347,382)  
(464,775)  
Earnings per share of DKK 10  
(4.9)  
(7.4)  
Diluted earnings per share of DKK 10  
(4.9)  
(7.4)  
The weighted average number of ordinary shares for the purpose of diluted earning  
per share reconciles to the weighted average number of ordinary shares used in the  
calculation of basic earnings per share as follows:  
Weighted average number of ordinary shares (thousand units)  
70,548  
63,213  
Weighted average number of treasury shares (thousand units)  
(129)  
(109)  
Weighted average number of outstanding ordinary shares used in the calculation  
of basic earnings per share (thousand units)  
70,419  
63,104  
Average dilutive effect of outstanding warrants under incentive schemes  
-
-
Weighted average number of outstanding ordinary shares used in the calculation  
of diluted earnings per share (thousand units)  
70,419  
63,104  
Outstanding warrants that may have an effect on the calculation of diluted earnings  
per share in the future.  
2022-programs  
1,013,923  
-
2021-program  
655,774  
706,469  
2020-programs  
1,142,109  
1,207,003  
2019-program  
599,493  
625,984  
2018-program  
240,708  
515,684  
2017-programs  
-
223,683  
2016-program  
-
77,661  
Outstanding warrants, cf. note 30  
3,652,007 3,356,484  
Accounting policies  
Earnings per share is calculated as the profit or loss  
for the year compared to the weighted average of the  
issued shares in the financial year. The basis for the  
calculation of diluted earnings per share is the weight-  
ed-average number of ordinary shares in the financial  
year adjusted for the dilutive effects of warrants.  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic
Annual Report 2022  
83  
Note 15  
Intangible assets  
Accounting policies  
Intangible assets are measured at historic cost less  
accumulated amortization and impairment losses. Cost  
of acquired product rights are measured at cash consid-  
eration and present value of any deferred payments  
for those rights. Furthermore costs of acquired product  
rights include transaction costs that are directly attribut-  
able to the acqusition.  
Internal development projects that meet the require-  
ments for recognition as intangible assets are measured  
at direct cost relating to the development projects.  
Amortization is provided on a straight-line basis over the  
useful economic lives of the assets.  
The useful lives of acquired product rights are estimated  
to be 20 years and software is estimated to be 3-5 years.  
Amortization of acquired product rights is recognized as  
part of cost of goods sold under production costs.  
Significant accounting estimates  
Product rights  
When determining the amortization period for  
acquired product rights, Management need to make  
an assessment of expected useful economic life. In the  
assessment Management take among other things the  
following components into consideration: The maturity  
of the products acquired, development in the market the  
acquired products are targeting, the current competitors,  
clinical development of new competing products and  
entry barriers to the market due to advanced production  
technology. Straight-line amortization reflects the use  
and impairment of the product rights.  
Management continuously updates the valuation  
model used when acquiring the product rights from  
GlaxoSmithKline to assess the value creation expected  
from the acquisition. The latest update of the valuation  
model shows a value above the net present value of the  
purchase price, hence there is no indications of impair-  
ment.  
As per December 31, 2022 Management still judge that  
the sales milestone of EUR 25 million included in Asset  
Purchase Agreement is not probable and therefore the  
present value has not been added to the cost of the  
product rights.  
Significant accounting judgments  
Management has made the following accounting judg-  
ment which significantly affect the amounts recognized  
in the consolidated financial statements:  
Phase 3 clinical trial in September 2022 and initial results  
are expected to be ready in mid-2023.  
In 2021 the Group ensured significant finance of the  
development through the funding obtained from the  
Danish Ministry of Health and a minimum demand  
agreed in the agreement with the Danish Ministry of  
Health.  
In the winter of 2022/2023, we have seen a high  
number of COVID-19 infections. It is evident though, that  
booster vaccinations have been necessary to control the  
pandemic. Management assesses that the booster vacci-  
nations will continue to be required, at least for vulner-  
able groups as is the case for example with the flu  
market, where annual booster vaccinations are given.  
Hence, with the development of ABNCoV2 as a universal  
booster vaccine with a better value proposition  
compared to the already approved vaccines, Manage-  
ment expects that the Company can take a reasonable  
share of the future COVID-19 vaccine market, initially  
targeting governments, but over time moving towards a  
more traditional market for private vaccinations.  
Acquired rights and development in progress  
Under the Group’s accounting policies and in accordance  
with common industry practice, development costs are  
generally expensed in the year they occur. During the  
development of ABNCoV2, the Group has, however,  
started capitalization of directly related development  
cost at commencement of the Phase 2 and 3 studies  
as – unlike most other development candidates - the  
feasibility of developing a final vaccine and obtain regu-  
latory approval is considered highly likely. The Phase 1  
and Phase 2 clinical trial showed positive results in 2021-  
22, further supported by positive six-month follow-up  
analysis for the Phase 2 clinical trial in October 2022.  
The follow-up analysis demonstrated that six months  
post the booster vaccination with ABNCoV2, the neutral-  
ization antibody titers against Wuhan and the Omicron  
variant remained high and at levels associated with a  
greater than 90% efficacy. The Group initiated the global  
Impairment  
The carrying amounts of intangible assets carried at cost  
or amortized cost are tested at least annually to deter-  
mine whether there are indications of any impairment  
in excess of that expressed in normal amortization. If  
that is the case, the asset is written down to the recov-  
erable amount, which is the higher of its fair value less  
costs to sell and its value in use. Impairment losses on  
intangible assets are recognized under the same line  
item as amortization of the assets.  
For development projects in progress, the recoverable  
amount is assessed annually, regardless of whether any  
indications of impairment have been found.  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic
Annual Report 2022  
84  
Note 15  
Intangible assets (continued)  
Product rights  
December 31, 2019 the Company acquired the product  
rights to two commercial products owned by Glax-  
oSmithKline - Rabipur/RabAvert and Encepur.  
The products have been on the market for more than  
20 years. There is no need to further develop the prod-  
ucts. Management assesses that it will require up to 10  
years of clinical development for competitors to bring  
a new competing product to the market likewise the  
production process required to produce these products  
is highly complex. Based on these factors Management  
assesses that the acquired product rights should be  
amortized over 20 years.  
The acquisition price for the two product rights consists  
of the upfront payment and the present value of the  
milestone payments included in the Asset Purchase  
Agreement with GlaxoSmithKline. The milestone  
payments relate to transfer and re-registration of  
marketing authorizations, technology transfer of  
different steps of the production and packaging activi-  
ties as well as a milestone payment when all services  
agreed to be rendered has been completed. The Asset  
Purchase Agreement specifies the above milestone  
payments for each product. In total EUR 470 million. The  
Asset Purchase Agreement also includes a sales mile-  
stone of EUR 25 million. The sales milestone is related  
to the total revenue of the two products. Manage-  
ment deems it unlikely that the sales milestone will  
be trickered, hence the sales milestone has not been  
recognized as part of the asset nor the deferred consid-  
eration as per December 31, 2021.  
2022  
Acquired  
Other  
rights and  
intangible  
Product development  
assets in  
DKK thousand  
rights  
in progress  
Software  
progress  
Total  
Costs as of January 1, 2022  
5,458,700  
733,770  
100,385  
134,371  
6,427,226  
Additions  
-
279,714  
3,006  
142,691  
425,411  
Transfer  
-
-
2,572  
(2,572)  
-
Exchange rate adjustments  
-
-
131  
-
131  
Cost as of December 31, 2022  
5,458,700  
1,013,484  
106,094  
274,490  
6,852,768  
Amortization as of January 1, 2022  
545,870  
-
77,400  
-
623,270  
Amortization  
272,935  
-
13,908  
-
286,843  
Exchange rate adjustments  
-
-
18  
-
18  
Amortization as of December 31, 2022  
818,805  
-
91,326  
-
910,131  
Carrying amount as of December 31, 2022  
4,639,895  
1,013,484  
14,768  
274,490  
5,942,637  
Geographical split of intangible assets – 2022  
Denmark  
5,941,664  
USA  
973  
Total intangible assets  
5,942,637  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic
Annual Report 2022  
85  
Note 15  
Intangible assets (continued)  
Deferred consideration for the acquired product rights  
are described in note 24.  
COVID-19 vaccine was high, hence milestone payments  
to AdaptVac were expected to become payable. Based  
on current regulatory plans and expectations for future  
revenue from sale of the COVID-vacine all sales mile-  
stones and part of the development milestones were  
assumed probable. At initial recognition in December  
2021 the net present value of the probable milestone  
payments was calculated amounting to DKK 596  
million, and was recognized as part of the "Acquired  
rights and development in progress". A corresponding  
liability was been recognized as deferred consideration  
(note 24).  
Acquired rights and development in progress  
In July 2020, the Company concluded a license and  
collaboration agreement with AdaptVac. The license  
agreement provides Bavarian Nordic the global  
commercialization rights to a COVID-19 vaccine candi-  
date based on AdaptVac’s technology. Under the terms  
of the agreement AdaptVac has been responsible for  
running a Phase 1/2 open label, dose-escalation trial  
sponsored by Radhould University Medical Center. The  
Company has assumed the responsibility for the further  
clinical development and manufacturing. At commence-  
ment of the positive Phase 2 trial the Company started  
capitalization of directly related development cost as  
the feasibility of developing a final vaccine and obtain  
regulatory approval is considered highly likely, see  
further description under "Significant accounting judge-  
ments".  
The Company made an upfront payment of EUR 4  
million to AdaptVac in 2020 when the license agree-  
ment was signed. The upfront payment was capitalized  
and recognized as "Acquired rights and development  
in progress". The Company has also committed to  
payment of potential future development and sales  
milestones and tiered royalties. At year-end 2020  
Management assessed that those milestone payments  
were not probable since no in-human studies had  
completed, hence milestone payments were not recog-  
nized as an asset and a liability as per December 31,  
2020. Based on the positive clinical results during 2021  
Management assessed at year-end 2021 that the like-  
lihood of future regulatory approval of the Company's  
Intangible assets in progress  
Rabipur/RabAvert and Encepur are currently manu-  
factured by GlaxoSmithKline and the basis of the  
technology transfer to Bavarian Nordic is an as-is  
transfer of the current manufacturing process. This  
transfer will be a staged process, starting with pack-  
aging then filling and ending with the transfer of bulk  
manufacturing. The Company will incur material costs  
in terms of internal labour and consultancy to handle  
the technology transfer and gain crucial knowledge  
about the manufacturing process. These costs will be  
capitalized as an intangible asset. As per December 31,  
2022 the capitalized costs amounts to DKK 255.3 million  
(DKK 125.2 million), recognized as intangible assets in  
progress.  
As part of the development plan for ABNCoV2 the filling  
process at Kvistgaard need to be scaled up to handle  
production for commercial launch. Cost related to the  
scale up activities are recognized as part of intangible  
assets in progress with an amount of DKK 14.2 million  
(DKK 3.6 million).  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic
Annual Report 2022  
86  
Note 15  
Intangible assets (continued)  
2021  
Acquired  
Other  
rights and  
intangible  
Product development  
assets in  
DKK thousand  
rights  
in progress  
Software  
progress  
Total  
Costs as of January 1, 2021  
5,458,700  
29,813  
87,587  
57,543  
5,633,643  
Additions  
-
703,957  
145  
96,160  
800,262  
Transfer  
-
-
18,921  
(18,921)  
-
Transfer to/from property, plant and equipment  
-
-
-
(559)  
(559)  
Disposals  
-
-
(6,280)  
-
(6,280)  
Exchange rate adjustments  
-
-
12  
148  
160  
Cost as of December 31, 2021  
5,458,700  
733,770  
100,385  
134,371  
6,427,226  
Amortization as of January 1, 2021  
272,935  
-
69,956  
-
342,891  
Amortization  
272,935  
-
13,681  
-
286,616  
Disposals  
-
-
(6,257)  
-
(6,257)  
Exchange rate adjustments  
-
-
20  
-
20  
Amortization as of December 31, 2021  
545,870  
-
77,400  
-
623,270  
Carrying amount as of December 31, 2021  
4,912,830  
733,770  
22,985  
134,371  
5,803,956  
Geographical split of intangible assets – 2021  
Denmark  
5,802,332  
Germany  
6
USA  
1,618  
Total intangible assets  
5,803,956  
Other intable assets in progress relates to IT invest-  
ments.  
Other intangible assets in progress include investments  
in software.  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic
Annual Report 2022  
87  
Note 16  
Property, plant and equipment  
Accounting policies  
Property, plant and equipment include land and build-  
ings, production equipment, leasehold improvements,  
office and IT equipment and laboratory equipment and  
is measured at cost less accumulated depreciation and  
impairment losses.  
Cost includes the costs directly attributable to the  
purchase of the asset, until the asset is ready for use.  
For assets constructed by the Group cost includes mate-  
rials, components, third-party suppliers and labour.  
Borrowing costs directly attributable to the construction  
of property, plant and equipment are included in cost.  
Other borrowing costs are recognized in the income  
statement.  
Depreciation is charged over the expected economic  
lives of the assets, and the depreciation methods,  
expected lives and residual values are reassessed indi-  
vidually for the assets at the end of each financial year.  
Assets are depreciated on a straightline basis over their  
estimated useful lives as follows:  
Buildings  
10–20 years  
Installations  
5–15 years  
Leasehold improvements  
5 years  
Office and IT equipment  
3–5 years  
Laboratory equipment  
5–10 years  
Production equipment  
3–15 years  
Management reviews the estimated useful lives of  
material property, plant and equipment at the end of  
each financial year.  
Impairment  
The carrying amounts of property, plant and equipment  
carried at cost or amortized cost are tested annually to  
determine whether there are indications of any impair-  
ment in excess of that expressed in normal deprecia-  
tion. If that is the case, the asset is written down to the  
recoverable amount, which is the higher of its fair value  
less costs to sell and its value in use. Impairment losses  
on property, plant and equipment are recognized under  
the same line item as depreciation of the assets.  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic
Annual Report 2022  
88  
Note 16  
Property, plant and equipment (continued)  
2022  
Other  
fixtures and  
fittings, other  
Land and  
Leasehold  
Plant and  
plant and  
Assets under  
DKK thousand  
buildings improvement  
machinery  
equipment  
construction  
Total  
Costs as of January 1, 2022  
546,771  
22,288  
424,291  
312,179  
578,707  
1,884,236  
Additions  
73,768  
6,147  
26,023  
146,421  
108,885  
361,244  
Transfer  
238,004  
11,802  
73,919  
167,745  
(491,470)  
-
Disposals  
-
-
(9,864)  
(428)  
-
(10,292)  
Exchange rate adjustments  
-
-
-
119  
8
127  
Cost as of December 31, 2022  
858,543  
40,237  
514,369  
626,036  
196,130  
2,235,315  
Depreciation and impairment losses as of January 1, 2022  
200,818  
12,277  
169,761  
88,712  
-
471,568  
Depreciation  
27,587  
3,196  
31,061  
26,360  
-
88,204  
Disposals  
-
-
(8,198)  
(301)  
-
(8,499)  
Exchange rate adjustments  
-
(1)  
-
70  
-
69  
Depreciation and impairment losses as of December 31, 2022  
228,405  
15,472  
192,624  
114,841  
-
551,342  
The expansion of the drug substance facility for future  
production of Rabipur/RabAvert and Encepur completed  
end of 2022.  
The Company has not incurred any borrowing costs  
directly attributable to the construction of the fill finish  
manufacturing facility, hence no borrowing costs have  
been capitalized.  
Mortgage loans of DKK 18.9 million are secured by  
mortgages totaling DKK 50.0 million on the property  
Bøgeskovvej 9/Hejreskovvej 10A, Kvistgaard. In addi-  
tion, as of December 31, 2022, mortgage deeds for a  
total of DKK 75.0 million have been issued. The carrying  
amount of assets mortgaged in security of mortgage  
loans is DKK 951.8 million (land and buildings: DKK  
630.1 million; plant and machinery: DKK 321.7 million).  
Carrying amount as of December 31, 2022  
630,138  
24,765  
321,745  
511,195  
196,130  
1,683,973  
Geographical split of property, plant and equipment – 2022  
Denmark  
1,626,673  
Germany  
56,564  
USA  
463  
Switzerland  
273  
Total property, plant and equipment  
1,683,973  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic
Annual Report 2022  
89  
Note 16  
Property, plant and equipment (continued)  
2021  
Other  
fixtures and  
fittings, other  
Land and  
Leasehold  
Plant and  
plant and  
Assets under  
DKK thousand  
buildings improvement  
machinery  
equipment  
construction  
Total  
Costs as of January 1, 2021  
548,291  
14,404  
485,024  
294,418  
213,309  
1,555,446  
Additions  
2,516  
597  
5,717  
11,871  
461,867  
482,568  
Transfer  
6,911  
7,811  
73,155  
9,148  
(97,025)  
-
Transfer from intangible assets  
-
-
-
-
559  
559  
Disposals  
(10,946)  
(518)  
(139,605)  
(3,369)  
-
(154,438)  
Exchange rate adjustments  
(1)  
(6)  
-
111  
(3)  
101  
Cost as of December 31, 2021  
546,771  
22,288  
424,291  
312,179  
578,707  
1,884,236  
Depreciation and impairment losses as of January 1,2021  
182,059  
10,691  
280,360  
71,180  
-
544,290  
Depreciation  
25,695  
2,104  
27,572  
20,420  
-
75,791  
Impairment losses  
-
-
278  
340  
-
618  
Disposals  
(6,936)  
(518)  
(138,449)  
(3,300)  
-
(149,203)  
Exchange rate adjustments  
-
-
-
72  
-
72  
Depreciation and impairment losses as of December 31, 2021  
200,818  
12,277  
169,761  
88,712  
-
471,568  
Assets under construction relates mainly the ongoing  
expansion of the drug substance facility for future  
production of Rabipur/RabAvert and Encepur (DKK 479  
million).  
The fill and finish manufacturing facility completed in  
2021 and the depreciation of the fill and finish building  
and equipment commenced.  
Mortgage loans of DKK 21.1 million are secured by  
mortgages totaling DKK 50.0 million on the property  
Bøgeskovvej 9/Hejreskovvej 10A, Kvistgaard. In addi-  
tion, as of December 31, 2021, mortgage deeds for a  
total of DKK 75.0 million have been issued. The carrying  
amount of assets mortgaged in security of mortgage  
loans is DKK 600.5 million (land and buildings: DKK  
346.0 million; plant and machinery: DKK 254.5 million).  
Carrying amount as of December 31, 2021  
345,953  
10,011  
254,530  
223,467  
578,707  
1,412,668  
Geographical split of property, plant and equipment – 2021  
Denmark  
1,369,996  
Germany  
41,775  
USA  
577  
Switzerland  
320  
Total property, plant and equipment  
1,412,668  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic
Annual Report 2022  
90  
Note 17  
Right-of-use-assets  
Accounting policies  
The right-of-use assets comprise the initial measure-  
ment of the corresponding lease liability. Right-of-use  
assets are subsequently measured at cost less accumu-  
lated depreciation and impairment losses.  
All operating leases with a lease term of more than 12  
months are recognized on the balance sheet as right-  
of-use-assets.  
For leases with a lease term of less than 12 months  
the lease payments are recognized as an operating  
expense on a straight-line basis over the term of the  
lease.  
The right-of-use-assets are measured at the present  
value of all future lease payments. When assessing the  
lease term, any extension or termination options are  
included in the assessment. The options are included  
in determining the lease term, if exercise is reason-  
ably certain. When determining the discount rates  
used to calculate the net present value of future lease  
payments, an incremental country specific borrowing  
rate is used, based on a government bond plus the  
Group’s credit margin, ranging from 2.5% to 3.0%. A  
single discount rate is used for a portfolio of lease  
assets with reasonable similar characteristics. Initial  
direct costs are not included in measurement of the  
right-of-use-assets. Non-lease components are not  
separated from lease components.  
2022  
Rent  
Car  
DKK thousand  
facility  
leasing Equipment  
Total  
Right-of-use assets as of January 1, 2022  
73,026  
1,742  
1,075  
75,843  
Additions  
917  
8,671  
-
9,588  
Modifications  
5,326  
986  
-
6,312  
Disposals  
(2,412)  
-
-
(2,412)  
Depreciations  
(19,475)  
(3,050)  
(500)  
(23,025)  
Reversal depreciations  
909  
-
-
909  
Exchange rate adjustments  
176  
43  
(1)  
218  
Right-of-use assets as of December 31, 2022  
58,467  
8,392  
574  
67,433  
2021  
Rent  
Car  
DKK thousand  
facility  
leasing Equipment  
Total  
Right-of-use assets as of January 1, 2021  
68,931  
2,312  
744  
71,987  
Additions  
-
902  
768  
1,670  
Modifications  
22,036  
(46)  
38  
22,028  
Depreciations  
(18,071)  
(1,480)  
(475)  
(20,026)  
Exchange rate adjustments  
130  
54  
-
184  
Right-of-use assets as of December 31, 2021  
73,026  
1,742  
1,075  
75,843  
Impact from change in lease terms, lease payments or  
modification of the lease contract is further described  
in note 27.  
Right-of-use assets are depreciated over the shorter  
period of lease term and useful life of the underlying  
asset. The depreciation starts at the commencement  
date of the lease. IAS 36 is applied to determine  
whether a right-of-use asset is impaired and any iden-  
tified impariment losses are accounted for as described  
in note 15.  
DKK thousand  
2022  
2021  
Amounts included in the income statement  
Interest expense leases  
1,888  
1,976  
Depreciation recognized on right-of-use assets  
23,025  
20,026  
Cost recognized for short term leases (less than 12 months)  
267  
427  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic
Annual Report 2022  
91  
Note 18  
Inventories  
2022  
2021  
DKK thousand  
Raw materials and supply materials  
206,211  
80,243  
Work in progress  
641,183  
79,904  
Manufactured goods and commodities  
234,097  
492,837  
Write-down on inventory  
(162,419)  
(172,941)  
Inventories  
919,072  
480,043  
Write-down on inventory as of January 1  
(172,941)  
(63,537)  
Write-down for the year  
(78,101)  
(171,643)  
Use of write-down  
46,031  
62,239  
Reversal of write-down  
42,592  
-
Write-down on inventory as of December 31  
(162,419)  
(172,941)  
Cost of goods sold amounts to, cf. note 4  
644,683  
539,789  
The inventory of Encepur and Rabipur/RabAvert prod-  
ucts amounted to DKK 577.9 million (DKK 305.4 million)  
as per December 31, 2022 incl. write-down.  
Write-down for the year amounted to DKK 78.1 million  
and mainly relates to Encepur products which have  
been challenged with delays at CMO's. The delays led  
to issues with seasonality and too low shelf life.  
Use of write-down in 2022 of DKK 46 million relates to  
scrap of old Encepur batches fully written down last  
year.  
Reversal of write-down of DKK 42.6 million mainly  
relates to Rabipur/RabAvert products since actual sales  
exceeded expected sales for the year.  
administration and management. The net realisable  
value is the estimated sales price in the ordinary course  
of business less relevant sales costs determined on the  
basis of marketability, obsolescence and changes in the  
expected sales price.  
Significant accounting estimates  
Production overheads are measured on the basis of  
actual costs. The basis of the actual costs is reassessed  
regularly to ensure that they are adjusted for changes  
in the utilization of production capacity, production  
changes and other relevant factors. Biological living  
material is used, and the measurements and assump-  
tions for the estimates made may be incomplete or  
inaccurate, and unexpected events or circumstances  
may occur, which may cause the actual outcomes to  
later deviate from these estimates. It may be necessary  
to change previous estimates as a result of changes in  
the assumptions on which the estimates were based  
or due to new information or subsequent events, for  
which certainty could not be achieved in the earlier  
estimates.  
Estimates that are material to the financial reporting  
are made in the determination of any impairment of  
inventories as a result of 'out-of-specification' products,  
expiry of products and sales risk.  
Accounting policies  
Inventories except for raw materials are measured  
at the lower of cost using the weighted average cost  
formula method less write-downs for obsolescence and  
net realisable value. Raw materials are measured at  
cost based on the FIFO method. For raw materials, cost  
is determined as direct acquisition costs incurred. The  
cost of finished goods produced in-house and work in  
progress includes raw materials, consumables, filling  
cost, QC testing and direct payroll costs plus indirect  
costs of production.  
Indirect costs of production include indirect materials  
and labour as well as maintenance of and depreciation  
on the machinery used in production processes, factory  
buildings and equipment used and cost of production  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic
Annual Report 2022  
92  
Note 19  
Trade receivables  
Credit risk  
Bavarian Nordic’s customers are predominantly public  
authorities and renowned wholesalers and therefore  
the credit risk is very low. There are overdue receiv-  
ables as of December 31, 2022 DKK 40 million (DKK 7  
million). As of December 31, 2022 a loss allowance of  
DKK 870 thousand (DKK 166 thousand) has been recog-  
nized.  
The Group has applied the simplified approach to  
measure the expected credit loss and a lifetime  
expected loss allowance for all trade receivables.The  
allowance is an estimate based on shared credit risk  
characteristics and the days past due. At the time of  
revenue recognition, Bavarian Nordic assesses the full  
lifetime expected credit losses. In addition, undue and  
due receivables are analyzed in an ongoing process.  
Based on the credit assessment, receivables analysis,  
historical experience and industry experience, it is  
estimated whether the receivables are recoverable  
or write-downs are needed. Bavarian Nordic monitor  
the credit exposure on all customers, both new and  
existing.  
The payment conditions for the customers, including  
credit periods and any payment of interest in case of  
non-payment, vary, but are always based on industry  
practice in the relevant market. The weighted average  
credit period is approximately 60 days for the sales of  
Encepur and Rabipur/RabAvert.  
The table details the risk profile for trade receivables.  
2022  
2021  
DKK thousand  
Trade receivables from smallpox vaccine sale  
329,897  
78,218  
Trade receivables from Encepur and Rabipur/RabAvert  
167,332  
162,546  
Trade receivables from other product sale  
-
137,731  
Trade receivables from contract work  
25,916  
3,129  
Trade receivables  
523,145  
381,624  
2022  
Gross  
Net  
carrying  
Loss  
carrying  
DKK thousand  
amount allowance  
amount  
Trade receivables  
Not past due date  
484,110  
-
484,110  
Overdue by 0-3 months  
39,435  
(823)  
38,612  
Overdue by 3-6 months  
470  
(47)  
423  
Trade receivables  
524,015  
(870)  
523,145  
2021  
Gross  
Net  
carrying  
Loss  
carrying  
DKK thousand  
amount allowance  
amount  
Trade receivables  
Not past due date  
374,583  
-
374,583  
Overdue by 0-3 months  
6,936  
(139)  
6,797  
Overdue by 0-3 months  
271  
(27)  
244  
Trade receivables  
381,790  
(166)  
381,624  
Accounting policies  
Receivables are measured at initial recognition at fair  
value and subsequently at amortized value usually  
equal to the nominal value, net of impairment based  
on expected credit losses.  
Write-downs are calculated using the ‘full lifetime  
expected credit losses’ method, whereby the likelihood  
of non-fulfilment throughout the lifetime of the finan-  
cial instrument is taken into consideration. A provision  
account is used for this purpose.  
Bavarian Nordic recognizes a loss allowance for  
expected credit losses and writes off trade receivables  
when there is information indicating that the debtor  
is in severe financial difficulty and there is no realistic  
prospect of recovery.
Subsequent recovery of amounts  
previously written down is credited against sales and  
distribution costs.  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic
Annual Report 2022  
93  
Note 20  
Other receivables  
2022  
2021  
DKK thousand  
Deposits  
5,086  
4,778  
Receivable VAT and duties  
-
55,973  
Derivative financial instruments at fair value  
31,894  
191  
Interest receivables  
11,369  
10,353  
Other receivables  
48,349  
71,295  
Classified as:  
Non-current assets  
5,086  
4,778  
Current assets  
43,263  
66,517  
Other receivables  
48,349  
71,295  
Note 21  
Prepayments  
2022  
2021  
DKK thousand  
Prepayments to CMO's  
351,322  
135,750  
Other prepayments  
10,149  
11,475  
Prepayments  
361,471  
147,225  
Classified as:  
Non-current assets  
207,537  
38,385  
Current assets  
153,934  
108,840  
Prepayments  
361,471  
147,225  
Scale-up activities to prepare for future production of  
drug substance for commercial launch of ABNCoV2 is  
taking place at the CMO who also produced the Phase  
3 clincial trial materials. Costs related to the scale-up  
activities are recognized as prepayments and will be  
recognized as inventory in concurrence with future  
purchase of products from the CMO. As per December  
31, 2022 DKK 192.6 million (DKK 21.8 million) has been  
recognized as non-current prepayments.  
As part of the scale-up activity future commercial  
batches have been produced. Since the ABNCoV2  
product is not yet approved the costs for this produc-  
tion, DKK 131.7 million, have been recognized as current  
prepayments. Will be reclassified to inventory once  
product approval is obtained.  
Part of the technology transfer of the production and  
packaging activities for Encepur and Rabipur/RabAvert  
takes place at CMO's (filing of Encepur, labelling and  
packing). Costs related to the technology transfer activ-  
ities are recognized as prepayments when costs incur  
and then recognized as inventory in concurrence with  
purchase of production services from the CMO's. As per  
December 31, 2022 DKK 14.9 million (DKK 16.6 million)  
has been recognized as non-current prepayments.  
Accounting policies  
Receivables are measured at initial recognition at fair  
value and subsequently at amortized value usually  
equal to the nominal value, net of impairment, to  
counter the loss after an individual assessment of risk  
of loss.  
Accounting policies  
Prepayments recognized under assets include costs  
paid in respect of subsequent financial years, including  
project costs incurred that relate to revenue of subse-  
quent years. Prepayments are measured at cost.  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic
Annual Report 2022  
94  
Note 22  
Other liabilities  
2022  
2021  
DKK thousand  
Financial instruments at fair value  
8,302  
1,351  
Liability relating to phantom shares  
11,102  
23,917  
Payable salaries, holiday accrual etc.  
107,952  
68,491  
Gross to net deduction accrual  
97,679  
37,134  
Other accrued costs  
22,319  
20,101  
Payable VAT and duties  
10,215  
-
Other liabilities  
257,569  
150,994  
Accounting policies  
Derivative financial instruments and liability relating  
to phantom shares are measured at fair value. For  
further details regarding measurement of fair value for  
phantom shares see note 30.  
Other financial liabilities are measured at initial  
recognition at fair value less any transaction costs.  
Subsequent other financial liabilities are measured at  
amortized cost using the effective interest method,  
whereby the difference between proceeds and the  
nominal value is recognized in the income statement  
as a financial expense over the period. Amortized cost  
usually equal to the nominal value.  
For a further description of financial instruments see  
note 23. The phantom share programs are described in  
note 30.  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic
Annual Report 2022  
95  
Note 23  
Financial risks and financial instruments  
2022  
2021  
DKK thousand  
Categories of financial instruments  
Trade receivables  
523,145  
381,624  
Other receivables  
16,455  
71,104  
Cash and cash equivalents  
575,407  
591,820  
Financial assets measured at amortized cost  
1,115,007 1,044,548  
Securities  
1,184,843  
2,626,261  
Transferred securities that are not derecognized  
1,084,916  
498,534  
Derivative financial instruments at fair value through the income statement  
(repo transactions)  
-
191  
Financial assets measured at fair value through the income statement  
2,269,759  
3,124,986  
Derivative financial instruments to hedge future cash flows (exchange rate)  
30,025  
-
Derivative financial instruments to hedge future cash flows (interest)  
1,869  
-
Financial assets used as hedging instruments  
31,894  
-
Deferred consideration  
2,612,093  
3,146,757  
Debt to credit institutions  
18,930  
393,269  
Security lending (repo transactions)  
1,103,661  
500,000  
Prepayment and loan from Government  
566,420  
160,511  
Lease liabilities  
70,321  
78,813  
Trade payables  
605,928  
263,611  
Other liabilities  
238,165  
125,726  
Financial liabilities measured at amortized cost  
5,215,518 4,668,687  
Derivative financial instruments at fair value through the income statement  
(repo transactions)  
8,302  
-
Liability relating to phantom shares  
11,102  
23,917  
Financial liabilities measured at fair value through the income statement  
19,404  
23,917  
Derivative financial instruments to hedge future cash flows (exchange rate)  
-
646  
Derivative financial instruments to hedge future cash flows (interest)  
-
705  
Financial liabilities used as hedging instruments  
-
1,351  
Accounting policies  
Derivative financial instruments  
On initial recognition, derivative financial instruments  
are measured at the fair value on the settlement date.  
Directly attributable costs related to the purchase  
or issuance of the individual financial instruments  
(transaction costs) are added to the fair value on initial  
recognition, unless the financial asset or the financial  
liability is measured at fair value with recognition of  
fair value adjustments in the income statement. Subse-  
quently, they are measured at fair value at the balance  
sheet date based on the official exchange rates, market  
interest rates and other market data such as volatility  
adjusted for the special characteristics of each instru-  
ment.  
Changes in the fair value of derivative financial instru-  
ments designated as and qualifying for recognition  
as effective hedges of future transactions (cash flow  
hedges) are recognized as comprehensive income.  
The ineffective portion is recognized immediately in  
the income statement. When the hedged transactions  
are realized, cumulative changes are recognized in the  
income statement together with the hedged transac-  
tion or in respect of a non-financial item as part of the  
cost of the transactions in question.  
For derivative financial instruments that do not qualify  
for hedge accounting, changes in fair value are recog-  
nized as financials in the income statement as they  
occur.  
The Company has designated certain derivative finan-  
cial instruments as cash flow hedges as defined under  
IFRS 9 "Financial Instruments". Hedge accounting is  
classified as a cash flow hedge when the hedges of  
a particular risk is associated with the cash flows of  
highly probable forecast transactions.  
Securities  
Securities consist of listed bonds, which are measured  
at fair value on initial recognition and as of the balance  
sheet date. The Group’s portfolio of securities is treated  
as "financial items at fair value through profit or loss",  
as the portfolio is accounted for and valued on the basis  
of the fair value in compliance with the Company's  
investment policy.  
Both realized and unrealized value adjustments are  
recognized in the income statement under financials.  
Policy for managing financial risks  
Through its operations, investments and financing the  
Group is exposed to fluctuations in exchange rates and  
interest rates. These risks are managed centrally in the  
Parent Company, which manages the Group´s liquidity.  
The Group pursues a treasury policy approved by the  
Board of Directors. The policy operates with a low risk  
profile, so that exchange rate risks, interest rate risks  
and credit risks arise only in commercial relations. The  
Group therefore does not undertake any active specula-  
tion in financial risk.  
The Group´s capital structure is regularly assessed by  
the Board of Directors relative to the Group´s cash flow  
position and cash flow budgets.  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic
Annual Report 2022  
96  
Note 23  
Financial risks and financial instruments (continued)  
Accounting policies (continued)  
Exchange rate risks on recognized financial assets and liabilities  
Cash  
and cash  
equivalents,  
Net  
DKK thousand  
securities Receivables  
Liabilities  
position  
2022  
EUR  
294,207  
355,193  
(3,156,284)  
(2,506,884)  
USD  
237,026  
148,254  
(156,497)  
228,783  
CHF  
2,175  
2,692  
(39,532)  
(34,665)  
2021  
EUR  
107,199  
193,837  
(3,416,438)  
(3,115,402)  
USD  
68,481  
205,224  
(319,201)  
(45,496)  
CHF  
2,216  
1,471  
(28,375)  
(24,688)  
Sensitivity analysis on exchange rates  
Likely change
Hypothetical Hypothetical  
in exchange  
change in  
change in  
rate  
equity  
net result  
DKK thousand  
2022  
Change if higher USD-rate than actual rate  
15%  
75,638  
56,962  
Change if higher EUR-rate than actual rate  
1%  
(22,207)  
(23,911)  
Change if higher CHF-rate than actual rate  
5%  
(583)  
(1,004)  
2021  
Change if higher USD-rate than actual rate  
15%  
34,724  
21,921  
Change if higher EUR-rate than actual rate  
1%  
(28,638)  
(30,165)  
Change if higher CHF-rate than actual rate  
5%  
140  
(235)  
Market risks  
The pharmaceutical market is characterized by the  
aim of authorities to reduce or cap healthcare costs  
in general. Market changes such as price reductions  
and launch of competing generic products may have a  
considerable impact on the earnings potential of phar-  
maceuticals. As a pharmaceutical production company  
Bavarian Nordic will be exposed to risks from instability  
in the supply chain, where lack of, or delays in, certain  
materials may impact the companys ability to deliver  
and hence the companys profitability. The Company is  
highly dependent on a stable IT environment and risks,  
incl. cyberattacks, may impact the profibaility of the  
Company.  
at maximum one year ahead. Regular assessments are  
made of whether the remaining net position should  
be hedged by currency forward contracts or currency  
option contracts.  
The exposure to EUR is not hedged as management  
believes that fluctuations in EUR are limited due to  
the Danish fixed-rate policy which is expected to be  
maintained. Thus the fluctuations in EUR do not have a  
significant impact on financial performance.  
The table shows the net effect it would have had on  
equity and profit for the year if the year-end exchange  
rates of USD, EUR and CHF had been 15%, 1% or 5%,  
respectively, higher than the actual exchange rates. A  
corresponding decrease in the actual exchange rates  
would have had an opposite (positive/negative) effect  
on net result and equity.  
Interest rate risk  
It is the Group's policy to hedge interest rate risks on  
loans whenever it is deemed that interest payments  
can be hedged at a satisfactory level relative to the  
related costs. Hedging will then consist of interest rate  
swaps that convert floating rate loans to fixed rate  
loans. Management determines the economic relation-  
ship between the hedged item and the hedging instru-  
ment to ensure a high hedge effectiveness. The interest  
rate risk involved in placing cash funds and investing in  
securities is managed on the basis of duration.  
Exchange rate risks  
The Group’s exchange rate exposure is primarily to USD  
and EUR. The exchange rate exposure to USD is hedged  
to the greatest possible extent by matching incoming  
and outgoing payments denominated in USD, looking  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic
Annual Report 2022  
97  
Note 23  
Financial risks and financial instruments (continued)  
Accounting policies (continued)  
Cash risks  
The Group´s bank deposits are placed in deposit  
accounts without restrictions. The Group's cash and  
cash equivalents totaled DKK 575.4 million as of  
December 31, 2022 (DKK 591.8 million).  
The Group's fixed rate bond portfolio expires as shown  
below. Amounts are stated excluding interest.  
Cash flow hedge – forward currency contracts  
Fair value  
Contract  
adjustment  
amount  
Fair value  
recognized in  
based on  
as of
other compre-  
DKK thousand  
Forward price  
agreed rates  
December 31 hensive income  
2022  
Forward currency contracts (USD/DKK)  
7.19 - 7.29  
543,454  
30,025  
30,671  
30,025  
30,671  
2021  
Forward currency contracts (USD/DKK)  
7,538  
(646)  
(646)  
(646)  
(646)  
Cash flow hedge – interest rate swap  
Fair value  
Contract  
adjustment  
amount  
Fair value  
recognized in  
based on  
as of
other compre-  
DKK thousand  
agreed rates  
December 31 hensive income  
2022  
Interest rate swap  
DKK – fixed rate 0.9625% p.a. (expiry 2031)  
19,192  
1,869  
2,574  
1,869  
2,574  
2021  
Interest rate swap  
DKK – fixed rate 0.9625% p.a. (expiry 2031)  
21,332  
(705)  
709  
(705)  
709  
Derivative financial instruments not designated as  
hedge accounting  
Currency forward contracts and currency option  
contracts which are not designated as hedge  
accounting are classified as financial assets/liabilities  
measured at fair value with value adjustments recog-  
nized through the income statement.  
There were no open currency contracts as of December  
31, 2022 or as per December 31, 2021 not designated as  
hedge accounting.  
Hedging of expected future cash flows  
The Company has concluded currency forward contracts  
of USD 75 million to hedge net cash position during  
2023.  
In 2016 the Company refinanced the old mortgage loans  
(fixed rate) and obtained a new mortgage loan with  
floating rate. The Company also concluded an interest  
rate swap to convert the floating rate loan to a fixed  
rate loan. The interest rate swap has the same maturity  
date and nominal amount as the mortgage loan to  
secure high effectiveness of the hedge.  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic
Annual Report 2022  
98  
Note 23  
Financial risks and financial instruments (continued)  
2022  
2021  
Fair value as of  
Effective Fair
value as of  
Effective  
DKK thousand  
December 31  
interest  
December 31  
interest  
Bond portfolio  
Within 0-2 years  
1,226,652  
3.4%  
1,201,688  
-0.5%  
Within 3-5 years  
492,898  
3.5%  
1,118,304  
-0.1%  
After 5 years  
550,208  
3.7%  
804,803  
1.0%  
Total  
2,269,758  
3.5%  
3,124,795  
0.0%  
Fluctuations in interest rate levels affect the Group's  
bond portfolio. An change in the interest rate level by  
1 percentage point relative to the interest rate level on  
the balance sheet date would have had an impact of  
DKK 73.3 million on the Group´s net result and equity  
(DKK 46.9 million).  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic
Annual Report 2022  
99  
Note 23  
Financial risks and financial instruments (continued)  
With respect to the Group´s debt to credit institutions, a  
change in the applicable interest rate by 1 percentage  
point would have had an impact on the Group's net  
result and equity of DKK 0.2 million (DKK 4.0 million).  
The European Investment Bank loan obtained in 2017  
was fully repaid in October 2022 (DKK 372.2 million).  
During 2022 the Company entered into further repo  
loan contracts (security lending) and increased the  
position to DKK 1,104 million (DKK 500 million). Further  
described below.  
Debt to credit institutions also include a mortgage loan  
of DKK 18.9 million (DKK 21.1 million), further described  
in note 26.  
The Group has a credit facility of DKK 20 million (DKK  
20 million) at Nordea. As of December 31, 2022, DKK 0.2  
million (DKK 0.2 million) of the credit facility is utilized  
for bank guarantees.  
sand (DKK 166 thousand) has been recognized as of  
December 31, 2022, cf. note 19.  
To manage credit risk regarding financial counterpar-  
ties, Bavarian Nordic only enters into derivative finan-  
cial contracts and money market deposits with financial  
counterparties possessing a satisfactory long-term  
credit rating from at least two out of the three selected  
ratings agencies: Standard and Poor’s, Moody’s and  
Fitch.  
Cash and cash equivalents are not deemed to be  
subject to any special credit risk as they are deposited  
with Nordea. The bond portfolio is invested in either  
Danish government bonds, Danish mortgage bonds or  
bonds issued by Danish banks with high ratings.  
Maturity of financial liabilities (including interest)  
2022  
Due within
Due between  
Due after  
DKK thousand  
1 year 1 and 5 years  
5 years  
Total  
Deferred consideration 1)  
297,460  
2,506,101  
-
2,803,561  
Credit institutions  
1,103,003  
10,355  
9,423  
1,122,781  
Prepayment and loan from Government 2)  
-
519,932  
70,503  
590,435  
Lease liabilities  
24,487  
45,834  
-
70,321  
Trade payables  
605,928  
-
-
605,928  
Other liabilities  
265,775  
-
-
265,775  
Non-derivative financial liabilities  
2,296,653  
3,082,222  
79,926  
5,458,801  
2021  
Due within
Due between  
Due after  
DKK thousand  
1 year 1 and 5 years  
5 years  
Total  
Deferred consideration 1)  
594,912  
2,803,523  
-
3,398,435  
Credit institutions  
887,689  
9,106  
10,409  
907,204  
Prepayment and loan from Government 2)  
-
164,184  
-
164,184  
Lease liabilities  
21,266  
57,547  
-
78,813  
Trade payables  
263,611  
-
-
263,611  
Other liabilities  
154,032  
-
-
154,032  
Non-derivative financial liabilities  
1,921,510  
3,034,360  
10,409  
4,966,279  
Derivative financial liabilities  
705  
-
-
705  
1) Further explained in note 24.
2) Further explained in note 25.  
Optimization of capital structure  
Management regularly assesses whether the Group´s  
capital structure best serves the interests of the Group  
and its shareholders. The overall goal is to ensure that  
the Group has a capital structure which supports its  
long-term strategy and growth target.  
Transferred financial assets  
that are not derecognized  
In 2022 the Company entered into transactions that  
transfer ownership of securities to a counterparty,  
while the Company retains the risks associated with  
the holding of the securities. As the Company retains  
all risks, the securities remain in the balance sheet, and  
the transactions are accounted for as loans received  
against collateral (repo transactions and security  
lending). The transactions involve selling the securities  
Credit risks  
The primary credit risk relates to trade receivables.  
The Company assesses the expected credit losses  
also considering changes in the macro environment  
that might impose an increased risk of losses. This is  
compared to the previous model where indications  
of credit losses were needed for the Company to  
recognize an expected loss. The Group´s customers are  
predominantly public authorities and renowned phar-  
maceutical companies and wholesalers, and the credit  
risk on the Group's receivables is therefore considered  
to be very low. A loss allowance of DKK 870 thou-  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic
Annual Report 2022  
100  
Note 23  
Financial risks and financial instruments (continued)  
to be repurchased at a fixed price at a later date. Coun-  
terparties are entitled to sell the securities or deposit  
them as collateral for loans.  
Securities (level 1)  
The portfolio of publicly traded government bonds,  
publicly traded mortgage bonds and bank bonds is  
valued at listed prices and price quotas.  
Transferred financial assets that are not derecognized  
DKK thousand  
2022  
2021  
Carrying amount of transferred securities  
1,084,916  
498,534  
Carrying amount of associated liabilities (security lending)  
(1,103,661)  
(500,000)  
Net position  
(18,745)  
(1,466)  
Fair value hierarchy for financial instruments measured at fair value  
2022  
DKK thousand  
Level 1  
Level 2  
Total  
Securities  
2,269,759  
-
2,269,759  
Financial assets measured at fair value through the income statement  
2,269,759  
-
2,269,759  
Derivative financial instruments to hedge future cash flow (currency)  
-
30,025  
30,025  
Derivative financial instruments to hedge future cash flow (interest)  
-
1,869  
1,869  
Financial assets/liabilities used as hedging instruments  
-
31,894  
31,894  
Derivative financial instruments at fair value (repo transactions)  
-
(8,302)  
(8,302)  
Liability relating to phantom shares  
-
(11,102)  
(11,102)  
Financial liabilities measured at fair value through the income statement  
-
(19,404)  
(19,404)  
2021  
DKK thousand  
Level 1  
Level 2  
Total  
Securities  
3,124,795  
-
3,124,795  
Derivative financial instruments at fair value (repo transactions)  
-
191  
191  
Financial assets measured at fair value through the income statement  
3,124,795  
191 3,124,986  
Derivative financial instruments to hedge future cash flow (currency)  
-
(646)  
(646)  
Derivative financial instruments to hedge future cash flow (interest)  
-
(705)  
(705)  
Financial assets/liabilities used as hedging instruments  
-
(1,351)  
(1,351)  
Liability relating to phantom shares  
-
(23,917)  
(23,917)  
Financial liabilities measured at fair value through the income statement  
-
(23,917)  
(23,917)  
Derivative financial instruments (level 2)  
Currency forward contracts, currency option contracts  
and currency swap contracts are valued according to  
generally accepted valuation methods based on rele-  
vant observable swap curves and exchange rates.  
Liability relating to phantom shares is determined using  
the Black-Scholes. The valuation is based on observable  
share price, interest rates and volatility rates.  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic
Annual Report 2022  
101  
Note 24  
Deferred consideration  
License agreement  
Under the terms of the license and collaboration agree-  
ment concluded with AdaptVac July 2020, the Company  
is committed to payment of potential future develop-  
ment and sales milestones and tiered royalties.  
In December 2021, the Company announced positive  
topline results from the Phase 2 clinical trial. These  
results was confirmed by the six-month follow-up  
analysis in October 2022, showing that the strong  
booster responses are maintained after six months post  
vaccination at levels associated with a high degree of  
efficacy. In September 2022, the Company initiated  
the Phase 3 clinical trial. The read-out are expected in  
beginning of 2023. Based on the positive clinical results  
Management assesses that the likelyhood of future  
regulatory approval of the Company's COVID-19 vaccine  
is high, hence milestone payments to AdaptVac are  
expected to become payable. Based on current regu-  
latory plans and expectations for future revenue from  
sale of the COVID-vacine all sales milestones and part  
of the development milestones are assumed probable  
and recognized as deferred consideration.  
The carrying amount are measured using a discount  
rate of 3.7% per annum. The discount rate has been  
determined at intial recognition based on an interest  
rate on a similar loan of the same size and maturity as  
the contingent milestone payments and the Company's  
credit rating as of December 31, 2021.  
The fair value of the deferred consideration as per  
December 31, 2022 amounts to DKK 553 million (DKK  
596 million), measured using the updated discount rate  
of 6.7% (3.7%). The discount rate has been determined  
based on the same components as described above.  
Royalties payable under the license and collaboration  
agreement with AdaptVac will be expensed in concur-  
rence with future sales, hence not assessed and recog-  
nized as a liability as of December 31, 2022.  
The cash flow from payment of deferred consideration  
will be recognized as cash flow from investment activ-  
ities.  
Due within
Due between  
Due after  
DKK thousand  
1 year  
1 and 5 year  
5 years  
Total  
2022  
Deferred consideration, product rights  
-
2,020,638  
-
2,020,638  
Deferred consideration, license agreement  
287,436  
304,019  
-
591,455  
Total  
287,436  
2,324,657  
-
2,612,093  
2021  
Deferred consideration, product rights  
577,667  
1,972,862  
-
2,550,529  
Deferred consideration, license agreement  
-
596,228  
-
596,228  
Total  
577,667  
2,569,090  
-
3,146,757  
Accounting policies  
Deferred consideration including contingent milestone  
payments is recognized when its payment is probable  
and it can be measured reliably and is at initial recog-  
nition measured at fair value which equals present  
value of future deferred payments. Subsequently, the  
deferred consideration is measured at amortized cost.  
This means that the difference between the present  
value of the consideration and the nominal amounts  
due is recognized in the income statement as a finan-  
cial expense over the period until expected payment  
date using the effective interest method.  
The expected phasing of future payments and the  
probability of contingent payments are assessed on  
each reporting date and the impact is recognized as a  
financial item.  
Product rights  
The Asset Purchase Agreement with GlaxoSmithKline  
includes milestone payments relating to transfer and  
registration of marketing authorizations, technology  
transfer of different steps of the production and pack-  
aging activities as well as a milestone payment when  
all services agreed to be rendered by GlaxoSmithKline  
has been completed. In total EUR 470 million. During  
2022 two milestone payments of a total of EUR 80  
million was paid. The payments are presented as  
cash flow from investment activities in the cash flow  
statement. The majority of the remaining milestone  
payments are expected to be payable in 2024. The  
completion milestone is expected to be payable begin-  
ning of 2025.  
The Asset Purchase Agreement with GlaxoSmithKline  
also includes a sales milestone of EUR 25 million. As per  
December 31, 2022 Management does not judge the  
sales milestone to be probable and therefore the sales  
milestone has not been recognized as either part of the  
product rights (note 15) nor the deferred consideration.  
The carrying amount are measured using a discount  
rate of 4% per annum. The discount rate was deter-  
mined at intial recognition based on an interest rate  
on a similar loan of the same size and maturity as the  
contingent milestone payments and the Company's  
credit rating as of December 31, 2019.  
The fair value of the deferred consideration as per  
December 31, 2022 amounts to DKK 1,937 million (DKK  
2,564 million), measured using the updated discount  
rate of 6.7% (3.7%). The discount rate has been deter-  
mined based on the same components as described  
above.  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic
Annual Report 2022  
102  
Note 25  
Prepayment and loan from Government  
repay the amount to the Danish Ministry of Health.  
Since the split between supply of vaccines and royalty  
payments is unknown at this stage Management has  
decided to recognize the received milestone payments  
under one common line item "Prepayment and loan  
from Government".  
Subsequent the financial liability part is measured at  
amortized cost. The prepayment part is accounted for  
as a prepayment under IFRS 15. The interest rate used  
that is implicit in the transaction is based on an assess-  
ment of the company’s incremental borrowing rate. The  
amortizations and the implicit interest are presented as  
amortization expenses under financial expenses.  
Due within
Due between  
Due after  
DKK thousand  
1 year  
1 and 5 year  
5 years  
Total  
2022  
Prepayment and loan from Government  
-
566,420  
-
566,420  
Total  
-
566,420  
-
566,420  
2021  
Prepayment and loan from Government  
-
160,511  
-
160,511  
Total  
-
160,511  
-
160,511  
Accounting policies  
Prepayment and loan from Government consists of an  
upfront payment and additional milestone payments  
from the Danish Ministry of Health to support the  
completion of the development of ABNCoV2, the  
Company’s COVID-19 vaccine candidate. The additional  
payments are contingent upon reaching of a number of  
predefined development milestones. All payments are  
potentially subject to repayment, however only upon  
successful marketing authorization of the vaccine by  
the European Commission. Half of the repayments shall  
be paid by delivery of vaccines to the Danish Ministry of  
Health whereas the remaining part of the repayments  
can be settled in either royalty payments from the  
sale of the vaccine to other customers or by delivery of  
further vaccines. Royalty payments are only triggered  
upon reaching a certain volume in sales. Upon approval  
of the vaccine the repayment obligation is adjusted  
by inflation. The Company considers it probably that  
approval will be obtained and the received payments  
will be repaid to the
Danish Ministry of Health.  
The repayment obligation is accounted for as a  
prepayment in respect of the part that shall be repaid  
by delivery of vaccines whereas the part that can  
be repaid either by delivery of further vaccines or  
by royalty payments is accounted for as a financial  
liability. Initially the payments from the Danish Ministry  
of Health is measured at the amount received that is  
considered equal to the fair value of the obligation to  
Agreement with Danish Ministry of Health  
In August 2021, the Company entered a funding agree-  
ment with the Danish Ministry of Health to further  
advance the development of ABNCoV2.  
The agreement is valued at up to DKK 800 million and  
aims to support the completion of the development  
towards licensure of ABNCoV2 as a booster vaccine.  
Under the agreement, Bavarian Nordic is entitled to  
an upfront payment of DKK 80 million, in addition to  
payments of up to DKK 720 million, which are contin-  
gent upon reaching a number of predefined milestones  
including among others Phase 3 development mile-  
stones and milestones related to upscaling of manu-  
facturing for commercial production of the vaccine.  
As per December 31, 2022 the Company has received  
the upfront payment of DKK 80 million and
milestone  
payments amounting to DKK 480 million.  
The Danish Ministry of Health could be entitled to an  
additional, capped royalty payment if the sales reach a  
certain threshold above the sales volume for the ordi-  
nary royalty payment.  
Based on current sales forecasts this additional royalty  
payment is not deemed likely and therefore not recog-  
nized. If the payment becomes current it will be recog-  
nized as a financial expense as the additional royalty  
payment is seen as an extra interest payment.  
The cap for the additional royalty payment is a fixed  
amount, calculated as a percentage of the loan amount.  
Significant accounting judgments  
Management has made the following accounting judg-  
ment which affect the recognition in the consolidated  
financial statements:  
Management assesses a high likelyhood of regula-  
tory approval of the vaccine, hence assumes that the  
already received milestone payments and the mile-  
stone payments to be received in the comming year  
will be repaid in either supply of vaccines or royalty  
payments.  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic
Annual Report 2022  
103  
Note 26  
Debt to credit institutions  
Due within
Due between  
Due after  
DKK thousand  
1 year  
1 and 5 year  
5 years  
Total  
2022  
Mortgage 1)  
1,922  
8,283  
8,725  
18,930  
Security lending (repo transactions)  
1,103,661  
-
-
1,103,661  
Total  
1,105,583  
8,283  
8,725  
1,122,591  
2021  
Mortgage 1)  
2,178  
8,673  
10,223  
21,074  
European Investment Bank (loan in DKK) 2)  
372,195  
-
-
372,195  
Security lending (repo transactions)  
500,000  
-
-
500,000  
Total  
874,373  
8,673  
10,223  
893,269  
1) Floating interest – swapped to fixed interest of 0.9625% – expiry 2031  
2) Fixed interest of 3.532% - bullet loan repaid in October 2022  
Cash flow from financing activities  
January  
Cash  
Non-cash  
December  
DKK thousand  
1, 2022  
movement  
movement  
31, 2022  
2022  
Mortgage  
21,074  
(2,144)  
-
18,930  
European Investment Bank (loan in DKK)  
372,195  
(372,195)  
-
-
Security lending (repo transactions)  
500,000  
603,661  
-
1,103,661  
Prepayment and loan from Government  
160,511  
400,000  
5,909  
566,420  
Lease liabilities  
78,813  
(21,981)  
13,489  
70,321  
Total liabilities from financing activities  
1,132,593  
607,341  
19,398  
1,759,332  
January  
Cash  
Non-cash  
December  
DKK thousand  
1, 2021  
movement  
movement  
31, 2021  
2021  
Mortgage  
23,247  
(2,173)  
-
21,074  
European Investment Bank (loan in DKK)  
372,195  
-
-
372,195  
Security lending (repo transactions)  
-
500,000  
-
500,000  
Prepayment and loan from Government  
-
160,000  
511  
160,511  
Lease liabilities  
74,623  
(19,507)  
23,697  
78,813  
Total liabilities from financing activities  
470,065  
638,320  
24,208  
1,132,593  
The fair value of the debt to credit institutions amounts  
to DKK 1,122.6 million (DKK 893.5 million). The fair  
value of mortgage debt is based on the market value  
of the underlying bonds set by the bank (level 2),  
whereas the fair value of the security lending is based  
on a discounted cash analysis flow of future payments  
of interest and principal by applying a market based  
discount rate (level 2).  
The tables below detail changes in the Group's liabil-  
ities arising from financing activities, both cash and  
non-cash changes. Liabilities arising from financing  
activities are those for which cash flows were, or future  
cash flows will be, classified in the Group's consolidated  
statement of cash flow as cash flows from financing  
activities.  
Accounting policies  
Loans are measured at the time of borrowing at fair  
value less any transaction costs. Subsequently, debt is  
measured at amortized cost. This means that the differ-  
ence between the proceeds of the loan and the amount  
to be repaid is recognized in the income statement over  
the term of the loan as a financial expense using the  
effective interest method.  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic
Annual Report 2022  
104  
Note 27  
Lease liabilities  
DKK thousand  
2022  
2021  
Non-current  
45,834  
57,547  
Current  
24,487  
21,266  
Lease liabilities  
70,321  
78,813  
Due within
Due between  
Due after  
DKK thousand  
1 year  
1 and 5 year  
5 years  
Total  
2022  
Lease liabilities  
24,487  
45,834  
-
70,321  
Total  
24,487  
45,834  
-
70,321  
2021  
Lease liabilities  
21,266  
57,547  
-
78,813  
Total  
21,266  
57,547  
-
78,813  
Accounting policies  
The lease liability is initially measured at the present  
value of the future lease payments (see further in note  
17), discounted by using an incremental country specific  
borrowing rate ranging from 2.5% to 3.0% applying  
only a single discount rate for a portfolio of lease assets  
with reasonable similar characteristics.  
The lease liability is subsequently measured by  
increasing the carrying amount to reflect interest on  
the lease liability using the effective interest method  
and by reducing the carrying amount to reflect the  
lease payments made.  
The lease liability is remeasured and corresponding  
adjustments are made to the related right-of-use-asset  
whenever:  
•
The lease term has changed, in which case the lease  
liability is remeasured by discounting the revised  
lease payments using a revised discount rate.  
•
The lease payments change due to changes in  
an index or rate, in which case the lease liability  
is remeasured by discounting the revised lease  
payments using an unchanged discount rate.  
•
A lease contract is modified and the lease modifi-  
cation is not accounted for as a seperate lease, in  
which case the lease liability is remeasured based on  
the lease term of the modified lease by discounting  
the revised lease payments using a revised discount  
rate at the effective date of the modification.  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic
Annual Report 2022  
105  
Note 28  
Prepayment from customers  
2022  
2021  
DKK thousand  
Prepayment from customers as of January 1  
16,904  
74,347  
Prepayments received during the year  
-
33,850  
Recognized as revenue during the year  
(16,904)  
(91,293)  
Prepayment from customers as of December 31  
-
16,904  
Note 29  
Related party transactions  
The Group Management and Board of Directors of  
Bavarian Nordic A/S are considered related parties.  
Besides the remuneration of the Board of Directors and  
the Executive Management, cf. note 8, and the share-  
based payments, cf. note 30, there are no transactions  
with related parties.  
Transactions with subsidiaries are eliminated in the  
consolidated financial statements, in accordance with  
the accounting policies.  
The HPV license and collaboration agreement with  
Janssen regarding production of Master Seed Virus has  
been terminated and therefore the upfront payment of  
DKK 16.9 million (USD 2.5 million) has been recognized  
as revenue in 2022.  
The recognition of revenue is described in note 3.  
Accounting policies  
Prepayments are recognized under liabilities and will  
be recognized in the income statement as the delivery  
of paid products takes place.  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic
Annual Report 2022  
106  
Note 30  
Share-based payment  
Accounting policies  
Share-based incentive plans in which employees can  
only opt to buy shares in the Company (warrants) are  
measured at the equity instruments’ fair value at the  
grant date and recognized in the income statement  
over the vesting period. The balancing item is recog-  
nized directly in equity. The fair value on the date of  
grant is determined using the Black-Scholes model.  
Cash-based incentive programs in which employees  
can have the difference between the agreed exer-  
cise price and the actual share price settled in cash  
(phantom shares) are measured at fair value at the date  
of grant and recognized in the income statement over  
the period when the final right of cash-settlement is  
obtained. Granted rights are subsequently re-measured  
on each balance sheet date and upon final settlement,  
and any changes in the fair value of the programs are  
recognized in the income statement. The balancing  
item is recognized under other liabilities.  
The fair value of the cash-based incentive programs is  
determined using the Black-Scholes model.  
Restricted stock units are measured at fair value at  
grant date. Based on the achieved cash bonus for  
members of the Executive Management, subject to the  
Board of Directors’ decision on the portion that should  
be converted to restricted stock units, the number of  
restricted stock units are calculated by dividing the  
allocated cash bonus amount by the share price of the  
Company at grant date. As the cash bonus has already  
been accrued and expensed in the income statement,  
the grant of restricted stock units has no additional  
impact on the income statement. The accrued liability  
for the converted cash bonus is reclassified to equity.  
Matching shares are measured at the same fair value  
as the initial restricted stock units and expensed over  
the three year vesting period. The balancing item is  
recognized directly in equity. Restricted stock units  
granted as sign-on bonus for members of the Executive  
Management and restricted stock units granted to the  
Board of Directors are expensed at grant date with the  
balancing item recognized directly in equity.  
The warrants are granted in accordance with the  
authorizations given to the Board of Directors by the  
shareholders. The Board of Directors has fixed the  
terms of and the size of the grants of warrants, taking  
into account authorizations from the shareholders, the  
Group's guidelines for incentive pay, an assessment of  
expectations of the recipient´s work efforts and contri-  
bution to the Group´s growth, as well as the need to  
motivate and retain the recipient. Grant takes place on  
the date of establishment of the program. Exercise of  
warrants is by default subject to continuing employ-  
ment with the Group. The warrants granted are subject  
to the provisions of the Danish Public Companies Act  
regarding termination of employees prior to their  
exercise of warrants in the case of recipients who are  
subject to the act.  
Incentive plans  
In order to motivate and retain key employees and  
encourage the achievement of common goals for  
employees, management and shareholders, the  
Company has established incentive plans by way of  
warrant programs and restricted stock units programs,  
the latter only for members of the Executive Manage-  
ment and Board of Directors.  
Furthermore, the Company has established three-year  
phantom share programs for all employees of the  
Group except for Executive Management and other  
employees receiving warrants.  
Warrants  
The Board of Directors has been granting warrants to  
the Company´s management and selected employees  
of the Company and its subsidiaries.  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic
Annual Report 2022  
107  
Note 30  
Share-based payment (continued)  
Outstanding  
Outstanding  
Can be  
Average  
as of  
as of
exercised as of  
exercise  
Warrant overview – 2022  
January 1  
Additions  
Exercised  
Annulled  
Terminated  
December 31  
December 31  
price (DKK)  
December 2016  
77,661  
-
-
-
(77,661)  
-
-
206  
July 2017  
34,074  
-
-
-
(34,074)  
-
-
340  
November 2017  
189,609  
-
(60)  
(1,526)  
(188,023)  
-
-
240  
November 2018  
515,684  
-
(266,923)  
(8,053)  
-
240,708  
240,708  
142  
November 2019  
625,984  
-
-
(26,491)  
-
599,493  
-
147  
January 2020  
30,039  
-
-
-
-
30,039  
-
156  
November 2020  
1,176,964  
-
-
(64,894)  
-
1,112,070  
-
207  
November 2021  
706,469  
-
-
(50,695)  
-
655,774  
-
353  
April 2022  
-
81,872  
-
-
-
81,872  
-
190  
December 2022  
-
932,051  
-
-
-
932,051  
-
225/271  
Total  
3,356,484  
1,013,923  
(266,983)  
(151,659)  
(299,758)  
3,652,007  
240,708  
Outstanding  
Outstanding  
Recognized costs in 2022 DKK 42.9 million compared to  
as of  
as of  
DKK 31.3 million in 2021.  
Warrant overview – 2022  
January 1  
Additions  
Exercised  
Annulled  
Terminated  
Transferred  
December 31  
Corporate Management  
743,346  
126,487  
-
-
(143,901)  
-
725,932  
Other Executive Management  
418,163  
185,457  
-
-
-
(174,070)  
429,550  
Other employees  
1,880,363  
701,979  
(145,833)  
(151,659)  
(65,579)  
(237,144)  
1,982,127  
Resigned employees  
314,612  
-
(121,150)  
-
(90,278)  
411,214  
514,398  
Total  
3,356,484  
1,013,923  
(266,983)  
(151,659)  
(299,758)  
-
3,652,007  
Weighted average exercise price (DKK)  
219  
253  
142  
242  
242  
-
231  
Weighted average share price at exercise (DKK)  
247  
Number of warrants which can be exercised as of December 31, 2022  
240,708  
at a weighted average exercise price of DKK  
142  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic
Annual Report 2022  
108  
Note 30  
Share-based payment (continued)  
Outstanding  
Outstanding  
as of  
as of  
Warrant overview – 2021  
January 1  
Additions  
Exercised  
Annulled  
Terminated  
Transferred  
December 31  
Corporate Management  
439,402  
137,030  
-
-
-
166,914  
743,346  
Other Executive Management  
723,326  
108,788  
(31,709)  
-
-
(382,242)  
418,163  
Other employees  
2,062,360  
470,438  
(327,617)  
(241,960)  
(14,725)  
(68,133)  
1,880,363  
Resigned employees  
167,901  
-
(135,275)  
-
(1,475)  
283,461  
314,612  
Total  
3,392,989  
716,256  
(494,601)  
(241,960)  
(16,200)  
-
3,356,484  
Weighted average exercise price (DKK)  
188  
307  
217  
194  
206  
-
219  
Weighted average share price at exercise (DKK)  
327  
Number of warrants which can be exercised as of December 31, 2021  
301,344  
at a weighted average exercise price of DKK  
242  
Specification of parameters for Black-Scholes model  
Nov. 2018 Nov. 2019  
Jan. 2020 Nov. 2020 Nov. 2021 Apr. 2022 Dec. 2022 3)  
Average share price  
159.00  
154.05  
171.20  
179.84  
307.20  
171.35  
224.70  
Average exercise price at grant  
179.60  
185.40  
197.00  
206.82  
353.06  
190.11  
270.91  
Average exercise price at grant - Executive Management  
224.70  
Average exercise price determined at date of rights issue March 30, 2020  
142.00  
146.60  
155.80  
Applied volatility rate 2)  
53.3%  
52.2%  
53.0%  
39.8%  
41.8%  
42.3%  
41.8%  
Expected life (years)  
3.0  
3.0  
3.0  
3.0  
3.0  
3.0  
3.0  
Expected dividend per share  
-
-
-
-
-
-
-
Risk-free interest rate p.a.  
-0.43%  
-0.69%  
-0.65%  
-0.66%  
-0.53%  
0.39%  
2.04%  
Fair value per share at grant 1)  
52  
45  
53  
41  
76  
47  
64  
Fair value per share at grant - Executive Management 1)  
78  
1) Fair value of each warrant at grant date applying the Black-Scholes  
model.  
2) The applied volatility is based on the historical volatility of  
the Bavarian Nordic share, except for programs issued since  
November 2020 where the volatility is based on the volatility for  
a peer group.  
3) The December 2022 program has two set of exercise conditions.  
Executive Management can subscribe future shares at a exercise  
price of DKK 224.70 per share equivalent to the market price  
of Bavarian Nordic's shares at the time of grant. Vesting of the  
warrants is subject to prior fulfilment of KPI's as determined by  
the Board of Directors. Other employees can subscribe future  
shares at a exercise price of DKK 270.91 per share, determined as  
the average market price (closing price) of the Company's shares  
on Nasdaq Copenhagen over a period of 15 business days prior to  
grant plus 15%.  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic
Annual Report 2022  
109  
Note 30  
Share-based payment (continued)  
Exercise periods  
Can be exercised wholly or partly in a period of 14 days commencing from the day of publication of:  
December 2022  
Annual Report 2025  
Interim Report Q1 2026  
Interim Report Q2 2026  
Interim Report Q3 2026  
Annual Report 2026  
Interim Report Q1 2027  
Interim Report Q2 2027  
Interim Report Q3 2027  
April 2022  
Interim Report Q2 2025  
Interim Report Q3 2025  
Annual Report 2025  
Interim Report Q1 2026  
Interim Report Q2 2026  
Interim Report Q3 2026  
Annual Report 2026  
Interim Report Q1 2027  
November 2021  
Annual Report 2024  
Interim Report Q1 2025  
Interim Report Q2 2025  
Interim Report Q3 2025  
Annual Report 2025  
Interim Report Q1 2026  
Interim Report Q2 2026  
Interim Report Q3 2026  
November 2020  
Annual Report 2023  
Interim Report Q1 2024  
Interim Report Q2 2024  
Interim Report Q3 2024  
Annual Report 2024  
Interim Report Q1 2025  
Interim Report Q2 2025  
Interim Report Q3 2025  
January 2020  
Annual Report 2022  
Interim Report Q1 2023  
Interim Report Q2 2023  
Interim Report Q3 2023  
Annual Report 2023  
Interim Report Q1 2024  
Interim Report Q2 2024  
Interim Report Q3 2024  
November 2019  
Annual Report 2022  
Interim Report Q1 2023  
Interim Report Q2 2023  
Interim Report Q3 2023  
Annual Report 2023  
Interim Report Q1 2024  
Interim Report Q2 2024  
Interim Report Q3 2024  
November 2018  
Annual Report 2021  
Interim Report Q1 2022  
Interim Report Q2 2022  
Interim Report Q3 2022  
Annual Report 2022  
Interim Report Q1 2023  
Interim Report Q2 2023  
Interim Report Q3 2023  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic
Annual Report 2022  
110  
Note 30  
Share-based payment (continued)  
Phantom shares  
In 2018, the Company established a three-year  
phantom share program for all employees of the  
Group except for management and other employees  
receiving warrants. The employees receive up to four  
phantom shares per month free of charge during the  
period from January 1, 2019 to December 31, 2021.  
Each employee who is a full-time employee during  
the entire term of the plan will be eligible to receive a  
maximum of 144 phantom shares. Following the rights  
issues in March 2020 the monthly grant increased to  
five phantom shares for the remaining grant period and  
the maximum increased to 183 phantom shares. The  
program exercised in January 2022.  
In 2019, the Company established a three-year phantom  
share program for all employees of the Group except for  
management and other employees receiving warrants.  
The employees receive up to four phantom shares per  
month free of charge during the period from January  
1, 2020 to December 31, 2022. Each employee who is a  
full-time employee during the entire term of the plan  
will be eligible to receive a maximum of 144 phantom  
shares. Following the rights issues in March 2020 the  
monthly grant increased to five phantom shares for the  
remaining grant period and the maximum increased to  
183 phantom shares.  
The program will exercise in January 2023.  
In 2020, the Company established a three-year  
phantom share program for all employees of the Group  
except for management and other employees receiving  
warrants. The employees receive up to five phantom  
shares per month free of charge during the period from  
January 1, 2021 to December 31, 2023. Each employee  
who is a full-time employee during the entire term of  
the plan will be eligible to receive a maximum of 180  
phantom shares.  
Grants are made on a monthly basis during the life of  
the programs as long as the employee is employed  
with the Group.  
On expiry of the programs, the employees may exer-  
cise the phantom shares granted to them and thus be  
entitled to a cash bonus calculated on the basis of the  
increase in the price of the Company´s shares. The exer-  
cise is conditional on the price of the Company´s shares  
being at least DKK 5 higher than the exercise price at  
the time of exercise.  
On expiry of the programs, former employees are  
entitled to settlement of the phantom shares granted  
during their term of employment.  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic
Annual Report 2022  
111  
Note 30  
Share-based payment (continued)  
2021-2023 phantom share program  
DKK thousand  
2022  
2021  
Outstanding as of January 1  
37,996  
-
Granted during the year  
41,136  
37,996  
Outstanding phantom shares as of December 31  
79,132  
37,996  
Liability in DKK thousand as of December 31  
3,732  
3,589  
Specification of parameters for Black-Scholes model  
Share price December 31  
213  
269  
Average share exercise price  
203  
203  
Expected volatility rate  
47%  
42%  
Expected life (years)  
1.0  
2.0  
Expected dividend per share  
-
-
Risk-free interest rate p.a.  
3.46%  
0.11%  
2020-2022 phantom share program  
DKK thousand  
2022  
2021  
2020  
Outstanding as of January 1  
68,873  
30,921  
-
Granted during the year  
41,627  
37,952  
29,554  
Adjustment following rights issue March 2020  
-
-
1,367  
Outstanding phantom shares as of December 31  
110,500  
68,873  
30,921  
Liability in DKK thousand as of December 31  
7,370  
8,604  
1,864  
Specification of parameters for Black-Scholes model  
Share price December 31  
213  
269  
187  
Average share exercise price  
147  
147  
147  
Expected volatility rate  
47%  
42%  
40%  
Expected life (years)  
-
1.0  
2.0  
Expected dividend per share  
-
-
-
Risk-free interest rate p.a.  
-
-0.02%  
-0.17%  
The expected volatility is based on the volatility for a  
peer group.  
Phantom shares granted in 2022 provided an expense  
of DKK 1.9 million, whereas the revaluation of previ-  
ously granted phantom shares provided an income of  
DKK 1.8 million, total net expense of DKK 0.1 million  
(net expense 2021: DKK 3.6 million).  
The liability is included in other liabilities, cf. note 22.  
The expected volatility is based on the volatility for a  
peer group.  
The 2020-2022 program will exercise in January 2023  
if the average share price for the period January 2 -  
January 13, 2023 will exceed the exercise price of DKK  
146.70. Otherwise the program will expire without  
exercise.  
Phantom shares granted in 2022 provided an expense  
of DKK 2.8 million, whereas the revaluation of previ-  
ously granted phantom shares provided an income of  
DKK 4.0 million, total net income of DKK 1.2 million (net  
expense 2021: DKK 6.7 million).  
The liability is included in other liabilities, cf. note 22.  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic
Annual Report 2022  
112  
Note 30  
Share-based payment (continued)  
2019-2021 phantom share program  
DKK thousand  
2022  
2021  
2020  
2019  
Outstanding as of January 1  
92,531  
55,095  
19,213  
-
Granted during the year  
-
37,436  
29,437  
19,213  
Adjustment following rights issue March 2020  
-
-
6,445  
-
Exercised during the year  
(85,367)  
-
-
-
Expired during the year  
(7,164)  
-
-
-
Outstanding phantom shares as of December 31  
-
92,531  
55,095  
19,213  
Liability in DKK thousand as of December 31  
-
11,724  
2,985  
864  
Specification of parameters for Black-Scholes model  
Share price December 31  
269  
187  
171  
Average share exercise price  
142  
142  
180  
Expected volatility rate  
42%  
40%  
51%  
Expected life (years)  
-
1.0  
2.0  
Expected dividend per share  
-
-
-
Risk-free interest rate p.a.  
-
-0.15%  
-0.17%  
The expected volatility for 2020 and 2021 is based on  
Revaluation of granted phantom shares and reversal of  
the volatility for a peer group, whereas the volatility for  
not exercised phantom shares provided a net income of  
2019 is based on the historic volatility of the Company.  
DKK 3.6 million (net expense 2021: DKK 8.7 million).  
The 2019-2021 program exercised in January 2022 at a  
The liability is included in other liabilities, cf. note 22.  
share price of DKK 241.61.  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic
Annual Report 2022  
113  
Note 30  
Share-based payment (continued)  
Restricted stock units  
In March 2021, the Board of Directors decided to post-  
pone the payment of half of the achieved cash bonus  
for members of the Other Executive Management for  
3 years, converting the postponed bonus of DKK 3.6  
million into 16,413 unconditional restricted stock units  
using the share price of the Company at grant date  
(DKK 222). The Board of Directors decided to grant  
additional restricted stock units free of charge on expiry  
of a 3 years period (so-called ""matching shares"")  
upon the recipient still being employed in March 2024.  
One matching share is granted for each two acquired  
restricted stock units. The maximum number of  
matching shares is 8,207. The initial granted restricted  
stock units and the potential matching shares total  
24,620 shares.  
At the annual general meeting in April 2021, the Board  
of Directors were granted a total of 7,127 unconditional  
restricted stock units corresponding to 50% of the  
annual fixed fee of DKK 2.0 million (excl. committee  
fee). The restricted stock units will be delivered after 3  
years in April 2024.  
Outstanding restricted stock units  
2022  
Outstanding  
Outstanding  
Granted  
Released  
as of
Value at grant  
as of January 1 during the year
during the year  
December 31  
date (DKK)  
Vesting date  
Executive Management:  
Conversion of cash bonus for 2021  
-
22,578  
-
22,578  
163  
Mar. 2025  
Matching shares - bonus 2021  
-
11,288  
-
11,288  
163  
Mar. 2025  
CEO retention plan  
-
17,109  
-
17,109  
156  
Apr. 2025  
Matching shares - CEO retention plan  
-
8,554  
-
8,554  
156  
Apr. 2025  
Sign-on bonus COO  
-
4,446  
-
4,446  
165  
Apr. 2025  
Matching shares - sign-on COO  
-
2,223  
-
2,223  
165  
Apr. 2025  
Conversion of cash bonus for 2020  
16,413  
-
-
16,413  
222  
Mar. 2024  
Matching shares - bonus 2020  
8,207  
-
-
8,207  
222  
Mar. 2024  
Conversion of cash bonus for 2019  
11,003  
-
-
11,003  
240  
Mar. 2023  
Matching shares - bonus 2019  
5,500  
-
-
5,500  
240  
Mar. 2023  
Sign-on bonus CMO  
8,651  
-
-
8,651  
149  
May 2023  
Matching shares - sign-on CMO  
4,325  
-
-
4,325  
149  
May 2023  
Conversion of cash bonus for 2018  
16,080  
-
(16,080)  
-
144  
Mar. 2022  
Matching shares - bonus 2018  
8,039  
-
(8,039)  
-
144  
Mar. 2022  
Executive Management  
78,218  
66,198  
(24,119)  
120,297  
Board of Directors:  
Fee 2022  
-
11,467  
-
11,467  
153  
Apr. 2025  
Fee 2021  
7,127  
-
-
7,127  
273  
Apr. 2024  
Fee 2020  
7,111  
-
-
7,111  
190  
Jun. 2023  
Fee 2019  
12,340  
-
(12,340)  
-
138  
Apr. 2022  
Board of Directors  
26,578  
11,467  
(12,340)  
25,705  
Total  
104,796  
77,665  
(36,459)  
146,002  
In May/June 2021, the Company bought back 31,747 of  
its own shares to meet the obligation to deliver up to  
31,747 shares to the members of the Executive Manage-  
ment and the Board of Directors in March/April 2024.  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic
Annual Report 2022  
114  
Note 30  
Share-based payment (continued)  
The grant of the initial restricted stock units to the Exec-  
utive Management (22,578 shares) had no impact on  
the income statement for 2022, as the corresponding  
cash bonus (DKK 3.7 million) was accrued in 2021,  
though the amount has been reclassified from "Salary  
and wages" to "Share-based payment" in the staff cost  
note (note 8). The obligation related to the matching  
shares amount to DKK 1.8 million measured at the same  
fair value as the initial restricted stock units (DKK 163).  
The obligation will be expensed over the three year  
vesting period.  
During 2022, DKK 9.2 million has been expensed and  
recognized as share-based payment related to Execu-  
tive Management, this includes the expensing of CEO  
retention plan and sign-on bonus to COO.  
The grant of restricted stock units to the Board of  
Directors (11,467 shares - DKK 1.8 million) were fully  
expensed at grant.  
Outstanding restricted stock units  
2021  
Outstanding  
Outstanding  
Granted  
Released  
as of
Value at grant  
as of January 1 during the year
during the year  
December 31  
date (DKK)  
Vesting date  
Executive Management:  
Conversion of cash bonus for 2020  
-
16,413  
-
16,413  
222  
Mar. 2024  
Matching shares – bonus 2020  
-
8,207  
-
8,207  
222  
Mar. 2024  
Conversion of cash bonus for 2019  
11,003  
-
-
11,003  
240  
Mar. 2023  
Matching shares – bonus 2019  
5,500  
-
-
5,500  
240  
Mar. 2023  
Sign-on bonus CMO  
8,651  
-
-
8,651  
149  
May 2023  
Matching shares – sign-on CMO  
4,325  
-
-
4,325  
149  
May 2023  
Conversion of cash bonus for 2018  
16,080  
-
-
16,080  
144  
Mar. 2022  
Matching shares – bonus 2018  
8,039  
-
-
8,039  
144  
Mar. 2022  
Sign-on bonus CFO 1)  
8,554  
-
(8,554)  
-
156  
Nov. 2021  
Matching shares – sign-on CFO 1)  
4,277  
-
(4,277)  
-
156  
Nov. 2021  
Conversion of cash bonus for 2017  
8,734  
-
(8,734)  
-
244  
Mar. 2021  
Matching shares – bonus 2017  
4,366  
-
(4,366)  
-
244  
Mar. 2021  
Executive Management  
79,529  
24,620  
(25,931)  
78,218  
Board of Directors:  
Fee 2021  
-
7,127  
-
7,127  
273  
Apr. 2024  
Fee 2020  
7,111  
-
-
7,111  
190  
Jun. 2023  
Fee 2019  
12,340  
-
-
12,340  
138  
Apr. 2022  
Fee 2018  
8,666  
-
(8,666)  
-
175  
Apr. 2021  
Board of Directors  
28,117  
7,127  
(8,666)  
26,578  
Total  
107,646  
31,747  
(34,597)  
104,796  
1) At vesting 6,400 shares were transferred to CFO Henrik Juuel, the remaining 6,431 restricted stock units were converted to a cash bonus of DKK 2.0 million.  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic
Annual Report 2022  
115  
Note 30  
Share-based payment (continued)  
Note 31  
Contingent liabilities and other contractual  
obligations  
DKK thousand  
2022  
2021  
Collaborative agreements  
Contractual obligations with research (CRO) and manufacturing (CMO) partners for long-  
term research projects.  
– Due within 1 year  
260,082  
131,865  
Total share-based payments  
Below a specification of all share-based payments  
expensed in 2022 and 2021. The amounts reconcile to  
note 8.  
DKK thousand  
2022  
2021  
Warrants  
42,937  
31,265  
Restricted stock units  
11,039  
7,319  
Share-based payment recognized directly in equity  
53,976  
38,584  
2021-2023 phantom share program  
143  
3,589  
2020-2022 phantom share program  
(1,234)  
6,740  
2019-2021 phantom share program  
(3,601)  
8,739  
Share-based payment recognized as a liability (change during the year)  
(4,692)  
19,068  
Total share-based payment expensed, cf. note 8  
49,284  
57,652  
Restricted stock units converted to cash bonus at exercise  
-
(795)  
Non-cash adjustment in cash flow statement  
49,284  
56,857  
Sales milestone to GlaxoSmithKline  
The Asset Purchase Agreement with GlaxoSmithKline  
regarding the acquisition of the product rights to  
Rabipur/RabAvert and Encepur includes a sales mile-  
stone of EUR 25 million. As per December 31, 2022  
Management does not judge the sales milestone to  
be probable and therefore the sales milestone has not  
been recognized as either part of the product rights  
(note 15) nor the deferred consideration for product  
rights (note 24).  
24. The remaining developement milestones related to  
filing for approval in further countries are not deemed  
likely and therefore not recognized.  
Agreement with Danish Ministry of Health  
Under the agreement with the Danish Ministry of  
Health to fund the development of ABNCoV2 the  
Company has an obligation of payment of an additional,  
capped royalty payment if the sales reach a certain  
threshold. Based on current sales forecasts this addi-  
tional royalty payment is not deemed likely and there-  
fore not recognized. If the payment becomes current  
it will be recognized as a financial expense as the  
additional royalty payment is seen as an extra interest  
payment. The cap for the additional royalty payment is  
a fixed amount, calculated as a percentage of the loan  
amount.  
License and collaboration agreement AdaptVac  
Under the license and collaboration agreement with  
AdaptVac the Company has an obligation of payment  
of potential future development and sales milestones  
and tiered royalties. Based on current regulatory plans  
and expectations for future sale of the Company's  
COVID-19 vaccine all sales milestones and part of the  
development milestones are deemed probable as per  
December 31, 2022 and the net present value of those  
future milestone payments have been recognized as  
deferrred consideration, see further description in note  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic
Annual Report 2022  
116  
Note 31  
Contingent liabilities and other contractual  
obligations (continued)  
Note 32  
Significant events after the balance sheet date  
License agreements National Cancer Institute  
The Group has license agreements with the National  
Cancer Institute (NCI) and Public Health Service (PHS) in  
the U.S. for PROSTVAC, CV301 and BN-Brachyury, respec-  
tively. The agreements include contingent liabilities for  
the Group to pay performance-based royalties, if and  
when certain milestone events are achieved. Further,  
the agreements include potential contingent liabilities  
for the Group to pay additional sublicensing royalties  
on the fair market value of consideration received, if  
and when the Group grants such sublicenses. Payments  
considered remote are not included in the amounts  
above.  
Company mortgage  
The Company has by letter of indemnity granted  
Nordea a floating charge on unsecured claims arising  
from the sale of goods and services and stocks of raw  
materials, intermediate products and finished products,  
DKK 150 million (DKK 150 million). The floating charge  
secures the operating credit line of DKK 20 million and  
the line for trading in financial instruments, DKK 50  
million (DKK 50 million).  
On February 15, 2023, the Company announced an  
update on its late-stage pipeline programs. The anal-  
ysis of data from the completed Phase 3 trial of the  
RSV vaccine candidate, MVA-BN® RSV, is progressing  
according to plan and topline results from the study  
are still anticipated in mid-2023. In the Phase 3 trial  
of the COVID-19 booster vaccine candidate, ABNCoV2,  
the recruitment of subjects ≥65 years of age is taking  
longer than anticipated, pushing the expected comple-  
tion of enrollment into the second quarter of 2023 with  
topline results now anticipated around mid-2023.  
On February 15, 2023, the Company announced an  
agreement with Emergent BioSolutions Inc. to acquire  
two marketed travel vaccines, Vivotif® for the preven-  
tion of typhoid fever and Vaxchora® against cholera as  
well as a Phase 3 vaccine candidate for the prevention  
of Chikungunya virus for a total consideration of up to  
USD 380 million, including USD 270 million in an upfront  
payment and up to USD 110 million in future conditional  
milestone payments. The acquisition also includes facil-  
ities and key personnel related to the acquired assets.  
On February 20, 2023, The Company announced  
successful completion of a directed issue and private  
placement of 7,046,839 new shares at an offer price of  
DKK 233 per share, raising gross proceeds of DKK 1,642  
million.  
Except as noted above, there have been no significant  
events between December 31, 2022 and the date of  
approval of these financial statements that would  
require a change to or additional disclosure in the  
financial statements.  
Lawsuits  
Based on management's assessment the Group is not  
involved in any lawsuits or arbitration cases which  
could have a material impact on the Group's financial  
position or results of operations.  
Note 33  
Approval of the consolidated financial statements  
The consolidated financial statements were approved  
by the Board of Directors and Corporate Management  
and authorized for issue on March 2, 2023.  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
117  
Financial statements – Parent company  
Contents  
Financial statements  
Notes  
12. Right-of-use-assets  
13. Investment in subsidiaries  
14. Inventories  
Income statements  
1. Significant accounting policies and significant accounting  
estimates and judgments  
Statements of financial position – Assets  
Statements of financial position – Equity and liabilities  
Statements of changes in equity  
2. Revenue  
3. Research and development costs  
4. Staff costs  
15. Lease liabilities  
16. Prepayment from customers  
5. Depreciation, amortization and impairment losses  
6. Fees to auditor appointed at the annual general meeting  
7. Financial income  
17. Other liabilities  
18. Related party transactions  
19. Contingent liabilities and other contractual obligations  
20. Mortgages and collateral  
8. Financial expenses  
9. Tax for the year  
21. Proposed appropriation of net profit/(loss)  
22. Significant events after the balance sheet date  
10. Intangible assets  
11. Property, plant and equipment  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
118  
Income statements  
For the years ended December 31, 2022 and 2021  
DKK thousand  
Note  
2022  
2021  
Note  
Revenue  
2
2,939,164  
1,401,431  
1,537,733  
1,938,362  
1,266,481  
671,881  
Notes with reference to the consolidated financial statements  
Production costs  
Gross profit  
4,5  
Revenue  
3
4
5
7
Production costs  
Sales and distribution costs  
Administrative costs  
Sales and distribution costs  
Research and development costs  
Administrative costs  
4
3,4,5  
4,5,6  
182,880  
1,206,121  
386,992  
168,903  
405,649  
327,031  
901,583  
Total operating costs  
1,775,993  
Income before interest and tax (EBIT)  
(238,260)  
(229,702)  
Income from investments in subsidiaries  
Financial income  
13  
7
124,551  
112,534  
(131,075)  
82,643  
Financial expenses  
8
341,274  
192,014  
Income before company tax  
(342,449)  
(470,148)  
Tax on income for the year  
9
28  
-
Net result for the year  
21  
(342,477)  
(470,148)  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
119  
Statements of financial position – Assets  
December 31, 2022 and 2021  
DKK thousand  
Note  
2022  
2021  
DKK thousand  
Current assets  
Note  
2022  
2021  
Non-current assets  
Product rights  
4,639,895  
1,013,484  
13,795  
4,912,830  
733,770  
21,360  
Inventories  
14  
881,346  
407,632  
Acquired rights and development in progress  
Software  
Trade receivables  
Receivables from subsidiaries  
Other receivables  
Prepayments  
399,936  
56,561  
253,850  
154,035  
85,239  
Other intangible assets in progress  
Intangible assets  
274,490  
134,371  
51,462  
10  
5,941,664  
5,802,331  
343,492  
851,451  
125,411  
618,535  
Land and buildings  
629,829  
1,428  
345,536  
1,882  
Receivables  
Leasehold improvements  
Securities  
2,269,759  
563,812  
3,124,795  
573,893  
Plant and machinery  
321,589  
489,558  
184,280  
254,530  
207,498  
560,551  
1,369,997  
Cash and cash equivalents  
Securities, cash and cash equivalents  
Other fixtures and fittings, other plant and equipment  
Assets under construction  
2,833,571 3,698,688  
4,566,368 4,724,855  
12,383,424 12,107,828  
Property, plant and equipment  
11 1,626,684  
Total current assets  
Total assets  
Right-of-use assets  
12  
13  
18,953  
25,871  
Investments in subsidiaries  
Other receivables  
210,422  
14,878  
4,455  
163,970  
16,559  
4,245  
Other financial non-current assets  
Financial assets  
229,755  
184,774  
Total non-current assets  
7,817,056  
7,382,973  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
120  
Statements of financial position – Equity and liabilities  
December 31, 2022 and 2021  
DKK thousand  
Note  
2022  
2021  
Note  
Equity  
Notes with reference to the consolidated financial statements  
Trade receivables  
Share capital  
707,354  
(1,462)  
704,684  
(1,111)  
19  
21  
23  
24  
25  
26  
28  
30  
Treasury shares  
Retained earnings  
Reserve for development costs  
Other reserves  
Equity  
Prepayments  
5,901,428  
395,015  
6,556,902  
19,275  
Financial risks and financial instruments  
Deferred consideration for product rights  
Prepayment and loan from Government  
Debt to credit institutions  
149,787  
95,455  
7,152,122  
7,375,205  
Prepayment from customers  
Liabilities  
Share-based payment  
Deferred consideration  
Prepayment and loan from Government  
Credit institutions  
2,324,657  
566,420  
17,008  
2,569,090  
160,511  
18,896  
Lease liabilities  
15  
7,732  
16,186  
Non-current liabilities  
2,915,817 2,764,683  
Deferred consideration for product rights  
Credit institutions  
287,436  
1,105,583  
12,526  
577,667  
874,373  
11,367  
Lease liabilities  
15  
16  
Prepayment from customers  
Trade payables  
-
16,904  
584,731  
153,788  
171,421  
2,315,485  
246,271  
157,175  
84,183  
Payables to subsidiaries  
Other liabilities  
17  
Current liabilities  
1,967,940  
Total liabilities  
5,231,302 4,732,623  
12,383,424 12,107,828  
Total equity and liabilities  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
121  
Statements of changes in equity  
December 31, 2022  
Reserve for  
costs  
Share  
capital  
Treasury  
shares  
Retained development  
Other  
reserves  
DKK thousand  
earnings  
Equity  
Equity as of January 1, 2022  
704,684  
(1,111)  
6,556,902  
19,275  
95,455  
7,375,205  
Net result for the year  
-
-
-
-
(342,477)  
(5,182)  
-
-
-
-
(342,477)  
(5,182)  
Exchange rate adjustments  
Change in fair value of financial instruments entered into to  
hedge future cash flows  
-
-
-
-
33,245  
33,245  
Share-based payment  
-
-
-
46,145  
-
53,976  
53,976  
Warrant programs exercised  
Warrant recharged  
2,670  
-
-
(10,897)  
37,918  
-
-
8,876  
-
-
8,876  
Warrant programs expired  
-
-
-
17,898  
-
(17,898)  
-
Costs related to issue of new shares  
Purchase of treasury shares  
Transfer regarding restricted stock units  
Reserve for development costs  
Equity as of December 31, 2022  
-
(111)  
-
-
(111)  
-
(716)  
365  
(8,612)  
3,729  
-
-
-
(4,094)  
-
(9,328)  
-
-
-
-
-
(375,740)  
5,901,428  
375,740  
395,015  
707,354  
(1,462)  
149,787  
7,152,122  
Transactions on the share capital and rules on changing  
Articles of Associations, see statement of changes in  
Group equity.  
Other reserves consist of costs for share-based  
payments and hedging reserves.  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
122  
Note 1  
Note 2  
Revenue  
Significant accounting policies and significant  
accounting estimates and judgments  
DKK thousand  
2022  
2021  
Accounting policies  
The financial statements of the Parent Company  
Bavarian Nordic A/S have been prepared in accordance  
with the Danish Financial Statements Act (Class D).  
statement of comprehensive income in the consol-  
idated financial statements are recognized directly  
in the statement of changes in equity in the Parent  
Company’s financial statements.  
MVA-BN smallpox vaccine sale  
Rabipur/RabAvert  
Encepur  
1,730,447  
669,061  
733,593  
544,274  
301,100  
365,091  
The financial statements are presented in Danish kroner  
(DKK), which also is the functional currency of the  
Parent Company. The accounting policies are unchanged  
from previous year.  
Other product sale  
Sale of goods  
105,139  
260,220  
Warrant recharged to subsidiaries is treated as the  
Parent Company’s issuance of equity in exchange for  
cash.  
2,805,747  
1,903,178  
Milestone payments  
Contract work  
83,048  
50,369  
-
35,184  
35,184  
Changes in accounting policies  
The accounting policies are unchanged from last year.  
The recharge is subsequently recognized in the income  
statement under the cost plus agreements with the  
subsidiaries. Income tax effects relating to warrant  
recharged is recognized in the income statement.  
Sale of services  
133,417  
Revenue  
2,939,164  
1,938,362  
Supplementary accounting policies for the Parent  
Company  
Accounting policies for investments in subsidiaries are  
described in note 13.  
Total revenue includes:  
As allowed under section 86 (4) of the Danish Finan-  
cial Statements Act, no cash flow statement has been  
prepared for the Parent Company, as it is included in  
the consolidated cash flow statement.  
Fair value adjustment concerning financial instruments entered into to hedge revenue  
-
(7,072)  
The Group's sale of RabAvert in US is handled and  
recognized in Bavarian Nordic Inc.. The Group's sale  
of Encepur and Rabipur in Switzerland is handled and  
recognized in Bavarian Nordic Switzerland AG. Both  
Bavarian Nordic Inc. and Bavarian Nordic Switzerland AG  
operate under a distribution agreement and purchase  
the products from Bavarian Nordic A/S. The internal  
sale of Rabipur/RabAvert has been lower than the sale  
to external customers in US and Switzerland, hence the  
Group Rabipur/RabAvert revenue is higher than the  
revenue recognized in the Group. In 2021 the situation  
was opposite due to high inventory build up in US at  
year-end 2021.The internal sale of Encepur in 2022  
exceeded the sale to customers in Switzerland, hence  
the Encepur revenue recognized in the Parent Company is  
higher than the Encepur revenue recognized in the Group.  
The contract with the United States Department of  
Defense for the development of a prophylactic vaccine  
against the equine encephalitis virus is concluded with  
Bavarian Nordic, Inc., whereas all costs related to the  
contract are covered by Bavarian Nordic A/S. Bavarian  
Nordic A/S re-invoice those costs to Bavarian Nordic,  
Inc. Net Bavarian Nordic, Inc. earns a mark-up, reducing  
the contract work revenue in the Parent Company  
compared to the contract work revenue in the Group.  
Pursuant to the schedule requirements of the Danish  
Financial Statements Act, entries recognized in the  
For further disclosures see the consolidated financial  
statements note 3.  
Accounting policies and significant  
accounting estimates  
See consolidated financial statements note 3.  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
123  
Note 3  
Note 4  
Research and development costs  
Staff costs  
DKK thousand  
2022  
2021  
DKK thousand  
2022  
2021  
Research and development costs incurred this year  
1,226,008  
427,527  
Wages and salaries  
Contribution based pension  
Social security expenses  
Other staff expenses  
Share-based payment  
Staff costs  
458,504  
38,552  
3,749  
371,127  
32,724  
3,928  
Of which:  
Contract costs recognized as production costs  
Research and development costs recognized in the income statement  
(19,887)  
(21,878)  
405,649  
34,529  
49,656  
584,990  
25,308  
53,290  
486,377  
1,206,121  
Fair value adjustment concerning financial instruments entered into to  
hedge research and development costs  
30,201  
-
Staff expenses are distributed as follows:  
Production costs  
311,474  
12,862  
243,502  
21,834  
Accounting policies  
See consolidated financial statements note 6.  
Sales and distribution costs  
Research and development costs  
Administrative costs  
69,798  
65,148  
149,025  
41,831  
116,609  
39,284  
Capitalized salaries  
Staff costs  
584,990  
486,377  
Average number of employees converted to full-time  
604  
688  
511  
533  
Number of employees as of December 31 converted to full-time  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
124  
Note 4  
Staff costs (continued)  
CEO and President of the Company Paul Chaplin and CFO  
Henrik Juuel constitute the Corporate Management in  
the Parent Company.  
The CEO's contract of employment contains standard  
DKK thousand  
2022  
2021  
terms for members of the management of Danish listed  
companies, including the extended period of notice  
that both parties are required to give. For the Company,  
the notice is maximum 18 months. In the event of a  
change of control, the term of notice for the Company  
will be extended to maximum 24 months.  
Staff costs include the following costs:  
COO Russell Thirsk and CPO Anu Kerns constitute the  
Company's member of the Other Executive Manage-  
ment. Former COO Henrik Birk resigned by the end of  
March 2022.  
Board of Directors:  
Remuneration  
5,475  
1,750  
7,225  
5,202  
1,950  
7,152  
Share-based payment  
Remuneration to Board of Directors  
Accounting policies  
See consolidated financial statements note 8.  
Incentive programs for management and other  
employees are disclosed in the consolidated financial  
statements note 30.  
Executive Management:  
Salary  
9,873  
2,068  
692  
8,661  
3,956  
678  
Paid bonus  
Other employee benefits  
Contribution based pension  
Share-based payment  
Corporate Management  
1,367  
13,485  
27,485  
2,048  
9,035  
24,378  
Salary  
5,211  
1,775  
163  
5,981  
1,917  
207  
Paid bonus  
Other employee benefits  
Contribution based pension  
Share-based payment  
Salary and benefits in notice period  
Other Executive Management  
698  
752  
3,698  
7,851  
19,396  
3,869  
7,378  
20,104  
Remuneration to Executive Management  
Total Management remuneration  
46,881  
54,106  
44,482  
51,634  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
125  
Note 5  
Note 6  
Depreciation, amortization and impairment losses  
Fees to auditor appointed at the annual  
general meeting  
DKK thousand  
2022  
2021  
DKK thousand  
2022  
2021  
Depreciation and amortization included in:  
Production costs  
Audit of financial statements  
Other assurance services  
Tax advisory  
1,961  
176  
1,942  
160  
349,893  
2,599  
346,012  
2,340  
Research and development costs  
Administrative costs  
20  
135  
27,807  
24,954  
Other services  
143  
213  
Depreciation and amortization  
380,299  
373,306  
Fees  
2,300  
2,450  
Hereof profit ()/loss from disposed fixed assets  
1,175  
5,259  
Impairment losses included in:  
Production costs  
-
618  
Impairment losses  
-
618  
For further disclosures see the consolidated financial  
statements note 9.  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
126  
Note 7  
Note 8  
Financial income  
Financial expenses  
DKK thousand  
2022  
2021  
DKK thousand  
2022  
2021  
Financial income from bank and deposit contracts  
Financial income from subsidiaries  
27  
30,256  
19,543  
1,739  
22,875  
11,045  
32,185  
1,677  
Interest expenses on debt  
15,346  
3,205  
17,011  
2,374  
39,056  
133,573  
-
Financial expenses to subsidiaries  
Financial income from securities  
Fair value adjustments on securities  
190,301  
103,049  
11,597  
Adjustment of deferred consideration due to change in estimated timing of payments  
Currency adjustment deferred consideration  
Net foreign exchange gains  
54,390  
-
Unwinding of the discount related to deferred consideration  
Currency adjustment deferred consideration  
Net loss on derivative financial instruments at fair value in the income statement  
Financial expenses  
8,318  
112,534  
13,122  
82,643  
17,776  
-
Financial income  
341,274  
192,014  
Accounting policies  
Accounting policies  
See consolidated financial statements note 11.  
See consolidated financial statements note 12.  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
127  
Note 9  
Tax for the year  
DKK thousand  
2022  
2021  
Accounting policies  
See consolidated financial statements note 13.  
lishment in Finland since we have one employee hired by  
the Parent Company working from home in Finland.  
Tax recognized in the income statement  
'Income()/expenses that are not taxable/deductible for  
tax purposes' primarily relates to the 30% step up deduc-  
tion on research and development costs according to  
Section 8B of the Danish Tax Assessment Act.  
Current tax on profit for previous years  
28  
-
Deferred tax  
Tax for the year recognized in the income statement  
28  
-
Recognized deferred tax assets relate to temporary  
differences between valuations for accounting and taxa-  
tion purposes and tax losses carried forward.  
Tax on income for the year is explained as follows:  
Income before company tax  
(342,449)  
(75,339)  
(470,148)  
(103,432)  
Current tax on profit for previous years relates to prelim-  
inary tax assessment from the Finnish Tax Authorities as  
they deem the Parent Company has a permanent estab-  
For further disclosures see the consolidated financial  
statements note 13.  
Calculated tax (22.0%) on income before company tax  
Tax effect on:  
Income from investments in subsidiaries  
(27,401)  
(16,871)  
28  
28,837  
2022  
Income()/expenses that are not taxable/deductible for tax purposes  
Current tax on profit for previous years  
Special tax credit  
(16,699)  
Adjustment  
Recognized  
-
January 1,  
to previous in the income  
Recognized December 31,  
DKK thousand  
Product rights  
2022  
year  
statement  
in equity  
2022  
(46,946)  
166,557  
-
-
94,007  
(2,713)  
-
Change in non-recognized tax asset  
(10,421)  
-
-
73,302  
-
62,881  
Adjustment to previous years non-recognized tax asset  
Tax on income for the year  
Acquired rights and development  
in progress  
28  
-
60,500  
370  
(2,659)  
-
-
-
-
-
(2,659)  
88,124  
287  
Property, plant and equipment  
Right-of-use-asset  
4,184  
23,440  
Tax recognized in equity  
(83)  
Tax for the year recognized in equity  
-
-
Development projects for sale  
Receivables  
32,446  
37  
-
-
154  
32,446  
191  
-
Financial instruments  
297  
-
-
(7,314)  
(7,017)  
27,405  
449,015  
(650,673)  
-
Share-based payment  
27,994  
361,415  
(472,638)  
-
-
20,479  
(24,663)  
-
5,282  
67,121  
(166,557)  
-
(5,871)  
Tax losses carried forward  
Not recognized tax asset  
Recognized deferred tax assets  
-
13,185  
-
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
128  
Note 10  
Intangible assets  
2022  
Acquired  
Other  
rights and  
intangible  
assets in  
progress  
Product development  
DKK thousand  
rights  
in progress  
Software  
Total  
Costs as of January 1, 2022  
Additions  
5,458,700  
733,770  
279,714  
-
95,930  
3,007  
134,371  
142,691  
(2,572)  
6,422,771  
425,412  
-
-
-
Transfer  
2,572  
Cost as of December 31, 2022  
5,458,700  
1,013,484  
101,509  
274,490  
6,848,183  
Amortization as of January 1, 2022  
Amortization  
545,870  
272,935  
818,805  
-
-
-
74,570  
13,144  
87,714  
-
-
-
620,440  
286,079  
906,519  
Amortization as of December 31, 2022  
Carrying amount as of December 31, 2022  
Carrying amount as of December 31, 2021  
4,639,895  
4,912,830  
1,013,484  
733,770  
13,795  
21,360  
274,490  
134,371  
5,941,664  
5,802,331  
Accounting policies  
See consolidated financial statements note 15.  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
129  
Note 11  
Property, plant and equipment  
2022  
Other  
fixtures and  
fittings, other  
plant and  
Land and  
Leasehold  
Plant and  
machinery  
Assets under  
construction  
DKK thousand  
buildings improvement  
equipment  
Total  
Costs as of January 1, 2022  
Additions  
545,592  
73,769  
238,004  
-
4,456  
424,289  
25,866  
73,919  
250,852  
138,479  
165,702  
(428)  
560,551  
101,356  
(477,627)  
-
1,785,740  
339,470  
-
-
Transfer  
2
-
Disposals  
(9,864)  
514,210  
(10,292)  
2,114,918  
Cost as of December 31, 2022  
857,365  
4,458  
554,605  
184,280  
Depreciation and impairment losses as of January 1, 2022  
200,056  
27,480  
-
2,574  
456  
169,759  
31,060  
43,354  
21,994  
(301)  
-
-
-
-
415,743  
80,990  
Depreciation  
Disposals  
-
(8,198)  
(8,499)  
Depreciation and impairment losses as of December 31, 2022  
227,536  
3,030  
192,621  
65,047  
488,234  
Carrying amount as of December 31, 2022  
Carrying amount as of December 31, 2021  
629,829  
1,428  
1,882  
321,589  
254,530  
489,558  
207,498  
184,280  
560,551  
1,626,684  
1,369,997  
345,536  
For collateral see the consolidated financial statements  
note 16.  
Accounting policies  
See consolidated financial statements note 16.  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
130  
Note 12  
Note 13  
Right-of-use-assets  
Investment in subsidiaries  
2022  
DKK thousand  
2022  
Rent  
facility  
Car  
Costs as of January 1, 2022  
Additions  
691,254  
49,198  
DKK thousand  
leasing Equipment  
Total  
Right-of-use assets as of January 1, 2022  
Additions  
24,428  
917  
536  
1,375  
1,058  
-
907  
25,871  
2,292  
Cost as of December 31, 2022  
740,452  
-
Net revaluation as of January 1, 2022  
Net share of profit/loss for the year  
Change in unrealized intra-group profits  
Exchange rate adjustments  
(649,399)  
898  
Modifications  
3,290  
(2,412)  
(10,545)  
909  
-
-
4,348  
Disposals  
(2,412)  
(12,055)  
909  
123,653  
(5,182)  
Depreciations  
(1,071)  
-
(439)  
-
Reversal depreciations  
Right-of-use assets as of December 31, 2022  
Net revaluation as of December 31, 2022  
(530,030)  
16,587  
1,898  
468  
18,953  
Carrying amount as of December 31, 2022  
Carrying amount as of December 31, 2021  
210,422  
163,970  
2021  
Car  
Rent  
DKK thousand  
facility  
leasing Equipment  
Total  
Non-current receivables from Bavarian Nordic, Inc. is recognized as part of "Investments in subsidiaries". During 2022  
the receivables increased by DKK 49.2 million, shown as an addition in the table.  
Impact from applying IFRS 16 as of January 1, 2021  
33,717  
-
1,284  
287  
515  
768  
38  
35,516  
1,055  
Additions  
Voting  
rights  
Modifications  
518  
(46)  
510  
Company summary  
Domicile  
Ownership  
Depreciations  
(9,807)  
24,428  
(989)  
536  
(414)  
907  
(11,210)  
25,871  
Subsidiaries  
Right-of-use assets as of December 31, 2021  
Bavarian Nordic GmbH  
Germany  
USA  
100%  
100%  
100%  
100%  
100%  
100%  
100%  
100%  
100%  
100%  
100%  
100%  
Bavarian Nordic, Inc.  
DKK thousand  
2022  
2021  
Bavarian Nordic Switzerland AG  
Bavarian Nordic Sweden AB  
Aktieselskabet af 1. juni 2011 I  
Aktieselskabet af 1. juni 2011 II  
Switzerland  
Sweden  
Denmark  
Denmark  
Amounts included in the income statement  
Interest expense leases  
598  
12,055  
145  
685  
11,210  
293  
Depreciation recognized on right-of-use assets  
Cost recognized for short term leases (less than 12 months)  
Accounting policies  
See consolidated financial statements note 17.  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
131  
Note 13  
Note 14  
Investment in subsidiaries (continued)  
Inventories  
Upon distribution of profit or loss, net revaluation of  
investments in subsidiaries is transferred to the net  
revaluation reserve according to the equity method  
under equity, if the net revaluation is positive. If the  
net revaluation is negative, it is recognized in retained  
earnings in equity.  
DKK thousand  
2022  
2021  
Accounting policies  
Investments in subsidiaries are recognized and meas-  
ured under the equity method. This means that, in the  
balance sheet, investments are measured at the pro  
rata share of the subsidiaries' equity plus or less unam-  
ortized positive, or negative, goodwill and plus or less  
unrealized intra-group profits or losses.  
Raw materials and supply materials  
Work in progress  
198,839  
641,182  
203,744  
(162,419)  
881,346  
79,068  
79,904  
Manufactured goods and commodities  
Write-down on inventory  
Inventories  
421,601  
(172,941)  
407,632  
Goodwill is calculated as the difference between cost  
of the investments and the fair value of the assets  
and liabilities acquired which have been measured at  
fair value at the date of acquisition. The amortization  
period for goodwill is usually five years.  
Subsidiaries with a negative equity value are measured  
at zero value, and any receivables from these subsidi-  
aries are written down by the Company’s share of such  
negative equity if it is deemed irrecoverable. If the  
negative equity exceeds the amount receivable, the  
remaining amount is recognized under provisions if the  
Company has a legal or constructive obligation to cover  
the liabilities of the relevant subsidiary.  
Write-down on inventory as of January 1  
Write-down for the year  
(172,941)  
(78,101)  
46,031  
(63,537)  
(171,643)  
62,239  
-
Use of write-down  
Reversal of write-down  
42,592  
Investments in subsidiaries are written down to the  
lower of recoverable amount and carrying amount.  
Write-down on inventory as of December 31  
(162,419)  
(172,941)  
Cost of goods sold amounts to  
603,598  
481,916  
Income from investments in subsidiaries' contains pro  
rata share of subsidiaries profits or losses after elimina-  
tion of unrealized intra-group profits and losses.  
For further details regarding development in inventory  
values see consolidated financial statements note 18.  
Accounting policies and significant  
accounting estimates  
See consolidated financial statements note 18.  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
132  
Note 15  
Note 16  
Lease liabilities  
Prepayment from customers  
DKK thousand  
2022  
2021  
DKK thousand  
2022  
2021  
Non-current  
Current  
7,732  
12,526  
20,258  
16,186  
11,367  
27,553  
Prepayment from customers as of January 1  
Prepayments received during the year  
16,904  
74,347  
33,850  
(91,293)  
16,904  
-
(16,904)  
-
Lease liabilities  
Recognized as income during the year  
Prepayment from customers as of December 31  
For further details of prepayment from customers, see  
consolidated financial statements note 28.  
Due within Due between  
Due after  
5 years  
DKK thousand  
1 year  
1 and 5 year  
Total  
Accounting policies  
See consolidated financial statements note 28.  
2022  
Lease liabilities  
12,526  
7,732  
-
-
20,258  
2021  
Lease liabilities  
11,367  
16,186  
27,553  
Accounting policies  
See consolidated financial statements note 27.  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
133  
Note 17  
Note 18  
Other liabilities  
Related party transactions  
The Corporate Management and Board of Directors of  
Bavarian Nordic A/S are considered related parties as  
they have significant influence over the Company.  
Bavarian Nordic Switzerland AG distributes and sells  
Encepur and Rabipur in Switzerland on behalf of  
Bavarian Nordic A/S. This is done under a Distribution  
Agreement.  
DKK thousand  
2022  
2021  
Derivative financial instruments at fair value in the income statement  
Liability relating to phantom shares  
Payable salaries, holiday accrual etc.  
Gross to net deduction accrual  
Other accrued costs  
8,302  
11,142  
1,351  
23,917  
49,165  
5,017  
4,733  
-
Main intercompany transactions:  
Bavarian Nordic GmbH provides research and develop-  
ment services to Bavarian Nordic A/S.  
75,495  
55,387  
8,317  
Bavarian Nordic Switzerland AG provides global  
commercial services to Bavarian Nordic A/S.  
Bavarian Nordic, Inc. distributes and sells RabAvert in  
the US on behalf of Bavarian Nordic A/S. This is done  
under a Distribution Agreement.  
Bavarian Nordic Sweden AB provides regional commer-  
cial services to Bavarian Nordic A/S.  
Payable VAT and duties  
12,778  
171,421  
Other liabilities  
84,183  
All services except for the distribution agreements are  
delivered under cost plus agreements and on arms  
length conditions.  
For further details of derivative financial instruments,  
see consolidated financial statements note 23. The  
phantom share programs are disclosed in the consoli-  
dated financial statements note 30.  
Bavarian Nordic, Inc. provides research and develop-  
ment services to Bavarian Nordic A/S.  
Bavarian Nordic, Inc. also provides services to Bavarian  
Nordic A/S in terms of commercial affair work towards  
the U.S. Government, with the purpose of ensuring an  
efficient communication and service to U.S. authorities,  
in order to maintain existing contracts and explore new  
product/contract opportunities on the U.S. market.  
The distribution agreements are honored according to  
OECD's guidelines for a Limited Risk Distributor.  
Accounting policies  
See consolidated financial statements note 22.  
Apart from intra-group transactions mentioned above  
and the remuneration of the Board of Directors and  
Corporate Management, cf. note 8 and note 30 in the  
consolidated financial statements, there are no transac-  
tions with related parties.  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
134  
Note 19  
Contingent liabilities and other contractual  
obligations  
Repayment obligation  
Repayment obligation regarding received prepayments  
see the consolidated financial statements note 28.  
Agreement with Danish Ministry of Health  
Under the agreement with the Danish Ministry of  
Health to fund the development of ABNCoV2 the  
DKK thousand  
2022  
2021  
Collaborative agreements  
Company has an obligation of payment of an additional,  
capped royalty payment if the sales reach a certain  
threshold. Based on current sales forecasts this addi-  
tional royalty payment is not deemed likely and there-  
fore not recognized. If the payment becomes current  
it will be recognized as a financial expense as the  
additional royalty payment is seen as an extra interest  
payment. The cap for the additional royalty payment is  
a fixed amount, calculated as a percentage of the loan  
amount.  
Contractual obligations with research (CRO) and manufacturing (CMO) partners for long-  
term research projects.  
Sales milestone to GlaxoSmithKline  
The Asset Purchase Agreement with GlaxoSmithKline  
regarding the acquisition of the product rights to  
Rabipur/RabAvert and Encepur includes a sales mile-  
stone of EUR 25 million. As per December 31, 2022  
Management does not judge the sales milestone to  
be probable and therefore the sales milestone has not  
been recognized as either part of the product rights nor  
the deferred consideration for product rights.  
– Due within 1 year  
260,082  
127,300  
License and collaboration agreement AdaptVac  
Under the license and collaboration agreement with  
AdaptVac the Company has an obligation of payment  
of potential future development and sales milestones  
and tiered royalties. Based on current regulatory plans  
and expectations for future sale of the Company's  
COVID-19 vaccine all sales milestones and part of the  
development milestones are deemed probable as per  
December 31, 2022 and the net present value of those  
future milestone payments have been recognized as  
deferrred consideration, see further description in  
note 24 in the consolidated financial statements. The  
remaining developement milestones related to filing  
for approval in further countries are not deemed likely  
and therefore not recognized.  
Joint taxation  
The Company is jointly taxed with all Danish subsid-  
iaries. As the administration company the Company  
stands surety with the other companies in the joint  
taxation of Danish corporate taxes and also withholding  
taxes on dividends, interest and royalties. Corpora-  
tion taxes and withholding taxes payable in the joint  
taxation pool was DKK 0 as of December 31, 2022. Any  
adjustments of the taxable joint taxation income or  
taxes withheld at source may have the effect that the  
Company's liability increases.  
Incentive agreements, company mortgage and  
lawsuits  
See the consolidated financial statements note 32.  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
135  
Note 20  
Note 21  
Mortgages and collateral  
Proposed appropriation of net profit/(loss)  
DKK thousand  
2022  
2021  
DKK thousand  
2022  
2021  
Guarantees for subsidiaries  
Retained earnings  
(342,477)  
(342,477)  
(470,148)  
(470,148)  
The Parent Company stands surety for a credit facility to a subsidiary of a maximum of  
The Parent Company stands surety for letter of credit to subsidiaries of a maximum of  
3,532  
2,335  
3,435  
2,335  
Total  
Mortgages  
See description regarding property, plant and equip-  
ment in note 16 in the consolidated financial state-  
ments.  
Note 22  
Significant events after the balance sheet date  
See description in note 32 in the consolidated financial  
statements.  
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
136  
Hellerup, March 2, 2023
Statement by
Corporate Management  
management on
Paul John Chaplin
President and CEO
Henrik Juuel
Executive Vice President and CFO
the Annual Report
The Board of Directors and the Corporate Manage-
ment have today considered and approved the
Annual Report of Bavarian Nordic A/S for the finan-
cial year January 1 - December 31, 2022.
In our opinion, the management commentary
contains a fair review of the development of the
Group's and the Parent’s business and financial
matters, the results for the year and of the Parent’s
financial position and the financial position as a
whole of the entities included in the consolidated
financial statements, together with a description of
the principal risks and uncertainties that the Group
and the Parent face.
Board of Directors  
The consolidated financial statements are presented
in accordance with International Financial Reporting
Standards as adopted by the EU. The parent financial
statements are presented in accordance with the
Danish Financial Statements Act. Further, the Annual
Report is prepared in accordance with Danish disclo-
sure requirements for listed companies.
Gerard W.M. van Odijk
Chairman of the Board
Anders Gersel Pedersen
Deputy Chairman
In our opinion, the Annual Report with the file name
bava-2022-12-31-en.zip is prepared, in all material
respects, in accordance with the ESEF Regulation.
Peter H. Kürstein-Jensen
Frank A.G.M. Verwiel
Anne Louise Eberhard
In our opinion, the consolidated financial statements
and the parent financial statements give a true and
fair view of the Group’s and the Parent’s financial
position at December 31, 2022, as well as of the
results of their operations and the Group’s cash
flows for the financial year January 1 - December 31,
2022.
We recommend the Annual Report for adoption at
the Annual General Meeting
Thomas Alex Bennekov
Employee-elected
Anja Gjøl
Employee-elected
Karen Merete Jensen
Employee-elected
Linette Munksgaard
Andersen
Employee-elected
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
137  
Independent auditor's report
To the shareholders of Bavarian Nordic A/S
Report on the Financial Statements
Opinion
position at 31 December 2022, and of the results of
its operations and cash flows for the financial year
1 January 2022 – 31 December 2022 in accordance
with International Financial Reporting Standards as
endorsed by the EU and additional requirements
under the Danish Financial Statements Act.
additional requirements applicable in Denmark. Our
responsibilities under those standards and require-
ments are further described in the Auditor’s respon-
sibilities for the audit of the consolidated financial
statements and the parent financial statements
section of this auditor’s report. We are independent
of the Group in accordance with the International
Ethics Standards Board for Accountants’ International
Code of Ethics for Professional Accountants (IESBA
Code) and the additional ethical requirements appli-
cable in Denmark, and we have fulfilled our other
ethical responsibilities in accordance with these
requirements and the IESBA Code. We believe that
the audit evidence we have obtained is sufficient
and appropriate to provide a basis for our opinion.
After Bavarian Nordic A/S was listed on Nasdaq OMX
Copenhagen in 1998, we were appointed auditors at
the Annual General Meeting held on May 27, 1999
for the 1999 financial year. We have been reap-
pointed annually at the Annual General Meeting for
a total consecutive engagement period of 24 years
up to and including the 2022 financial year.
We have audited the consolidated financial state-
ments and the parent financial statements of
Bavarian Nordic A/S for the financial year 1 January
2022 – 31 December 2022, which comprise the
income statement, statements of financial position,
statement of changes in equity and notes, including
a summary of significant accounting policies, for the
Group as well as the Parent, and the statement of
comprehensive income and the cash flow statement
of the Group (collectively referred to as the “Finan-
cial Statements”). The consolidated financial state-
ments are prepared in accordance with International
Financial Reporting Standards as endorsed by the EU
and additional requirements of the Danish Financial
Statements Act, and the parent financial statements
are prepared in accordance with the Danish Financial
Statements Act.
Further, in our opinion, the parent financial state-
ments give a true and fair view of the Parent’s
financial position at 31 December 2022, and of the
results of its operations for the financial year 1
January 2022 – 31 December 2022 in accordance with
the Danish Financial Statements Act.
Key audit matters
Key audit matters are those matters that, in our
professional judgement, were of most significance
in our audit of the consolidated financial state-
ments and the parent financial statements for the
financial year 1 January 2022 – 31 December 2022.
These matters were addressed in the context of our
audit of the consolidated financial statements and
the parent financial statements as a whole, and in
forming our opinion thereon, and we do not provide
a separate opinion on these matters.
Our opinion is consistent with our Long-form Audi-
tor’s report issued to the Audit Committee and the
Board of Directors.
To the best of our knowledge and belief, we have
not provided any prohibited non-audit services
as referred to in Article 5(1) of Regulation (EU) No
537/2014.
Basis for opinion
We conducted our audit in accordance with Inter-
national Standards on Auditing (ISAs) and the
In our opinion, the consolidated financial statements
give a true and fair view of the Group’s financial
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
138  
Key audit matter
How our audit addressed the key audit matter
Statement on the management commentary
Management is responsible for the management
commentary.
Capitalisation of development costs and prepayments related to ABNCoV2  
We have assessed the appropriateness of capitalizing the develop-
ment costs regarding ABNCoV2. In this context, we:
Acquired rights and incurred development costs related to ABNCoV2 development
project (COVID-19 booster vaccine), now in Phase 3, amount to DKK 1,013 million, and
prepayments for CMO product supply amount to DKK 324 million. Intangible assets in
progress related to costs for the scale up activities amounts to DKK 14 million. Total
capitalised development costs and prepayments related to the ABNCoV2 development
project amount to DKK 1,351 million as of 31 December 2022.
•
inquired Management about the overall development of the Phase
3 study and their assessment of the criteria for capitalisation of
development costs. Based on our knowledge of the study and the
industry, we have challenged their judgement of the criteria and
obtained an understanding of Management’s process for the judge-
ment and tested internal controls over the judgement.
Our opinion on the consolidated financial state-
ments and the parent financial statements does not
cover the management commentary, and we do not
express any form of assurance conclusion thereon.
During the past two years, significant development activities have been conducted
and directly related development costs from commencement of the Phase 2 studies
have been capitalised together with the cost of the acquired rights as Management
considers the feasibility of completing a final compound and obtaining regulatory
approval probable. Management’s assessment is based on that the development of
other COVID-19 vaccine candidates in the market based on similar technology have
shown successful completion rates.
•
evaluated the nature and the attribution of the capitalised develop-
ment costs consisting of capitalised future milestone payments for
the acquired rights, external CMO costs, investment in production
facilities, test inventory batches and internal labor costs, based on
documentation obtained from Management.
In connection with our audit of the consolidated
financial statements and the parent financial state-
ments, our responsibility is to read the management
commentary and, in doing so, consider whether the
management commentary is materially inconsistent
with the consolidated financial statements and
the parent financial statements or our knowledge
obtained in the audit or otherwise appears to be
materially misstated.
•
•
tested the external costs, on a sample basis, by agreeing such costs
to contracts and external invoices and evaluated the attribution to
the ABNCoV2 development project.
Management has obtained significant funding from the Danish Ministry of Health to
support the development activities and a significant part of the purchase price for the
acquired rights is deferred. Repayment of the funding to the Danish Ministry of Health
and the milestone payment for the acquired rights are contingent on obtaining certain
milestones after completion of Phase 3.
obtained specification of hours incurred by employees that are
directly attributable to the development activities, which were
approved by Management. We tested the hours incurred on the
development project to approved timesheets. We discussed with
project managers to understand the nature of work performed by
these employees.
Moreover, it is our responsibility to consider whether
the management commentary provides the information
required under the Danish Financial Statements Act.
The audit of capitalised development costs regarding ABNCoV2 is considered a key
audit matter due to the significant judgement involved in assessing whether the
capitalisation criteria have been met.
Based on the work we have performed, we conclude
that the management commentary is in accordance
with the consolidated financial statements and the
parent financial statements and has been prepared in
accordance with the requirements of the Danish Finan-
cial Statements Act. We did not identify any material
misstatement of the management commentary.
•
evaluated agreements and assessed whether the disclosures; note
1, 2, 15, 21, 24 and note 25 in the consolidated financial statements
meet the requirements of IFRS.
Refer to note 1 “Significant accounting policies”, note 2 “Significant accounting esti-
mates and judgements”, note 15 “Intangible assets”, note 21 “Prepayments”, note 24
“Deferred consideration” and note 25 “Prepayment and loan from Government” to the
consolidated financial statements.
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
139  
Management's responsibilities
for the Financial Statements
Auditor's responsibilities for the
audit of the Financial Statements
to provide a basis for our opinion. The risk of
not detecting a material misstatement resulting
from fraud is higher than for one resulting from
error, as fraud may involve collusion, forgery,
intentional omissions, misrepresentations, or the
override of internal control.
statements and the parent financial statements
or, if such disclosures are inadequate, to modify
our opinion. Our conclusions are based on the
audit evidence obtained up to the date of our
auditor’s report. However, future events or condi-
tions may cause the Group and the Entity to cease
to continue as a going concern.
Management is responsible for the preparation
of consolidated financial statements that give a
true and fair view in accordance with International
Financial Reporting Standards as endorsed by the EU
and additional requirements of the Danish Financial
Statements Act as well as the preparation of parent
financial statements that give a true and fair view
in accordance with the Danish Financial Statements
Act, and for such internal control as Management
determines is necessary to enable the preparation
of consolidated financial statements and parent
financial statements that are free from material
misstatement, whether due to fraud or error.
Our objectives are to obtain reasonable assurance
about whether the consolidated financial statements
and the parent financial statements as a whole are
free from material misstatement, whether due to
fraud or error, and to issue an auditor’s report that
includes our opinion. Reasonable assurance is a
high level of assurance, but is not a guarantee that
an audit conducted in accordance with ISAs and
the additional requirements applicable in Denmark
will always detect a material misstatement when it
exists. Misstatements can arise from fraud or error
and are considered material if, individually or in the
aggregate, they could reasonably be expected to
influence the economic decisions of users taken on
the basis of these consolidated financial statements
and these parent financial statements.
• Obtain an understanding of internal control
relevant to the audit in order to design audit
procedures that are appropriate in the circum-
stances, but not for the purpose of expressing an
opinion on the effectiveness of the Group’s and
the Parent’s internal control.
• Evaluate the overall presentation, structure and
content of the Financial Statements, including
the disclosures in the notes, and whether the
Financial Statements represent the underlying
transactions and events in a manner that gives a
true and fair view.
• Evaluate the appropriateness of accounting poli-
cies used and the reasonableness of accounting
estimates and related disclosures made by
Management.
• Obtain sufficient appropriate audit evidence
regarding the financial information of the enti-
ties or business activities within the Group to
express an opinion on the consolidated financial
statements. We are responsible for the direc-
tion, supervision and performance of the group
audit. We remain solely responsible for our audit
opinion.
In preparing the consolidated financial statements
and the parent financial statements, Management
is responsible for assessing the Group’s and the
Parent’s ability to continue as a going concern, for
disclosing, as applicable, matters related to going
concern, and for using the going concern basis of
accounting in preparing the consolidated financial
statements and the parent financial statements
unless Management either intends to liquidate the
Group or the Entity or to cease operations, or has no
realistic alternative but to do so.
As part of an audit conducted in accordance with
ISAs and the additional requirements applicable in
Denmark, we exercise professional judgement and
maintain professional scepticism throughout the
audit. We also:
• Conclude on the appropriateness of Manage-
ment’s use of the going concern basis of
accounting in preparing the consolidated financial
statements and the parent financial statements,
and, based on the audit evidence obtained,
whether a material uncertainty exists related to
events or conditions that may cast significant
doubt on the Group's and the Parent’s ability to
continue as a going concern. If we conclude that
a material uncertainty exists, we are required
to draw attention in our auditor’s report to the
related disclosures in the consolidated financial
We communicate with those charged with govern-
ance regarding, among other matters, the planned
scope and timing of the audit and significant audit
findings, including any significant deficiencies in
internal control that we identify during our audit.
• Identify and assess the risks of material misstate-
ment of the consolidated financial statements
and the parent financial statements, whether
due to fraud or error, design and perform audit
procedures responsive to those risks, and obtain
audit evidence that is sufficient and appropriate
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
140  
We also provide those charged with governance
with a statement that we have complied with rele-
vant ethical requirements regarding independence,
and to communicate with them all relationships and
other matters that may reasonably be thought to
bear on our independence, and, where applicable,
safeguards put in place and measures taken to
eliminate threats.
Delegated Regulation (EU) 2019/815 on the European
Single Electronic Format (ESEF Regulation), which
includes requirements related to the preparation
of the annual report in XHTML format and iXBRL
tagging of the consolidated financial statements
including notes.
issue a report that includes our opinion. The nature,
timing and extent of procedures selected depend on
the auditor’s judgement, including the assessment
of the risks of material departures from the require-
ments set out in the ESEF Regulation, whether due
to fraud or error. The procedures include:
Copenhagen, 2 March 2023  
Deloitte  
Statsautoriseret Revisionspartnerselskab  
Business Registration No 33 96 35 56  
Management is responsible for preparing an annual
report that complies with the ESEF Regulation. This
responsibility includes:
• Testing whether the annual report is prepared in
XHTML format;
From the matters communicated with those charged
with governance, we determine those matters
that were of most significance in the audit of the
Financial Statements of the current period and are
therefore the key audit matters. We describe these
matters in our auditor’s report unless law or regula-
tion precludes public disclosure about the matter or
when, in extremely rare circumstances, we deter-
mine that a matter should not be communicated in
our report because the adverse consequences of
doing so would reasonably be expected to outweigh
the public interest benefits of such communication.
• Obtaining an understanding of the company’s
iXBRL tagging process and of internal control over
the tagging process;
• Evaluating the completeness of the iXBRL tagging
of the consolidated financial statements including
notes;
• Evaluating the appropriateness of the company’s
use of iXBRL elements selected from the ESEF
taxonomy and the creation of extension elements
where no suitable element in the ESEF taxonomy
has been identified;
• Evaluating the use of anchoring of extension
elements to elements in the ESEF taxonomy; and
• Reconciling the iXBRL tagged data with the
audited consolidated financial statements.
• The preparing of the annual report in XHTML
format;
• The selection and application of appropriate iXBRL
tags, including extensions to the ESEF taxonomy
and the anchoring thereof to elements in the
taxonomy, for financial information required to be
tagged using judgement where necessary;
• Ensuring consistency between iXBRL tagged
data and the consolidated financial statements
presented in human readable format; and
• For such internal control as Management deter-
mines necessary to enable the preparation of
an annual report that is compliant with the ESEF
Regulation.
Kirsten Aaskov  
Mikkelsen  
State-Authorised Public  
Eskild Nørregaard  
Jakobsen  
State-Authorised Public  
Report on compliance with
the ESEF Regulation
Accountant  
Accountant  
As part of our audit of the Financial Statements of
Bavarian Nordic A/S, we performed procedures to
express an opinion on whether the annual report of
Bavarian Nordic A/S for the financial year 1 January
2022 to 31 December 2022 with the file name
bava-2022-12-31-en.zip is prepared, in all mate-
rial respects, in compliance with the Commission
Identification No (MNE)  
no 21358  
Identification No (MNE)  
no 21358  
In our opinion, the annual report of Bavarian Nordic
A/S for the financial year 1 January to 31 December
2022 with the file name bava-2022-12-31-en.zip is
prepared, in all material respects, in compliance
with the ESEF Regulation.
Our responsibility is to obtain reasonable assurance
on whether the annual report is prepared, in all mate-
rial respects, in compliance with the ESEF Regulation
based on the evidence we have obtained and to
 
Introduction  
Our strategy and business  
Sustainability  
Corporate information  
Financial review  
Financial statements  
Bavarian Nordic Annual Report 2022  
141  
Other information  
Forward-looking statement  
This annual report contains forward looking state-  
ments. The words “believe”, “expect”, “anticipate”,  
“intend” and “plan” and similar expressions iden-  
tify forward looking statements. Actual results or  
performance may differ materially from any future  
results or performance expressed or implied by such  
statements. The important factors that could cause  
our actual results or performance to differ materi-  
ally include, among others, risks associated with  
product discovery and development, uncertainties  
related to the outcome and conduct of clinical trials  
including unforeseen safety issues, uncertainties  
related to product manufacturing, the lack of market  
acceptance of our products, our inability to manage  
growth, the competitive environment in relation  
to our business area and markets, our inability to  
attract and retain suitably qualified personnel, the  
unenforceability or lack of protection of our patents  
and proprietary rights, our relationships with affil-  
iated entities, changes and developments in tech-  
nology which may render our products obsolete,  
and other factors. For a further discussion of these  
risks, please refer to the section “Risk Manage-  
ment” in this Annual Report. Bavarian Nordic does  
not undertake any obligation to update or revise  
forward looking statements in this Annual Report  
nor to confirm such statements in relation to actual  
results, unless required by law.  
 
Bavarian Nordic A/S
Philip Heymans Alle 3
DK-2900 Hellerup
Denmark
CVR no: 16 27 11 87  
RabAvert®, Rabipur®, Encepur®, JYNNEOS®, IMVANEX®, IMVAMUNE® and MVA-BN®  
are registered trademarks owned by Bavarian Nordic.